Clinical Protocol TCD601B102  
 
A 12 -Month, Randomized, Controlled, Open -Label, Dose Escalation Study 
evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics 
(PD) of an anti -CD2 monoclonal antibody, TCD601(siplizumab) compared to anti-
thymocyte globulin (rATG), as induction therapy in de novo Renal Transplant 
Recipients  
 
NCT Number :  [STUDY_ID_REMOVED]  
 
Release Date :  02-Mar-2022  
ITB-MED  Page 1 of 117 
Protocol TCD601B102 (2 .0) Confidential  
TCD601(siplizumab)  
Clinical Protocol  TCD601 B102 
A 12 -Month,  Randomized, Controlled,  Open -Label, Dose Escalation 
Study evaluating Safety, Tolerability, Pharmacokinetics (PK) and 
Pharmacodynamics (PD) of an anti -CD2 monoclonal antibody, 
TCD601 (siplizumab ) compared to anti -thymocyte globulin ( rATG), as 
induction therapy in de novo  Renal Transplant Recipients  
Document Type: Clinical Study Protocol  
IND Number:  144519  
EUDRACT Number:  2020 -000419 -56 
Current Version : 2.0 
Protocol History  Protocol incorporating Amendment No. 01, v2.0  
Protocol v1.0; Released 27Sep2020  
Clinical Trial Phase:  IIA 
Release Date: 02-Mar-2022
Property of ITB-MED LLC  Confidential 
 This document contains proprietary and confidential material belonging to ITB -MED.  Its 
contents may not be used, divulged, published, or otherwise disclosed without the consent of 
ITB-MED  
ITB-MED   Page 2 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Table of Contents  
Table of Contents .................................................................................................................2  
List of Tables  .......................................................................................................................8  
List of Figures ......................................................................................................................9  
List of Abbreviations .........................................................................................................10  
Protocol History .................................................................................................................13  
Protocol Synopsis ..............................................................................................................14  
1 Introduction ........................................................................................................................20  
1.1 Background ............................................................................................................20  
1.1.1  Transplant Induction Therapy ...............................................................21  
1.1.2  CD2 Biology ..........................................................................................22  
1.1.3  TCD601 (siplizumab): Mechanism of Action .......................................22  
1.1.4  Relevant Data Summary  ........................................................................23  
1.1.4.1  In Vitro Pharmacology .................................................................23  
1.1.4.2  Toxicology Data...........................................................................23  
1.1.4.3  Teratogenicity and Reproductive Toxicology Data .....................24  
1.1.4.4  Human Safety and Tolerability Data ...........................................25  
1.1.4.5  Human Pharmacokinetic Data  .....................................................25  
1.1.4.6  Human Pharmacodynamic Data  ..................................................26  
1.2 Study Purpose ........................................................................................................27  
2 Objectives and Endpoints ..................................................................................................28  
3 Study Design ......................................................................................................................29  
3.1 General Overview  ..................................................................................................29  
4 Study Design Rationale .....................................................................................................32  
4.1 Dose/Regimen and Treatment Duration Rationale ................................................33  
4.1.1  Siplizumab Tissue Distribution / Effect Compartment .........................35  
4.2 Rationale for Active Control ..................................................................................36  
4.3 Rationale for Background Immunosuppression .....................................................37  
4.4 Purpose and Timing of Interim Analyses/Design Adaptations ..............................37  
4.5 Risks and Benefits ..................................................................................................38  
4.5.1  Siplizumab  .............................................................................................38  
ITB-MED   Page 3 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
4.5.1.1  Infusion and Inflammatory Reactions and Cytokine Release ......39  
4.5.1.2  Immunosuppression and Infections .............................................40  
4.5.1.3  Lymphoproliferative Disorders ....................................................41  
4.5.1.4  Other Hypothetical Risks .............................................................42  
4.5.2  Risks of ATG Induction Therapy ..........................................................43  
4.5.3  Risks of SARS-CoV- 2 (COVID -19) .....................................................44  
4.5.4  Risk Mitigation Strategy  .......................................................................46  
5 Population ..........................................................................................................................49  
5.1 Inclusion Criteria  ...................................................................................................49  
5.2 Exclusion Criteria  ..................................................................................................49  
6 Treatmen ts .........................................................................................................................51  
6.1 Method of Treatment Assignment .........................................................................51  
6.2 Investigational Product ..........................................................................................52  
6.2.1  Identification of Investigational Product ...............................................52  
6.2.2  Management of Investigational Product ................................................52  
6.2.3  Investigational Product Dosing Regimen ..............................................53  
6.2.4  Preparation of Siplizumab .....................................................................53  
6.2.5  Premedication for Siplizumab  Infusion .................................................53  
6.2.6  Siplizumab  Administration  ....................................................................54  
6.2.7  Provisional Dose Levels ........................................................................54  
6.2.8  Dose Escalation Guidelines  ...................................................................54  
6.3 ATG: Standard of Care Control .............................................................................56  
6.3.1  ATG Dose and Duration ........................................................................56  
6.3.2  Preparation of ATG ...............................................................................56  
6.3.3  Premedication for ATG Infusion ...........................................................56  
6.3.4  Administration of ATG Infusion ...........................................................56  
6.3.5  Management of ATG Therapy  ..............................................................56  
6.4 Concomitant Immunosuppression .........................................................................56  
6.4.1  MMF Administration  ............................................................................57  
6.4.2  TAC Administration  ..............................................................................58  
6.4.3  Corticosteroid Administration  ...............................................................58  
ITB-MED   Page 4 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
6.5 Infectious Prophylaxis Treatment ..........................................................................58  
6.6 Other Concomitant Treatments  ..............................................................................60  
6.7 Treatment of Adverse Events  .................................................................................60  
6.7.1  Treatment of Acute Rejection Episodes  ................................................60  
6.7.2  Management of BK Viremia  .................................................................60  
6.7.3  Management of Delayed Graft Function (DGF)  ...................................61  
6.7.4  Primary Graft Non -Function (PGNF) ...................................................61  
6.7.5  Management of EBV -PTLD  .................................................................62  
6.8 Treatment Exposure and Compliance ....................................................................62  
6.9 Prohibited Treatment .............................................................................................62  
7 Informed Consent Procedures............................................................................................63  
8 Visit Assessments ..............................................................................................................63  
8.1 Subject Id entification  .............................................................................................64  
8.2 Screen Failure Assessments  ...................................................................................64  
8.3 Efficacy / Pharmacodynamic Assessments  ............................................................64  
8.4 Safety Assessments  ................................................................................................64  
8.4.1  Physical Examination  ............................................................................64  
8.4.2  Vital Signs  .............................................................................................65  
8.4.3  Height and Weight .................................................................................65  
8.4.4  Labo ratory Evaluations .........................................................................65  
8.4.4.1  Hematology ..................................................................................66  
8.4.4.2  Clinical Chemistry  .......................................................................66  
8.4.4.3  Lipid Panel ...................................................................................66  
8.4.4.4  Urine Dipstick  ..............................................................................66  
8.4.4.5  Pregnancy  .....................................................................................66  
8.4.4.6  Renal Function .............................................................................66  
8.4.4.7  Coagulation Studies .....................................................................66  
8.4.4.8  EBV -DNA PCR  ...........................................................................66  
8.4.4.9  CMV DNA PCR  ..........................................................................67  
8.4.4.10  Donor Specific Antibodies (DSA) ...............................................67  
8.4.4.11  Immunogenicity ...........................................................................67  
ITB-MED   Page 5 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
8.4.4.12  Viral Testing and Surveillance.....................................................67  
8.4.5  EBV -PTLD Surveillance  .......................................................................67  
8.4.6  Imaging: PTLD Surveillance .................................................................69  
8.4.7  Renal Biopsy .........................................................................................69  
8.4.8  Treated Biopsy Proven Acute Rejection  ...............................................69  
8.4.9  Graft Loss  ..............................................................................................69  
8.4.10  Death  .....................................................................................................70  
8.5 Pharmacokinetic Assessments ...............................................................................70  
8.6 Assessment of Treatment Exposure and Compliance ............................................70  
8.7 Exploratory Biomarker Assessments .....................................................................71  
9 Study Discontinuation and Completion .............................................................................71  
9.1 Discontinuation ......................................................................................................71  
9.1.1  Safety Stopping Rules ...........................................................................71  
9.1.2  Discontinuation of Study Treatment .....................................................72  
9.1.3  Withdrawal of Informed Consent  ..........................................................73  
9.1.4  Lost to Follow-up ..................................................................................73  
9.1.5  Early Study Termination by the Sponsor ..............................................73  
9.2 Study Completion ..................................................................................................73  
9.3 Subject Replacement  ..............................................................................................74  
10 Safety Monitoring and Reporting ......................................................................................74  
10.1  Definition of Adverse Events and Reporting Requirements ..................................74  
10.1.1  Adverse Events  ......................................................................................74  
10.1.2  Serious Adverse Events .........................................................................75  
10.1.3  Adverse Events of Special Interest  ........................................................76  
10.1.4  SAE Reporting ......................................................................................76  
10.1.5  Pregn ancy Reporting .............................................................................77  
10.1.6  Early Phase Safety Monitoring ..............................................................77  
10.1.7  Reporting of Study Treatment Errors ....................................................77  
11 Data Monitoring Committee  ..............................................................................................77  
12 Data Analysis and Statistical Methods  ..............................................................................78  
12.1  Analysis sets ...........................................................................................................78  
ITB-MED   Page 6 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
12.2  Subject Demographics and other Baseline Characteristics  ....................................78  
12.3  Treatments  ..............................................................................................................79  
12.3.1  Concomitant Immunosuppressants ........................................................79  
12.3.2  Other Co -Medications ...........................................................................79  
12.4  Analysis of the Primary Endpoint(s) ......................................................................79  
12.4.1  Definition of Primary Endpoint(s) ........................................................79  
12.4.2  Statistical Model, Hypothesis, and Method of Analysis .......................80  
12.4.3  Handling of Missing Values/Censoring/Discontinuations ....................80  
12.5  Analysis of Secondary Endpoints ..........................................................................80  
12.5.1  Efficacy and/or Pharmacodynamic endpoint(s) ....................................80  
12.5.2  Safety Endpoints ....................................................................................81  
12.5.3  Pharmacokinetics  ...................................................................................83  
12.5.4  Biomarkers  ............................................................................................84  
12.5.5  PK/PD Relationships  .............................................................................84  
12.6  Analysis of Exploratory Endpoints ........................................................................84  
12.7  Interim Analyses  ....................................................................................................84  
12.8  Dosing Decision Data Review  ...............................................................................85  
12.9  Sample Size Calculation  ........................................................................................85  
13 Study Conduct ...................................................................................................................85  
13.1  Sponsor Responsibilities ........................................................................................85  
13.2  Investigator Responsibilities  ..................................................................................85  
13.3  Site Initiation  ..........................................................................................................86  
13.4  Data Quality Control ..............................................................................................86  
13.4.1  Data Collection  ......................................................................................86  
13.4.2  Data Management  ..................................................................................86  
13.4.3  Monitoring Procedures ..........................................................................87  
13.4.4  Protocol Adherence and Amendments ..................................................87  
13.4.5  Quality Assurance .................................................................................88  
13.5  Study Site Closure ..................................................................................................88  
13.5.1  Records Retention  .................................................................................88  
14 Ethical Considerations .......................................................................................................89  
ITB-MED   Page 7 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
14.1  Regulatory and Ethical Compliance ......................................................................89  
14.2  Publication of Study Protocol and Results .............................................................89  
15 References  ..........................................................................................................................90  
16 Appendices ........................................................................................................................93  
16.1  Appendix 1:  Schedule of Assessments .................................................................93  
16.2  Appendix 2:  Amendment No.1 – Summary of Changes ......................................96  
16.3  Appendix 3: Investigator Agreement Page ..........................................................108  
16.4  Appendix 4: US- Specific CellCept® Pregnancy and Safety Information ............109  
16.5  Appendix 5: Guidelines for MMF Dose Reduction  .............................................111  
16.6  Appendix 6: Tacrolimus Drug- Drug Interactions  ................................................112  
16.7  Appendix 7: Updated 2018 Banff Classification .................................................114  
ITB-MED   Page 8 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
List of T ables  
Table 1 -1  Peripheral CD4, CD8, and NK cell depletion following siplizumab 
(MEDI -507) administration in patients with CD2 Positive T -cell 
lymphoma in Study MI-CP099 ......................................................................... 27  
Table 2 -1 Objectives and Related Endpoints .................................................................... 28  
Table 3 -1 Dosing Regimen................................................................................................ 30  
Table 4 -1 Renal transplantation pooled analysis: Opportunistic infections ...................... 41  
Table 6 -1 Treatment Assignment  ...................................................................................... 51  
Table 6 -2 Provisional dose levels ...................................................................................... 54  
Table 12 -1 Non-compartmental pharmacokinetic parameters  ............................................ 83  
 
ITB-MED   Page 9 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
List of Figures  
Figure 1-1  Mean CD3 lymphocyte profile following siplizumab (MEDI-507) 
administration in study MI-CP027.................................................................... 26  
Figure 3-1  TCD601B102 Study Design ............................................................................. 29  
Figure 3-2  TCD601B102 Treatment Regimen ................................................................... 30  
Figure 4-1  Mean predicted siplizumab serum concentrations in study TCD601B102: 0.2 and 0.6 mg/kg.............................................................................................. 34
 
Figure 4-2  Mean predicted, log- transformed, siplizumab  serum concentrations in 
study TCD601B102 following 0.2 and 0.6 mg/kg siplizumab  
administration  ................................................................................................... 36  
ITB-MED   Page 10 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
List of Abbreviations 
ABC Antibody Biodistribution Coefficient  
ADCC  Antibody -Dependent Cell-mediated Cytotoxicity  
ADCP  Antibody -Dependent Cellular Phagocytosis  
AE Adverse Event  
AKI Acute Kidney Injury  
ALP Alkaline Phosphatase  
ALT Alanine Aminotransferase  
APC Antigen Presenting Cell 
aPTT Activated Partial Thromboplastin time 
AST Aspartate Aminotransferase  
ATG Anti-thymocyte Globulin  
ATL Adult T -cell Leukemia  
AUC  Area Under the Curve  
BID Twice a day  
BMI Body Mass Index  
BMT  Bone Marrow Transplantation  
BPAR Biopsy Proven Acute Rejection  
BUN  Blood Urea Nitrogen  
CDC  Complement -dependent cytotoxicity   
CDR  Complementarity -determining regions  
CIT Cold Ischemia time  
CMV  Cytomegalovirus   
CNI Calcineurin Inhibitor  
CS Corticosteroids  
CsA Cyclo sporine  
CSR  Clinical Study Report  
CTCAE  Common Terminology Criteria for Adverse Events  
CTS Chimeric Transition Syndrome  
CV Coefficient of Variation  
DGF  Delayed Graft Function  
DLT Dose Limiting Toxicity  
DMC  Data Monitoring Committee  
DSA Donor Specific Antibodies  
EBV Epstein -Barr Virus  
eCRF  Electronic Case Report Form  
EDC Electronic Data Captur e 
eGFR  Estimated Glomerular Filtration Rate  
ELISA  Enzyme -linked Immunosorbent assay  
EOS  End of Study  
eTMF  Electronic Trial Master File  
EU European Union  
FACS  Fluorescence -activated Cell Sorter 
FAS Full Analysis Set  
FDA Food and Drug Administration  
ITB-MED   Page 11 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
FRP Females of reproductive potential  
GCP  Good Clinical Practice  
GGT  Gamma Glutamyl Transferase  
GvHD  Graft -versus -host disease  
HbsAg  Hepatitis B Surface Antigen  
Hbg Hemoglobin  
HBV Hepatitis B virus  
HCV  Hepatitis C virus  
HLA Human Leukocyte Antigen  
HIV Human Immunodeficiency Virus 
IMPDH  Inosine Monophosphate Dehydrogenase  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use  
IEC Independent Ethics Committee  
INR International Normalized Ratio  
IRB Institutional Review Board  
IV Intravenous  
IWRS  Interactive Web Response System  
IVIG Intravenous Immun oglobulin  
KDIGO  Kidney Disease Improving Global Outcomes  
KDOQI  Kidney Disease Outcomes Quality Initiative  
LGL Large Granular Lymphocytic Leukemia   
LLOQ  Lower Limit of Quantification  
LOCF  Last-Observation -Carried -Forward  
LPD Lymphoproliferative Disorder  
MDRD  Modification of Diet in Renal Disease  
MLR  Mixed lymphocyte reaction  
M-M Michaelis -Menten  
MMF  Mycophenolate Mofetil  
MoA Mechanism of Action  
MPA  Mycophenolic acid  
NCI National Cancer Institute  
NSAID  Nonsteroidal anti -inflammatory drug  
PCP Pneumocys tis Pneumonia  
PCR  Polymerase Chain Reaction  
PD Pharmacodynamic(s)  
PGNF  Primary Graft Non -Function  
pMHC Peptide -major histocompatibility complex  
PK Pharmacokinetic(s)  
PPK Population Pharmacokinetic(s)  
PRA Panel Reactive Antibodies  
PRED  Prednisolone  
PT Prothrombin Time 
PTT Partial Prothrombin Time  
ITB-MED   Page 12 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
PTLD  post-transplant lymphoproliferative disorder  
PVAN  Polyoma Virus Associated Nephropathy  
QMS  Quality Management System  
QNAT  Quantitative Nucleic Acid Testing  
rATG  rabbit anti -thymocyte globulin  
RBC  Red Blood Cell(s)  
RO Receptor occupancy  
REMS  Risk Evaluation and Mitigation Strategy  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
s.c. Subcutaneous  
SCr Serum Creatinine  
SD Standard deviation  
SID Subject Identification Number  
SMQ  Standardized MedDRA Query  
SoC Standard of Care  
SOC  System Organ Class  
SOP  Standard Operating Procedure  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
SVR Sustained Viral Response  
TAC Tacrolimus  
TB Tuberculosis  
tBPAR  treated Biopsy Proven Acute Rejection  
TCD601 or siplizumab  Investigational Product  
TCMR  T-cell Mediated Rejection  
TCR T-cell Receptor  
TDM  Therapeutic Drug Monitoring  
TMDD  Target -Mediated Drug Disposition  
ULN upper limit of normal  
ULOQ upper limit of quantification  
US United States  
VL Viral Load  
WBC  White Blood Cell(s)  
WHO  World Health Organization  
 
  
ITB-MED   Page 13 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Protocol History  
Amendment 01:  
This document (TCD601B102 Protocol Version 2.0) incorporates changes  and editorial updates 
to harmonize the US clinical study protocol with TCD601B101 Protocol Ve rsion 2.0, which is 
active in the EU.  Key revisions include the addition of an inclusion criterion, which requires study 
subjects to have a n egative SARS -CoV- 2 test at screening, an outline of the Risks associated with 
COVID- 19 disease (See Section 4.5.3), and Risk Mitigation Strategies to minimize exposure to 
SARS -CoV- 2 (See Section 4.5.4).  These revisions and additions are in consideration of the 
ongoing global SARS -CoV -2 pandemic  and harmonize with FDA and EU guidance documents  
and updated global protocol template. 
A tabulation of all changes can be reviewed  in Appendix 2 of this protocol. 
ITB-MED   Page 14 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Protocol Synopsis  
Product 
Name/Number  TCD601 (siplizumab)  
Protocol Number  TCD601B10 2 
Protocol Title  A 12-month, randomized, controlled, open -label, dose escalation study evaluating safety, 
tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an anti -CD2 monoclonal 
antibody, TCD601  (siplizumab) , compared to  anti-thymocyte globulin  (rATG), as induction 
therapy in de novo renal transplant recipients  
Investigation Type  Interventional; Drug (biologic)  
Purpose and Rationale  The purpose of this study is to investigate the safety, tolerability, pharmacokinetics  and 
pharmacodynamics  of escalating doses of TCD601 (siplizumab), an anti -CD2 monoclonal 
antibody, compared to a rabbit polyclonal anti -thymocyte globulin ( rATG), as induction 
therapy  in de novo renal transplant patients.  All subjects  will receive the same standard of 
care (SoC)  background immunosuppression.  
This trial will focus on profiling the safety, tolerability, PK and PD activity of siplizumab  in the 
setting of standard-of -care immunosuppression in a moderate immunologic risk renal 
transplant population.  
Overall, results of this study will be used to inform the siplizumab  dose and regimen 
selection for investigation in later phases of clinical development and serve as proof -of-
principal study in the replacement of SoC , polyclonal, T -cell depleting induction therapy.  
Primary Objective  To assess the safety, tolerability, PK and PD of siplizumab  compared  to rATG, in de novo  
renal transplant recipients at 12 months  post-transplant . 
Secondary Objectives  • To measure changes in peripheral lymphocyte immunophenotype  
• To measure the time -course and duration of siplizumab  induced lymphocyte depletion 
and recovery  
• To measure peripheral CD2-receptor occupancy following siplizumab  administration 
over time  
• To assess the incidence of treated biopsy proven acute rejection (tBPAR) at 12 month s 
• To assess the incidence of treatment emergent de novo , donor specific antibodies 
(DSA) at 12 months  
• To assess the incidence of antibody meditated rejection at 12 months  
• To assess renal function via eGFR using the Modification of Diet in Renal Disease 
(MDRD) equation  at Months 3, 6, 12 or EOS  
Exploratory Objectives  •  
 
  
  
 
  
   
    
  
  
  
Study Design  TCD601B10 2 is a 12-month, multi -center, randomized, controlled , open -label , dose 
escalation study to evaluate the safety, tolerability, PK and PD of siplizumab  compared to 
rATG, as induction therapy,  in de novo  renal transplant recipients. All subject s will receive 

ITB-MED   Page 15 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
background immunosuppression with standard exposure tacrolimus ( TAC), mycophenolate 
mofetil ( MMF ) and corticosteroids  (CS). 
Following a screening period of up to 4 -weeks to confirm study eligibility , up to 24  moderat e 
immunological risk , de novo renal transplant candidates  will be enrolled into the study.  
Eligible subjects will be sequentially  assigned to one of t wo Cohort s (A or B) using a time -
lagged dose escalation methodology . Within each Cohort, it is planned th at 12 subject s will 
be randomized to siplizumab or rATG, in an 8: 4 ratio prior t o renal transplantation on Study 
Day 0, as outlined below:   
    
Subjects randomized to siplizumab will receive two intravenous (IV) doses on Day 0 and 
Day 4  post-transplant  as follows:    
Siplizumab  Dosing Arms: 
 Arm 1 : 0.2 mg/kg (n=8)  
 Arm 2 : 0.6 mg/kg (n=8)  
Subjects randomized to rATG  (Arm 3), will receive three intravenous (IV) doses of 1.5 mg/kg 
on Days 0 , 1 and 2, regardless of Cohort assignment . 
Siplizumab  and rATG will be combined with concentration-controlled TAC (BID) dosing to a 
whole blood trough concentration 4-11 ng/mL , and MMF  or equivalent  (BID) , and should be 
started within 24 hours post -transplant . Subjects will also rec eive CS per local practice with 
a minimum of 5.0  mg/d prednisone or equivalent until Month 12.  
Dose Escalation Criteria:  
28 days following the last investigational product administration in  the 4th siplizumab treated 
subject in each treatment Cohort  and prior to dose escalation to the subsequent Cohort , a 
review  of all available safety, tolerability and PD data will be conducted by ITB-MED in 
collaboration with the Investigator s.  This 28 -day safety period allows sufficient time for  
subjects to reach full -receptor occupancy, maximum pharmacodynamic activity, and for the 
presentation of ac ute, drug related toxicities.  
In the event there is no evidence of  acute, dose limiting toxicity  (DLT) , randomization to the 
next dose level may be initiated. Alternatively, a decision to terminate the dosing arm could 
be reached.  It is also possible addi tional and/or  intermediate dose level(s) could be added 
during the course of the study  per amendment . Cohorts may be added at any dose level 
below the maximum tolerated dose in order to better understand safety, PK or PD.  
This escalation data review will be repeated prior  to dose escalation/termi nation decisions 
for each Cohort .  The review of subject data and dose escalation may occur before all 
subjects have been randomized to a given Cohort .  If the next dose level is opened to 
subject  assignment,  Cohorts  will be back filled to achieve a final sample size of 12 subjects.  
In addition to the review of data for dose decision purposes as noted above, an independent 
Data Monitoring Committee (DMC) will conduct an ongoing review of cumulative  PK, PD , 
safety , Adverse Events (AEs) and Serious Adverse Event (S AE) data as well as EBV- viral 
load and PTLD surveillance results , including clinically relevant changes on physical exam 
and clinical laboratory assessments  and ad hoc imaging. The Committee will convene on a 
quarterly basis or as described in the DMC Charter. If at any time the observed AEs meet or 

ITB-MED   Page 16 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
exceed the  a priori  defined stopping criteria, the study will be placed on hold  pending a 
review . 
Interim Analy sis: 
A formal interim analysis  will occur once 50% of subjects in Cohort 1 and 2 complete their  6-
month study assessment .  
This formal interim analysis will be conducted to assess the safety/tolerability (e.g., AEs, 
SAEs , clinical laboratory assessments, v ital signs, PK data and PK/PD activity (e.g., 
immunophenotyping and CD2 receptor occupancy). The  analysis will  also include 
assessment of biopsy proven acute rejection (BPAR) , graft losses deaths,  and key safety 
endpoints. In the event the acute rejection rate exceeds a clinically relevant threshold set 
forth in the protocol and DMC charter, or the a priori  defined stopping rules, enrollment will 
be suspended to allow for the early termination of any treatment cohort where the 
benefit/risk of siplizumab  is deemed unacceptable.  
Safety stopping rules:  
In addition to the formal interim analyses  and escalation data reviews for dosing decision 
purposes, the following Safety Stopping Rules will be in effect at any timepoint in the study.  
Although the stopping  criteria do not incorporate an absolute requirement for causality, the 
potential relationship between an AE(s) and siplizumab will be evaluated carefully on a case-
by-case basis between ITB -MED and the Investigator. Following a review of the AE (s), a 
decision to permanently discontinue enrollment or re-initiate dosing will be made by the 
DMC. Dose limiting toxicities (DLTs) will be assessed according to the standardized toxicity grading scale, the National Cancer Institute (NCI) CTCAE version 5.0 (NCI 2017): 
 One (1) subject death or graft loss within the first month with the exception 
of technical failures .  
 One (1) subject presents with histologically  confirmed EBV-PTLD . 
 One (1) subject with Grade 3 or higher cytokine release syndrome within 24 
hours of any siplizumab  administration . 
 One (1) subject with any Grade 4 toxicity, considered drug related as 
determined by the Investigator within the first 28 days .  
 Two (2) subjects with sustained (> 7 days) Grade 3 neutropenia (neutrophil 
counts 200/mm3 to < 500 to; 0.2 to <0.5 x 10e9/L) considered related to 
siplizumab . 
 Two (2) or more subjects presenting with Grade 3 or higher toxicity 
considered related as determined by the Investigator, including infusion 
reactions, within 24 hours of any siplizumab  administration . 
 Three (3) or more subjects per cohort presenting with Grade IIA or higher 
BPAR (T -cell mediated rejection (TCMR); central pathology) during the first 
6 months post -transplant . 
Following discharge from the hospital, subjects will have study assessments conducted weekly through Week 10 and then monthly from Month 3 through Month 12 or end of study 
(EOS). All subjects  enrolled will be followed for a minimum of 12 months.   
Population  Up to 24  moderate immunological risk, adult, de novo renal transplant patients  
Planned Study Sites Up to 5 study sites within the United States  (US) 
Key Inclusion Criteria  
 Subjects eligible for inclusion in this study have to fulfill all of the following criteria:  
• Able to understand the study requirements and provide written informed consent before 
any study  assessment is performed.  
• Male or female patients ≥ 18 to 70 years of age.  
• Recipients of a de novo  renal allograft from a heart -beating deceased, living unrelated 
or non -Human Leukocyte Antigen ( HLA)  identical living related donor.  
ITB-MED   Page 17 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
• Recipients of a kidney with a cold ischemia time (CIT) < 30 hours; hypothermic machine 
perfusion within the same timeframe is acceptable.  
• Subjects who test negative for SARS -CoV-2 via molecular testing (PCR)  
Key Exclusion Criteria  
 Subjects meeting any of the following criteria are not eligible for inclusion in this study : 
• Transplant recipients sero-negative for Epstein-Barr virus (EBV ).  
• Multi -organ transplant recipients . 
• Subjects who have received a kidney allograft previously,  e.g., re-transplant . 
• Recipient of a kidney from an HLA identical living related donor . 
• Recipient of a kidney from a donor after cardiac death. 
• Subjects at high immunological risk for rejection as determined by local practice [(e.g., presence of pre-existing DSA, recipient of high Kidney  Donor Profile Index ≥ 85 kidney 
(where assessed)].  
• Subjects with donor specific anti -HLA antibody as measured by complement -dependent 
cytotoxicity assay (CDC), enzyme -linked immunosorbent assay (ELISA), or flow 
cytometry within 90 days prior to transplant  or as  performed per the center’s local 
practice.  
• Complement -dependent cytotoxicity (CDC)  crossmatch positive transplant (isolated 
positive B cell crossmatches are not an exclusion criterion).  
• ABO incompatible recipient . 
• History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ  of the cervix.  
• Subjects with clinically significant laboratory abnormality that would preclude participation in the study (e.g., >2.5 x Upper Limit of Normal (ULN) values for (a) liver 
function chemistries (ALT, AST, alkaline phosphatase (ALP)), (b) bilirubin, (c) 
coagulation studies ( INR/PT, aPTT).  
• Patient with any of the following:  hemoglobin (Hbg) < 8 mg/dL, WBC count ≤ 2,000/mm3 
or platelet count ≤ 75,000/mm
3. 
• Sero-positive for Human Immunodeficiency Virus (HIV) or Hepatitis B Surface Antigen 
(HBsAg). Subjects who are sero -positive for Hepatitis C virus (HCV) are excluded 
without proof of sustained viral response (SVR) after anti -HCV treatment.  
• Recipient of a kidney from a donor who tests positive for HIV, HBsAg/HBc positive or 
HCV.  
• History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g., siplizumab , ATG, TAC, MMF , CS). 
• Any additional contraindication to the use of TAC or M MF according to the national 
labeling information of these products (refer to the local product label).  
• Evidence of TB infection (after anti -TB treatment, patients with history of latent TB may 
become eligible according to national guidelines).  
• Patient with severe systemic infections, current or within the two weeks prior to randomization.  
• Subjects with any other clinically significant medical condition, active infection or laboratory abnormality that would, in the judgment of the investigator, interfere with the 
subject’s ability to participate in the study.  
• Subjects who, in the opinion of the investigator, are not capable of giving informed consent for the study or who are unable or unwilling to adhere to the study requirements outlined in the protocol.  
• Use of other investigational products or enrollment in another investigational drug study within 30 days of screening or 5 half -lives of the medication, whichever is longer.  
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.  
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception 
during dosing and for 24 weeks after the study medications have been stopped.  
ITB-MED   Page 18 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Investigational 
Product  Siplizumab 
Reference Product ( Active 
Control ) rabbit anti -thymocyte globulin (rATG ; Thymoglobulin; Genzyme) 
Background Therapy  • Immediate release t acrolimus (TAC) 
• Mycophenol ate mofetil (M MF) or equivalent  
• Corticosteroids (CS) 
Treatment Regimen  Prior to surgery, on Day 0, eligible subject s will be sequentially  assigned to one of 2 Cohorts 
(A or B) and then r andomized to one of two dosing arms in a n 8:4 ratio ( siplizumab:  rATG) 
as follows:  
 
Cohort  Arm Subjects (n)  Product  Dosing Regimen  
Cohort A  Arm 1  8 Siplizumab  0.2 mg/kg (Days 0 and 4) 
Arm 3 4 rATG  1.5 mg/kg (Day s 0, 1 and 2)  
Cohort B  Arm 2  8 Siplizumab  0.6 mg/kg (Days 0 and 4)  
Arm 3 4 rATG  1.5 mg/kg (Day s 0, 1 and 2)  
Background Treatment:  
Subjects acr oss all treatment arms will receive triple regimen background  
immunosuppressive therapy  (TAC/MMF/CS ). 
Concomitant Treatments : 
• Premedication (prior to siplizumab  and rATG infusions): diphenhydramine,  paracetamol  
or acetaminophen  
• Cytomegalovirus (CM V), pneumocystis pneumonia (PCP) prophylaxis, per local practice   
• Oral Candida treatment , per local practice   
PK/PD 
Assessments    PK: Siplizumab  and TAC  
• Siplizumab  (total and free) - Dosing on Days 0 and Day 4:  
 Sampling pre-dose (0h), 1h, 3h, 6h, and 24h after the first dose on Day 0;  
 Sampling pre-dose (0h), 1h, 3h, and 6h on Day 4;  
 Additional collection on Days 2 ,3, 7, 14, 21, 28, 35, 42, 49, 56, 63*, 70*, 84*, 112*, 
140*, 168*, 196*, 224*, and 252* (*Note: collections designated with an asteri sk may 
be truncated based on half -life of siplizumab and serum concentrations below limit of 
quantification)  
• anti-siplizumab  antibodies: Day s 0, 28, 56, 84, 168, and EOS    
• TAC: Day s 0, 1, 7, 14, 21, 28, month 3, 6, 12 post -transplant and as needed following a 
change in dose based on local standard of care (SoC)   
• PD:   
 PD sampling times to be linked with relevant PK timepoints  
 Peripheral lymphocyte immunophenotyping (FACS analysis) – CD2, CD3, CD4, 
CD5, CD8, CD19, CD25, CD27, CD38, CD45RA, CD45RO, CD59, CD127, CD138, 
CD154, FoxP3, HLA -DR 
 Peripheral CD2 receptor occupancy  
Safety Assessments  • AEs and SAEs  
• Clinically significant changes in clinical chemistry, hematology, vital signs, and serology  
• EBV-viral load measurement via PCR  
• Renal function  
• Comprehensive  Physical Examination  
ITB-MED   Page 19 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Data Analysis  All information obtained on AEs will be displayed by treatment and subject. The number and 
percentage of subjects with AEs will be tabulated by body system and preferred term with a 
breakdown by treatment arm. A subject with multiple AEs within a body system is only counted once towards the total of this body system. No formal statistical analysis will be done for the safety and tolerability evaluation.  
Siplizuma b serum  concentration data will be listed by treatment, subject, and visit/sampling 
time point. Descriptive summary statistics will be provided by treatment and visit/sampling time point, including the frequency ( n, %) of concentrations below the lower limit of 
quantification (LLOQ), which will be reported as zero. Summary statistics will include mean (arithmetic and geometric), standard deviation (SD), coefficient of variation (CV) (arithmetic 
and geometric), median, minimum and maximum. Concentrations below LLOQ will be 
treated as zero in summary statistics. A geometric mean will not be reported if the dataset 
includes zero values.  
The magnitude and duration of pharmacodynamic effect of siplizumab will be characterized 
by measuring the change in peripheral immunophenotype, including all subsets of T -, B- and 
NK-cells. Similarly, biomarkers, such as inflammatory cytokines and CD2 RO  will be 
summarized by cohort, treatment and subject. Summary  statistics will also be provided such 
as mean, median, SD, minimum and maximum, by treatment and by  visit/time for all PD and 
biomarker data.  The relationship between siplizumab  concentration PK and PD 
(immunophenotype) will be explored. Modeling of PK/PD data using a population approach will be performed as appropria te. 
Sample Size Determination  No formal sample size and power analysis has been performed. A sample size of 8 subjects 
for each arm  was chosen based on practical considerations, including the need to 
adequately characterize siplizumab  PK and PD activity i n renal transplant patients in the 
immediate post -transplant time period while balancing the overall exposure in a mechanistic 
profiling study.  
Study Duration  All subjects enrolled will be followed for a minimum of 12 months.   
ITB-MED   Page 20 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
1 Introduction 
1.1 Background 
Since the first successful human kidney transplantation by Murray et al. in 1954 ( Murray et al 
1958),  numerous immunosuppressive regimens have been developed for clinical application.  The 
ultimate goal of immunosuppression in kidney transplantation is to prevent acute rejection and 
maintain allograft function while balancing the risk of adverse effects ( Tanriover et al 2015).  
Immunosuppressive agents are categorized as (1) induction therapy that is administered in the perioperative period and (2) m aintenance therapy that transplant recipients require for lifelong use 
(KDIGO 2009).   To maximize efficacy and minimize adverse effects, current immunosuppressive 
regimens are typically based on combinations of two or three immunosuppressive drugs  with or 
without induction.  O ptimal combinations of th erapies must be individualized based on the risk 
and benefit for each individual recipient ( Bia et al 2010 ).   
The contemporary standard of care (SoC)  maintenance regimen is based on a calcineurin inhibitor 
(CNI), such as cyclosporine (CsA, Neoral) or tacrolimus ( TAC, Prograf) which inhibits T -cell 
activation, in combination with a T -cell proliferation inhibitor. CNIs  are generally considered the 
primary immunosuppressant or “corner stone” of the immunosuppressive regimen.  Immunosuppressive drugs which are typically paired with a CNIs include antiproliferative agents such as mycophenolic acid (MPA) based drugs (Mycophenolate Mofetil ( MMF ), CellCept or 
Myfortic) which block inosine monophosphate dehydrogenase (IMPDH) or mTOR inhibitors such 
as sirolimus (rapamycin, Rapamune) or everolimus (Certican/Zortress).  In addition to a CNI (e.g., 
TAC)  and an ant iprolifera tive agent (e.g., MMF) corticosteroids are usually started  in the 
peri-transplant period and continued post-transplant in a triple therapy  standard of care regimen .  
CNI based standard of care regimens have resulted in excellent one- year patient and graft survival 
rates  of 94.7% for deceased donor kidneys and 98.1% for living donor kidneys in the U nited 
States  (US), with low (7 -8%) one -year acute rejection rates ( Hart et al 2020 ). However, use of 
currently available immunosuppressive drugs is still limited by mechanism- based side effects and 
poor long- term graft and patient survival.  Side effects such as hypertension, dyslipidemia and 
diabetes as well as gastro -, hematologic -, neuro- and nephrotoxicity are common and result in poor 
long- term patient survival.   
Induction therapy use varies based on recipient risk and regional preference. T here are two broad 
categories of induction therapies, lymphocyte -depleting antibodies, such as polyclonal rabbit 
anti-thymocyte globulin ( ATG, Thymoglobulin) and nondepleting monoclonal antibodies such as 
basiliximab (Simulect) and formerly daclizumab (Zenapax; withdrawn from US in 2009) that 
inhibit T -cell activation ( Hardinger et al 2013 ).  In the past , the lymphocyte depleting murine 
anti-human CD3 mAb, muromonab- CD3 (O rthoclone; OKT3, withdrawn 2010) and humanized 
anti-CD52 antibody alemtuzumab (Campath / Lemtrada) have sometimes been  used (off- label ) in 
high- risk transplant patients .  Currently, in the US , lymphocyte -depleting antibodies are 
increasingly favored for induction (7 3.6% of adult renal transplants) over IL -2 receptor antagonists 
(IL2-RAs; 20 .6%) (Hart et al 2020 ) whereas almost an inverse use of ATG and IL2- RA is se en in 
Europe (EU).   
ITB-MED   Page 21 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
1.1.1  Transplant Induction T herapy  
Basiliximab is a non -depleting, chimeric murine and human monoclonal antibody that specifically 
targets CD25, or the IL -2 receptor (IL2 -RA), on the surface of T -lymphocytes.  Administration of 
basiliximab in the peri -transplant time period inhibits IL -2 mediated lymphocyte activation, a 
critical signaling pathway involved in allograft rejection.  Basiliximab is generally well tolerated 
with minimal toxicities or infusion reactions and does not result in lymp hocyte depletion.  When 
combined with a CsA, MMF , and corticosteroid -based  (CS) immunosuppression regimen 
clinically relevant suppression of IL2 receptor activity following basiliximab administration is 
approximately 59 ±17 days ( Simulect PI 2018).  
ATG is a polyclonal mixture of chimeric (rabbit / human) immunoglobulins derived from the 
serum of rabbits inoculated with human thymocytes.  The precise mechanisms underlying the therapeutic efficacy of ATG  are not entirely known, although T -cell depletion p lays a critical role. 
Quantitative analysis by Popow and colleagues demonstrated that ATG is largely comprised of 
T-cell specific antibodies to CD2 (7.5%), CD4 (1.2%) and CD8 (14.3%).  In addition, a high 
proportion of antibodies to cell surface markers li ke CD11a/CD18 and CD45 that are broadly 
expressed on all leukocytes as well as antigens expressed on endothelial cells and cells of non-hematopoietic origin like CD98, CD99, CD147 and MHC class I ( Popow et al 2013) .  Th is broad 
expression of pleiotropic antibodies has been linked to the exaggerated pharmacology and off -
target toxicities  expected with ATG administration . In addition, both in vitro  and in vivo  studies 
have suggested a number of other possible ATG mechani sms, including lymphocyte surface 
antigen modulation and transcription factor activation. ATG may disrupt immune cell processes, 
such as cytokine production, chemotaxis, endocytosis, stimulation and proliferation, as well as leukocyte- endothelial cell adhesion. Finally, ATG  may also promote cell death via the induction 
of apoptosis, antibody-dependent cell-mediated cytotoxicity  (ADCC) and complement -mediated 
cytolysis (CDC)  of various immune cells ( Andress et al 2014) Considering the profound 
immunologic consequences of complete, long- term, lymphocyte depletion, polyclonal induction 
with ATG is not a benign therapy.  The benefits of reduced acute rejection rates can come with the 
risks associated with over -immunosuppres sion and mechanism -based side effects. A course of 
ATG induction results in profound lymphocyte depletion for >12 months with slow recovery and 
inversion of CD4/CD8 populations that can take an additional 2- 3 years to reach pre-transplant 
levels ( Hardinger et al 2004 ).  Mechanistic side effects such as infusion reactions, cytokine release 
syndrome, increased risk of infections and post -transplant lymphoproliferative disorder (PTLD) 
have also been reported with ATG administr ation.  
Lymphocyte- depleting agents are primarily used in patients with immunologic risk factors for 
acute rejection . Whereas  IL2 receptor antagonists (IL2 -RA) and induction- free regimens are 
primarily utilized in patients with low immunologic risk ( e.g., living donor renal transplant) 
(Hardinger et al 2013). The current Kidney Disease Improving Global Outcomes (KDIGO) 
Transplant Work Group guidelines recommend IL2- RA as a first -line induction agent in all types 
of donor -recipient profiles to reduce risk of acute rejection and allograft loss. These 
recommendations are primarily  based on a meta- analysis that predominantly used 
cyclosporine- based maintenance immunosuppression ( KDIGO 2009 ). A recent retrospective 
analysis by Tanriover  and colleagues assessed the use of induction therapy in living donor renal 
recipient s on immunosuppression with TAC/MPA ±  prednisolone (PRED) (assessment period 
ITB-MED   Page 22 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
2000–2012).  Their conclusions were (i) There was no benefit from use of IL -2RA induction versus 
no induction in patients maintained on TAC/MPA/PRED with respect to acute rejection or graft 
survival (ii) ATG use was associated with 22% (combined with steroids) and 27% (in the setting 
of steroid withdrawal) reduction in the risk of acute rejection compared with IL -2RA in this 
population. ( Tanriover et al 2015).  
Overall, antibodies with a high specificity for single T -cell receptors (TCR) and low 
immunogenicity, such as s iplizumab , may present an opportunity to develop very specific and 
substantial immunomodulation in the immediate post-t ransplant time period. Considering the 
efficacy of ATG and safety profile of basiliximab, developing a therapy that targets and modulates 
the various T -cell clones without the indiscriminate lymphocyte activation  and depletion, could be 
useful in bridging the gap between these two therapies.  
1.1.2  CD2 Biology  
Human  CD2  (also known as LFA -2, for  leukocyte function- associated  antigen -2) is a monomeric 
transmembrane glycoprotein of 45–50 kDa. CD2  is expressed early during human thymocyte 
development and is found on about half of thymocytes, thymic B -cells, NK cells and almost all 
mature peripheral T -cells.  CD2  functions as an intercellular adhesion molecule, binding to its 
ligand LFA -3 (CD58) in humans with high affinity.  Human LFA -3 is a surface glycoprotein that 
contains two extracellular Ig -like domains and is expressed on B- cells and antigen presenting cells 
(APCs); particularly macrophages.  
The CD2 -CD58 complex functions as an intercellular adhesion complex, forming a conjugate  and 
induced a conformation change.  The formation of the conjugate gives the T -cell receptor  (TCR ) 
a longer interval to scan various  peptide- major histocompatibility complex  (pMHC ) combinations 
presented by the APCs , determine if a match has been made, and, if so, complete the intracellular 
signaling and co- stimulation necessary for T -cell activatio n (Springer et al 1987; Davis and van 
der Merwe 1996; Seed and Aruffo 1987 ). The interactio n of CD58 with CD2 has been found to be 
essential for the activation of cellular immunity, such as CD8+ cytotoxic T -lymphocytes and NK 
cell-mediated cytotoxic reactions ( Rölle  et al 2016 , Leitner et al 2015 ). In addition, CD2 is 
up-regulated on both activated and memory T -cells while CD58 -ligation to CD2 activates NK and 
dendritic cells, lowers the threshold for T -cell activation and enhances T -cell responsiven ess to 
pro-inflammatory cytokines such as IL -12 (Lo et al 2011) .  Furthermore, CD2 -ligation of B -cell 
specific CD58 induces the upregulation of CD40 expression, suggesting that CD2 may also play a role in the stimulation and/or d elivery of T- cell help to B- cells.  
1.1.3  TCD601  (siplizumab) : Mechanism of A ction  
Siplizumab  (TCD601; previously known as MEDI -507) is a non- agonistic, humanized, anti -CD2 
monoclonal antibody of the IgG1κ class.  Siplizumab binds to a unique epitope on human CD2, distinct from the CD58 binding site, with high affinity (kd – 5 nM), inhibiting co-s timulation and 
T-cell activation.  In addition, the Fc portion of the siplizumab antibody binds to Fc γR receptors 
on NK cells resulting in ADCC  and antibody- dependent cellular phagocytosis  (ADCP) mediated 
depletion of CD2+ lymphocytes.  S iplizumab also dem onstrates selective immunomodulatory 
activity with depletion of memory T -cells (Tmem; high CD2 expression) and sparing of regulatory 
T-cells (Treg; low CD2 expression) in vitro  and in vivo  based on the differential expression of 
ITB-MED   Page 23 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
CD2 on lymphocytes . Conside ring this activity, siplizumab is expected to modulate T -cell memory 
and immune reactivity in the setting of transplantation . For complete information on the  mechanism 
of action ( MoA ) please refer to the latest edition of the siplizumab  Investigator’s Brochure  (IB). 
1.1.4  Relevant Data Summary  
Data regarding the pharmacology, toxicology, pharmacokinetics (PK), and pharmacodynamics 
(PD) activity of siplizumab have been obtained from in vitro  experiments, non- clinical studies and 
clinical trials  in 779 patients .  Siplizumab only cross -reacts with one non- human primate species, 
the chimpanzee ( Damschroder et al 2004 ). Key results relevant to this trial are highlighted in this 
section. For  complete information on these studies please refer to the latest edition of the siplizumab  
Investigator’s Brochure  (IB).  
1.1.4.1  In Vitro Pharmacology  
Tissue cross- reactivity of siplizumab was assessed in human tissues.  Siplizumab binds to CD2 
bearing cells including human lymphoid tissue and T -cell rich regions of thymus, lymph node, 
spleen, tonsil, stomach as well as small and large intestine and lung tissue.  Siplizumab did not 
bind to other tissues, including reproductive organs  and neur al tissues , that do not present the CD2 
target.  
In pharmacology studies, siplizumab induced lymphocyte hypo- responsiveness and T - and NK 
cell depletion in a mixed lymphocyte reaction (MLR) assay at concentrations of 50 ng/mL and greater ( Branco 1999).   Maximal depletion ( via ADCC) of CD2+ lymphocytes was measured with 
siplizumab concentrations between 10 and 100 ng/mL.  In vivo activity was further investigated 
in a human -xenomouse model  where weekly MEDI -507 administration for 6 months increased 
survival of mice bearing a CD2+ human adult T- cell leukemia (ATL) cell line .   
1.1.4.2  Toxicology Data  
Toxicology studies with single and multiple doses of siplizumab were conducted in primates 
(chimpanzees) and rodent models. Studies in rodents were conducted to assess off -target 
pharmacologic toxicity. In rats, after daily administration of MEDI -507 at 35 mg/kg or 70 mg/kg 
for 10 days, no gross or microscopic changes were observed.  The lack of cross -reactivity between 
rat an d human CD2 means this model cannot detect the on- target pharmacologic activity expected 
to exhibit in humans.   
To further explore the safety and pharmacologic activity of siplizumab, one single and three 
repeated dose toxicology studies  were conducted in chimpanzees.  All animals were administered 
one (0.143 mg/kg) to three, IV doses of 0.143, 0.43, 0.60, 1.43 or 5 mg/kg MEDI-507. Following doses up to 1.43 mg/kg MEDI -507, 4/7 animals presented with a transient, acute, toxic event (e.g., 
brief apnea, respi ratory symptoms or seizure activity) around the time of the first infusion.  All 
animals recovered within 24 hours and symptoms did not re occur upon re -challenge. With the 
highest dose, 5 mg/kg MEDI -507, animals (n=2) presented with symptoms of mild/modera te 
hypotension and diarrhea following the first dose.  Symptoms in both animals resolved within a few hours and did not recur on subsequent administrations, resembling an infusion reaction.   
ITB-MED   Page 24 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
A mild, transient decrease in platelet count around the time of first infusion was noted and 
attributed to activation of the reticuloendothelial system by large numbers of antibody- coated 
lymphocytes.  In addition, a mild, transient increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) w as noted at Day 7 that subsequently normalized by the next 
assessment on Day 42. Across all MEDI -507 treated animals, a rapid, dose -dependent depression 
in absolute lymphocyte counts and CD2- bearing lymphocyte subsets was noted by day 2; after the 
second dose. Recovery to pre-administration values occurred between 4- 8 weeks after MEDI -507 
administration. One animal that received MEDI -507 developed pneumonia of the right lung and 
died on study Day 29. On autopsy, it was noted that lymphoid tissues were atrophic, consistent with a treatment- related effect, however a causal relationship between the infection and MEDI -507 
administration was not certain as pneumonia can occur in this animal group. For additional details, please refer to the s iplizumab  IB. 
1.1.4.3  T eratog enicity and Reproductive T oxicology Data 
The reproductive/developmental toxicity profile of s iplizumab  has not been fully characterized. 
In consideration of the patient population and overall risk benefit profile, women of childbearing 
potential must utilize highly effective contr aception methods to avoid becoming pregnant while 
receiving s iplizumab  and fo r 24 weeks after the last dose.  
Women who are nursing may not participate in this trial. The washout period of 24 weeks after the last dose is justified based on predicted PK profiles at 5 mg/kg, where s iplizumab  is predicted to 
be fully cleared from plasma and tissues  by 12 weeks.  The additional  12 weeks is a safety margin 
to assure complete clearance of s iplizumab  and recovery of lymphocyte activity. 
Concomitant medication s may  present a separate reproductive risk and are to be used according to 
local g uidelines and label .  Please refer to original package leaflets  for complete information and 
guidance and the risks and potential toxicities of each concomitant medication .   
In addition, specific guidance on MPA can be located below. 
Mycophenolate ( MMF; mycophenolate mofetil or MPA; mycophenolic acid) is a confirmed 
teratogen associated with an increased rate of spontaneous abortion and congenital malformation 
compared with other immunosuppressants. M PA containing products carry a warn ing for female 
patients in the US and EU who may become pregnant  and must not be used during pregnancy 
unless there is no suitable alternative to prevent transplant rejection. Use during pregnancy is associated with increased risks of first trimester pregn ancy loss and pregnancy should be ruled out 
by use of a sensitive serum or urine test before starting mycophenolate ; confirmation immediately 
before starting the medicine is also recommended.  
Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning. Mycophenolate should not be used in women of childbearing potential unless they are 
using highly effective contraception. Some local labels for MPA recommend male contraception 
(condom). Due to the risks related to the drug’s use during pregnancy, a Risk Evaluation and Mitigation Strategy (REMS) program has been established in the US  for products containing 
mycophenolate and details pertaining to this program are provided in Appendix 4. 
ITB-MED   Page 25 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Please refer to local labeling and guidelines for the use of MPA in w omen of childbearing potential , 
including use of contraception and wash- out periods following discontinuation of MPA  containing 
products.  
1.1.4.4  Human Safety and T olerability Data 
In subjects, the safety, tolerability, PK  and PD activity of siplizumab has been investigated in 
clinical trials across 4 distinct patient populations with hematologic T -cell malignancies, acute 
graft -versus-host disease (GvHD) , psoriasis or following de novo renal transplantation.   
In clinical trials, single -and multiple doses of MEDI -507 from 0.0004 mg/kg to 15 mg/kg IV and 
0.1 to 10 mg subcutaneous (s.c.) have been administered to over 779 patients including 23 de novo 
renal transplant patients who have received mul tiple doses of 0.012 to 0.6 mg/kg. Across all patient 
populations, the most common adverse events  (AEs) reported following MEDI -507 administration 
included lymphopenia (Grade 1- 3) as well as a first dose effect manifesting as an infusion related 
reaction (Grade 1 -2; pyrexia, chills, nausea and fatigue).   
The decrease in lymphocytes is dose -dependent and expected based on the known pharmacology 
of siplizumab. For s ubjects who present with infusion reactions, the events were generally mild, 
transient and resolved spontaneously or were managed with nonsteroidal anti -inflammatory  drugs 
(NSAIDs ) and antihistamin es. Serious a dverse events  (SAEs) were reported more frequently in 
patients with lymphoma and GvHD; including 36 deaths  related to complications of GvHD  
and  9 cases of EBV -LPD .  In renal transplant and psoriasis patients, a total of 59 SAEs were 
reported in 47 patients. There was one death in a renal transplant patient reported as a complication 
of a post-transplant cardiac procedure not related to MEDI-507 administration.   
1.1.4.5  Human Pharmacokinetic Data 
Siplizumab pharmacokinetics  have been characterized with doses from 0.06 to 4.8 mg/kg in 
patients with T -cell lymphoma , psoriasis as well as patients following de novo renal 
transplantation .  The disposition of s iplizumab  was mainly the consequence of its interaction 
(i) through the Fc region and FcRn receptor (a high- capacity  receptor responsible for IgG 
homeostasis by recycling/salvage), and (ii) through the  Complementarity  – determining  regions  
(CDR ), to CD 2 expressed on T-c ells, leading to receptor mediated clearance.  As with all IgG 
monoclonal antibodies, the primary route of elimination of s iplizumab  is via proteolytic 
catabolism, occurring at sites that are in rapid equilibrium with plasma.  S iplizumab  also binds to 
Fc receptors  on NK cells resulting in T- and NK -cell deplet ion via ADCC or ADCP mechanisms  
and subsequent clearance of drug via target -mediated drug disposition ( TMDD) .  In addition to 
depletion of CD2- bearing lymphocytes and proteolysis, binding and internalization of 
siplizumab -CD2 complexes all results in rapid and saturable routes of clearance.  
Siplizumab pharmacokinetics in renal transplant patients  can be described by a 1- compartment 
model with 2 parallel mechanisms of clearance, linear and Michaelis -Menten (MM) elimination . 
Siplizumab binds to FcRn receptors in vitro  with an EC50 of 273.3 nM (0.04 µg/mL) . Upon 
saturation, linear FcRn mediated recycling and standard IgG clearance dominates as expected.  
However, at concentrations below ~1.7 μg/mL (MM K M EC50 0.34 µ g/mL ), TMDD elimination 
ITB-MED   Page 26 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
is the dominate clearance pathway and results in an inflection  point and transition to very rapid 
clearance. 
Preliminary mo deling of the limited PK/PD data available in renal transplant patients  and T -cell 
lymphoma patients suggests a strong population effect on the pharmacokinetics of siplizumab 
(MEDI -507).  In renal transplant patients , the apparent PK half-life (T1/2) is 8.5 days .  In lymphoma 
patients, where there is an abundance of CD2+ lymphocytes and CD2 target to which siplizumab 
can bind, a higher clearance and shorter T 1/2 has be en estimated of approximately 4.75 days . The 
primary difference  is inflection point concentration at which linear clearance transitions to a more 
rapid clearance.   In T-cell lymphoma patients, this transition occurs at a concentration ~40-fold 
higher (15 µ g/mL)  than renal transplant patients (0.35 µ g/mL) .  
1.1.4.6  Human Pharmacodynamic Data 
The primary PD  markers measured across study populations are related to peripheral T -cell counts 
and CD2 receptor occupancy. In study MI -CP027, which enrolled de novo renal transplant 
patients, the 0.06 and 0.12 mg/kg doses were pharmacologically active with a short half -life of 
14-49 hours and loss of PD activity (rapid lymphocyte recovery) and around Day 8 as illust rated 
below ( Figure 1-1).  
Figure 1-1 Mean CD3 lymphocyte profile following siplizumab (MEDI -507) administration in 
study MI -CP027  
 
SOURCE: MI -CP027; Mean (+/ - standar d error) CD3 lymphocyte phenotypes by dose level at day 1 pre- infusion and 
at days 2 (P= 0.027), 3 (P= 0.016), 8 (P= 0.17), 33 (P = 0.21), and 60 (P = 0.20).  
Note: N = 4 (0.012 and 0 .06 mg/kg ); N = 5 (0.12)  
 
In Study MI -CP099, conducted in T -cell lymphoma patients , doses from 0.4–4.8 mg/kg of 
siplizumab were administered as 1–3 consecutive daily doses every 14 days for 1–8 cycles.  As 
presented in  Table 1 -1, depletion of CD4, CD8 and NK cells is near complete with a 4.8 mg/kg 
administered every 2 weeks  achieving ~97% suppression of circulating peripheral T -cells and 90% 
suppression NK cells.  

ITB-MED   Page 27 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Table 1-1  Peripheral CD4, CD8, and NK cell depletion following siplizumab (MEDI -507) 
administration in patients with CD2 Positive T -cell lymphoma in Study MI -CP099  
1.2 Study Purpose 
The purpose of this study is to investigate the safety, tolerabilit y, pharmacokinetics  and 
pharmacodynamics  of escalating doses of TCD601 ( siplizumab ), an anti -CD2 monoclonal 
antibody, compared to a rabbit polyclonal anti -thymocyte globulin ( rATG ), as induction therapy  
in de novo renal transplant patients . All subject s will receive the same standard of care (SoC) 
background immunosuppression.  This trial will focus on profiling the safety, tolerability, PK  and 
PD activity of siplizumab  in the setting of standard-of- care immunosuppression in a moderate 
immunologic risk renal transplant  population.  
Overall, results of this study will be used to inform the siplizumab  dose and regimen selection for 
investigation in later phases of clinical development and serve as proof -of-principal study in the 
replacement of SoC, polyclonal, T-cell depleting induction therapy.  Dose and regimen  N CD4(%)  CD8 (%)  NK (%)  
Multiple Doses Q2 weeks      
0.6 mg/kg (0.2 mg/kg X 3)  3 88.5 81.3 68.3 
1.2 mg/kg (0.4 mg/kg X 3)  4 64.3 76.3 81.3 
2.4 mg/kg (0.4, 0.8, 1.2 mg/kg)  3 87.1 84.9 92.2 
3.4 mg/kg (0.4, 1.2, 1.8 mg/kg)  3 96.2 75.1 92.2 
4.8 mg/kg (0.4, 1.8, 2.6 mg/kg)  3 97.1 96.4 89.7 
Single Dose Weekly      
3.4 mg/kg  3 98.9 94.2 73.4 
4.8 mg/kg  1 NA NA NA 
N= subjects  
SOURCE:  MI-CP099 CSR; Reported percentages are the amount of depletion i.e., 90% would represent 10% of 
baseline lymphocytes remain in the peripheral circulation.  Mean due to variability; Multiple  dose arms, total dose of 
0.6-4.8 mg/kg administ ered over 3 days i n divided doses as indicated.  
ITB-MED   Page 28 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
2 Objectives and Endpoints  
Table 2-1 Objectives and R elated Endpoints  
Objective(s)  Endpoint(s)  
Primary Objective  Endpoints for primary objective  
To assess the safety, tolerability, PK and PD of siplizumab 
compared to rATG , in de novo renal transplant recipients at 12 
months post -transplant.  • Adverse events  
• Serious adverse events  
• Clinically significant changes in clinical 
chemistry, hematology, vital signs, serology  
• siplizumab PK  
• Immunophenotyping  
• CD2 RO  
• eGFR via MDRD  
Secondary Objectives Endpoints for secondary objectiv es 
Exploratory Objectives Endpoint s for exploratory objectives • To measure changes in peripheral lymphocyte immunophenotype  
• To measure the time -course and duration of siplizumab  
induced lymphocyte depletion and time to recovery  
• To measure peripheral CD2 -receptor occupancy  following 
siplizumab  administration over time  
• To assess the incidence of treated biopsy proven acute rejection (tBPAR) at 12 months  
• To assess the incidence of treatment emergent de novo , 
donor specific antibodies (DSA) at 12 months  
• T o assess the incidence of antibody meditated rejection at 12 
months  
• To assess renal function via eGFR  using MDRD equation at 
Months 3, 6, 12 or EOS  • Immunophenotyping via FACS  
• Lymphocyte counts  
• CD2 RO  
• Anti-siplizumab Ab  
• Incidence of BPAR 
• de novo-DSA  / anti -HLA antibody  
measurement  
• incidence of AMR 
 
•  
 
 
  
  
 
  
 
   
  
 
   
  
    
  
  
  
  
  
 
  
  
 

ITB-MED   Page 29 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
3 Study D esign  
3.1 General Overview  
The TCD601B102 study is a 12-month, randomized, controlled, open- label , dose escalation study 
to evaluat ing safety, tolerability, pharmacokinetics and pharmacodynamics of an anti -CD2 
monoclonal antibody, siplizumab , compared to anti-thymocyte globulin (rATG), as induction 
therapy in de novo  renal transplant recipients. All subjects  will receive background 
immunosuppression with standard exposure tacrolimus (TAC), mycophenolate mofetil (MMF) 
and corticosteroids (CS).  
Up to 24 moderate immunological risk, de novo renal candidates  will be enrolled into the study.   
Figure 3-1 TCD601B10 2 Study Design  
 
 
During the screening period (Day -28 to - 1) and after informed consent has been signed, baseline 
subject information will be obtained in accordance with local regulations, including date of birth 
(month and year), age, sex (with childbearing status for females), race and ethnicity. In addition, relevant medical history (including CKD, ESRD and dialysis history)  and current medical 
conditions at screening, a physical examination, vital signs, laboratory assessments, and a pregnancy test for female subjects of child -bearing potential will also be obtained.   

ITB-MED   Page 30 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Transplant procedures will also include information on the renal transplant procedure, recipient 
and donor transplant background, recipient and donor viral serology and recipient/donor HLA  
testing results.  
Procedures performed prior to consent as part of medical standard of care may be considered in 
the determination of subject eligibility (e.g., HLA/ABO typing, laboratory results). Additionally, if the screening and study Day 0 visits occur in close proximity (i.e., within a 24- hour timespan), 
screening assessments are not required to be repeated.  
Day 0 is defined as the day of transplant/day of first dose  of study product . Upon confirmation of 
eligibility for the study,  and no later than Day 0 (Day of Transplant), the subject will be randomized 
and assigned a treatment number within the electronic data capture (EDC) System/Interactive Web 
Response System (IWRS). Every effort should be made to randomize the subject on Day 0, but when logistical considerations prevent this from occurring ( e.g., central pharmacy requirements), 
the subject may be randomized up to 24 hours pre-transplant.  
Eligible subjects will be sequentially assigned to one of two  Cohorts (A or B ) using a time -lagged 
dose es calation methodology as illustrated in Figure 3-2 below.  
Figure 3-2 TCD601 B102 Treatment Regimen  
 
Within each Cohort, it is planned that 12 subject s will be randomized between siplizumab (at two  
dose levels, increasing per Cohort as above ) or rATG  control, in an 8: 4 ratio prior to renal 
transplantation on Study Day 0, as outlined in Table 3-1. 
Table 3-1 Dosing Regimen   
Cohort  Arm Subjects (n)  Product  Dosing Regimen  
Cohort A  Arm 1  8 Siplizumab  0.2 mg/kg (Days 0 and 4)  
Arm 3 4 rATG  1.5 mg/kg (Day 0, 1 and 2)  
Cohort B  Arm 2  8 Siplizumab  0.6 mg/kg (Days 0 and 4)  
Arm 3 4 rATG  1.5 mg/kg (Day 0, 1 and 2)  
Subjects randomized to receive  siplizumab  will receive two intravenous (IV) doses on Days 0 and 
Day 4 post -transplant. T he first dose  will be administered intravenously, peri-operatively and must 
be completed prior to revascularization and perfusion of the allograft . The second and final dose 
of siplizumab  will be administered intravenously on Day 4 post-transplant (Study Day 4) .  Subjects 

ITB-MED   Page 31 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
randomized to the r ATG control arm (Arm 3) will receive three intravenous (IV) doses of 
1.5 mg/kg on Days 0, 1 and 2, regardless of Cohort assignment. 
Siplizumab and rATG  will be combined with  concentration -controlled TAC  (BID) dosing to a 
whole blood trough concentration 4- 11 ng/mL , and MMF or  equivalent ( BID), and should be 
started within 24 hours post -transplant. Subjects will also receive CS per local practice with a 
minimum of 5.0 mg/d prednisone or equivalent until Month 12.  Dose escalation  from one Cohort to the next  will be determined 28 days following the last 
investigational product administration in the 4
th siplizumab treated subject in each treatment 
Cohort and prior to dose escalation to the subsequent Cohort, a  review  of all available safety, 
tolerability and PD data  will be conducted by ITB -MED in collaboration with the Investigators.  
This 28- day safety period allows sufficient time for  subjects to reach full -receptor occupancy, 
maximum pharmacodynamic activity, and for the presentation of acute , drug related toxicities.  
In the event  there is no evidence of acute, dose limiting toxicity  (DLT), randomization to the next 
dose level may be initiated . Alternatively, a decision to terminate the dosing arm could be reached.  
It is also possible for additional and/or intermediate dose level to be added during the course of 
the study per amendment  (See Section 13.4.4). Cohorts may be added at any dose level below the 
maximum tolerated dose in order to better understand safety, PK or PD. 
This escalation data review will be repeated prior to dose escalation/termination decisions for each 
Cohort.  The review of subject dat a and dose escalation may occur before all subjects have been 
randomized to a given Cohort.  If the next dose level is opened to subject assignment, Cohorts will 
be back filled to achieve a final sample size of 12 subjects.  
Dose escalation will be based on  a priori  defined criteria outlined in Section 6.2.8. 
In addition to the review of data for dose decision purposes as noted above, an independent Data 
Monitoring Committee (DMC) will conduct an ongoing review of cumulative PK, PD , safety , 
Adverse Events  (AEs ) and Serious Adverse Event (S AE) data as well as EBV -viral load and PTLD 
surveillance results , including clinically relevant changes on physical exam and clinical laboratory 
assessments and ad hoc imaging. The Committee will convene on a quarterly basis or as described 
in the DMC Charter. If at any time the  observed AEs meet or exceed the a priori -defined stopping 
criteria , the study will be placed on hold pending a review as outlined in Section 9.1.1. 
Additionally , a formal interim analysis will occur once 50% of subjects assigned to the treatment 
Cohorts complete their 6-month study assessment.   
This formal interim analysis will be conducted to assess the safety/tolerability (e.g., AEs , SAEs , 
clinical laboratory ass essments, vital signs, PK data and PK/PD activity (e.g., immunophenotyping 
and CD2 receptor occupancy).  The analysis will also include assessment of biopsy proven acute 
rejection (BPAR), graft losses deaths, and key safety endpoints. In the event the acute  rejection 
rate exceeds a clinically relevant threshold set forth in the protocol and DMC charter, or the a 
priori  defined stopping rules, enrollment will be suspended to allow for the early termination of 
any treatment cohort where the benefit/risk of sip lizumab  is deemed unacceptable.  
Following transplantation, subjects should be treated post -operatively per standard-of- care clinic 
practice and per the assessments outlined in the protocol. Following discharge  from the hospital 
ITB-MED   Page 32 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
and unless more frequent cli nic visits are required for laboratory specimen collection, subjects  will 
present to the clinical site for study visits weekly up to and including Week 10 and then monthly 
through Month 12 or EOS, and as outlined per the Schedule of Assessments  outlined in  
Appendix 1.   
All randomized subjects are expected to continue in the study up to Month 12 regardless of being 
on or off assigned treatment. Subjects  who are randomized but not transplanted or administered 
their first dose of s iplizumab  will be replaced.  
4 Study Design  Rationale  
The goal of induction therapy is to prevent acute rejection during the early post-transplant time 
period by providing a high degree of immunosuppression at the time of transplant surgery and 1 -2 
months thereafter. Escalating doses of s iplizumab  will be administered in place of SoC (e.g., 
rATG) induction therapy in combination with a TAC/M MF/CS based treatment regimen .   The 
time course , depth and duration of lymphocyte depletion and immunomodulation will be profiled 
in combination with the assessment of safety, tolerability, PK and PD activity .  CD2 represents a 
unique target for induction considering the broad expression and function in T- cell activation, 
co-stimulation  and alloantigen recognition. This trial will characterize the safety, tolerability, PK 
and PD activity of 0.2 mg/kg and 0.6 mg/kg siplizumab in comparison to rATG induction, in the 
setting of de novo renal transplantation .   
Siplizumab  will be administered in two  separate IV infusions over a ~5-day time period. The first 
infusion will be administered on study day 0 at the time of  transplant (pre- or intra -operatively) .  
The infusion is to be completed prior to revascularization and reperfusion of the allograft to assure 
both donor and alloreactive T -lymphocytes are suppressed and depletion is initiated in the hours 
and days post-transplant.  The second dose will be administered on post-operative Day 4. PK and PD data will be analyzed during the trial and the Population PK/PD model will be revised 
after each dose escalation  to predict the concentration- exposure- response for the next dose  as 
appropriate . Overall, the escalation scheme is designed to colle ct data and measure siplizumab 
concentrations that demonstrate a positive benefit/risk profile while providing approximately 
45 days of T- cell and NK -cell suppression and immunomodulation.  
The randomized, controlled, open-label, dose escalation design selected for this multicenter study will allow for a cautious asses sment and evaluation of the multiple dose s iplizumab  safety, 
tolerability, PK and PD when added to TAC/M MF/CS based treatment  regimen  in comparison to 
standard of care induction with rATG.  
Although the ideal study would employ a double -blind, double -dummy methodology to minimize 
bias, in consideration of the inherent complexity of this study (multiple  arms, frequent visits, 
siplizumab  PD activity, interim assessment after each dose , the diff erent  dosing schedules of 
siplizumab and ATG and extensive investigations), it has been decided to utilize an open- label 
design. This open- label design will not only minimize the risks for s ubjects  during the initial 
investigation of s iplizumab  should the need for rapid intervention arise, such as emergent SAEs, 
but also avoids the additional difficulties associated with placebo infusions in the control group. It 
is recognized that Investigator bias can affect the management of subject s receiving investigat ional 
ITB-MED   Page 33 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
treatment; especially in an open -label study setting. In general, such scrutiny biases the study in 
favor of the control arm. As such, efforts to minimize bias for or against the s iplizumab  treatment 
arms will be managed through the use of a limited number of high- quality transplant centers with 
similar SoC and subject  management.       
Due to the unknown tolerability and PD activity, t his study will enroll a moderate immunological 
risk de novo patient population who would typically be treated with ATG induction. This 
population was selected since they typically present a lower  risk of post -transplant complications, 
including delayed graft function (DGF) and provide a fair assessment of clinical activity while not 
requiring the highest level of i mmunosuppression. While it is recommended per current KDIGO 
guidelines, that ALL renal transplant patients receive induction with anti -IL2R therapy ( KDIGO 
2009), due to the expected overlapping activity with s iplizumab , inhibition of T -cell activation, 
anti-IL2R or other T -cell depleting induction (e.g., ATG) will not be allowed in combination with 
siplizumab in this trial. In the setting of acute rejection prophylaxis with induction or no induction 
in the planned study population, the risk of ‘ omitting ’ SoC  induction is manageable. Without 
induction and SoC therapy (TAC, MMF  and CS) 12-month BPAR rates of 12.4% and 13.3% for 
living and deceased donor allografts have been reported, respectively ( Tanriover 2015). These 
rates (BPAR) are similar to those in patients treated with anti-IL2 induction of 11.7% and 12.4%, respectively in the same population ( Tanriover 2016).  
Overall, safety risks will be reviewed on a regular basis by ITB-MED  and an external  independent 
DMC , with particular attention given to acute rejection s, infusion reactions, serious infections, 
EBV -reactivation and malignancies associated to those (e.g., PTLD) . 
4.1 Dose/ Regimen and Treatment Duration Rationale 
While siplizumab (MEDI -507) has been administered to 779 subjects, the characterization of PK 
and PD activity following IV administration remains incomplete.  A n initial  population P K/PD 
model has been  developed based  on data collected in previous siplizumab (MEDI -507) trials in 
renal transplant, T- cell lymphoma, a GvHD and patients with psoriasis.  
The following section support s the rationale for the investigation of two siplizumab  doses via a 
two-dose regimen.  
As described in Section 1.1.4.5, siplizumab pharmacokinetics in renal transplant patients can be 
described by a 1- compartment model with 2 parallel mechanisms of clearance, linear and 
Michaelis -Menten (MM) elimination.  
Mean, predicted, time-concentration profiles  of the two -dose regimen planned in renal transplant 
patients  have been simulated and are  presented in Figure 4-1.  
ITB-MED   Page 34 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Figure  4-1 Mean predicted siplizumab  serum concentrations in study TCD601B102 : 0.2 and 
0.6 mg/kg  
 
Figure 4 -1:  Solid curves represent the mean predicted time- concentration profile of siplizumab following two simulated 
0.2 or 0.6 mg/kg siplizumab doses on Study Day 0 and 4 in de novo renal transplant patients.   
 
Siplizumab  concentrations  are predicted to increase in a dose proportional manner with me an 
Cmax (peak) concentrations of approximately  µg/mL  following the second dose of 0.2 
or 0.6 mg/kg on Study Day 4. The apparent  PK half -life is predicted to be ~  days at both doses 
with peak concentrations exceeding the TMDD inflection point of ~  µ g/mL.  
Dose escalation in the TCD601B102 trial will start with 0.2 mg/kg, which is 3-fold less than  the 
highest dose investigated in the setting of previous renal transplantation studies (0.6 mg/kg; 
Studies NKD03 and ITN036)  and ~1.7-fold higher than the 0.12 mg/kg dose investigated in the 
MI-CP027 renal transplant induction study.  A semi -log dose escalation up to 0.6 mg/kg will allow 
for adequate characterization of the PK/PD profile and investigation of lymphocyte 
pharmacodynamics. Importantly, all of the siplizumab doses proposed in this trial have been administered to subjects previously with good safety and tolerab ility, however due to the nature of 
the renal transplant population, cautious dose escalation will be conducted to ensure subject safety is managed closely during this trial.   
It is planned to administer  the first dose prior to revascularization of the allograft to ensure both 
donor and recipient alloreactive T -lymphocytes are rapidly suppressed and depletion is initiated 
within hours of allograft perfusion. It is expected that initial distribution within the periphery and 
various tissue compartments as well as ADCC mediated depletion of lymphocytes will result in enhanced siplizumab  clearance following the first dose. Therefore, a second dose of siplizumab  
will be administered on Day 4 with the intent of replenishing the free -siplizumab (TCD601) to 
account  for redistribution of CD2 bearing lymphocytes as well as maintain saturation of the TMDD 
clearance pathways ; maintaining  prolonged serum concentrations above the tissue and peripheral 
concentration  threshold of µg/mL.  

ITB-MED   Page 35 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Considering the apparent -day half-life predicted from previous trials in renal transplant patients 
(MI-CP027) and acute GvHD (MI -CP046) following bone marrow transplantation with 
siplizumab (MEDI -507) high serum concentrations will be required to prolong the peripheral 
immune modulation and T -cell suppression during the first month post -transplant; a time when 
patients are at the highest risk of acute rejection.  Based on current modeling presented in 
Figure 4-1 it is antic ipated that two doses of 0.6 mg/kg will result in ~30 days above the  µg/mL  
target.   While the 0.2 mg/ kg dose is not expected to provide the same duration of PK coverage, 
accounting for the post -depletion lymp hocyte dynamics and redistribution from lymphoid tissues , 
the pharmacodynamic activity induced by selective T -cell depletion is expected to persist 
following siplizumab clearance.   
While the duration of activity in renal transplant recipients is yet to be determined, PK/PD 
modeling planned prior to the dose escalation step will allow for a near real -time 
exposure- response analysis during the trial and modification of the escalation scheme or dosing 
regimen  per amendment .  
4.1.1  Siplizumab  Tissue Distribution / E ffect Compartment  
Recent characterization of monoclonal antibody distribution by Shah and Betts allows for the 
rational targeting of various tissue compartments based on the expected distribution of therapeutic antibodies as a percentage of the free plasma concentration ( Shah & Betts 2013) .  In the setting of 
solid organ transplantation, the peripheral (vascular) compartment is not the only location of 
alloreactivity. Acute cellular rejection occurs within the parenchyma and vasculature of the allograft.  Similarly, allorecognition occurs, to a large extent, in lymph nodes and secondary 
lymphoid tissues; therefore, these tissues represent an equally important compartment outside of the peripheral vasculature to target.  For renal tissue, an antibody biodistribution coefficient (ABC) 
of 13.7% of plasma concentration (CV% ( ± 3.10) was reported whereas the ABC for lymph nodes 
is 8.46 ± 11.4% ( Shah & Betts 2013).  
Completed siplizumab (MEDI -507) studies have assessed the effect of anti -CD2 therapy on 
peripheral lymphocytes and lymphocyte subsets as well as peripheral target saturation and binding.  It is expected that administering sufficient siplizumab  to achieve adequate exposure in both the 
peripheral and relevant tissue compartments will lead to more complete immune regulation. Based 
on the expected PD activity outlined in Section 1.1.4.6, where siplizumab concentrations of 
 µg/mL are required for adequate T and NK cell modulation and depletion, peripheral siplizumab 
trough (C0) concentrations  of   µg/mL  and  µ g/mL  would result in adequate target 
engagement and lymphocyte suppression in renal tissue and lymph nodes, respectively .  
As discussed in Section 1.1.4.5, population phar macokinetics  (PPK) modeling suggests that 
concentrations of siplizumab above the MM K
M of  µg/mL , which represents the EC50 
concentration , is necessary to maintain  saturation of the TMDD pathway a nd linear clearance in 
renal transplant patients.  T o maintain full CD2 RO , target engagement  and saturate clearance 
mechanisms , the relevant concentration is 3 -5-fold greater than the K M; a concentration of  
 µg/mL . This concentration is represented by the inflection point and transition from linear - 
to non- linear clearance, occurring around the  mg/mL concentration  range in the simulations . 
This concentration also represents a key threshold (  µg/mL ) for T -cell engagement and depletion , 

ITB-MED   Page 36 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
where maintenance of trough concentrations above the threshold in the periphery a re expected for 
approximately  following 0.6 mg/kg siplizumab  (Figure 4-2).   
Figure  4-2 Mean predicted, log -transformed, siplizumab  serum concentrations in study 
TCD601B10 2 following 0.2 and 0.6 mg/kg siplizumab  administration  
 
Figure 4-2: Horizontal dashed lines represent predicted trough concentrations at  ug/mL.   Solid curves 
represent the mean predicted time- concentration profile of siplizumab (semi-log scale) following two simulated 0.2 or 
0.6 mg/kg siplizumab doses on Study Day 0 and 4 in de novo renal transplant patients.   
 
Based on the known variability of siplizumab (MEDI -507) PK, and proposed target tissue 
concentration s, a mean minimum serum concentration above  µg/mL  would be required to 
maintain tissue concentrations above the  µg/mL  threshold to induce immunomodulatory activity 
in renal and lymph tissue, respectively. These concentration thresholds are represented as 
horizontal dashed lines in  Figure 4-2. It is expected that following the second 0.6 mg/kg dose of 
siplizumab  a short duration, above the tissue exposure threshold will be achieved.   
4.2 Rationale for Active Control 
In the completed renal transplant siplizumab  clinical trials, no controlled studies have been 
performed , therefore the comparative safety and efficacy data will allow for a better estimation of 
effect size and AE rates for future clinical trials in this population.  The use of a n active control 
arm was selected to allow for enrollment and randomization of a relevant  moderate immunologic 
risk patient population who would be generally treated with ATG induction therapy . In addition, 
the comparative safety , biomarker  and pharmacodynamic  data within the control population will 
facilitate  a more comprehens ive assessment of siplizumab  safety and tolerability  in comparison to 
SoC.  
ATG is the most frequently used depleting agent for induction therapy in solid organ 
transplantation. The use of r ATG (Thymoglobulin; Genzyme)  is more common in North Americ a 
compared to Europe. In Europe ATG- F (ATG- Fresenius ; Grafalon, Fresenius Biotech  GmbH, 
Munich, Germany ) is used for those deceased donor transplant recipients that are considered at 

ITB-MED   Page 37 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
risk for  DGF and may  be effective in reducing ischemia reperfusion injury in this setting 
(Guirado 2018).   
The mechanism of action of both ATG products is lymphodepleting, therefore there are 
mechanistic similarities a s well as diff erences between r ATG, ATG-F and siplizumab. The ATG  
products are both generated by immunization of rabbits but us e different immunogens, namely 
fresh human thymocytes  for ATG and a Jurkat T -cell line for ATG- F. Furthermore, the proportion 
of antibodies  directed  at CD2 in ATG has been estim ated as 7.5% ( Popow et al 2013) . However, 
ATG- F targets CD28, CD29, CD45, CD49, CD98, and CD147 but rarely targets  CD3, CD4, CD44, 
and HLA -DR, thus r ATG  and ATG -F may have different immunosuppressive activities  
(Song et  al 2020) , further supporting the restriction to r ATG in this clinical trial.   For these reasons 
rATG is considered an appropriate control for this  induction study. 
4.3 Rationale for Background Immunosuppression 
In adult de novo  kidney transplant recipients, the use of T AC, MMF and CS is an 
approved regimen for renal transplantation across the world and is the current SoC used in more 
than 90% of kidney transplants . Over  the past decade, the clinical use of CNIs , including TAC, 
has focused on minimization of the CNI to mitigate many of the associated adverse effects. Current 
clinical use of TAC with an MMF -based regimen and CS results in excellent graft and patient 
survival as well  as low rates of acute rejection. When T AC is combined with an MMF -based 
regimen and induction using an IL -2 antagonist, the labeled trough concentration range for T AC 
is 4-11 ng/mL (e.g., Prograf® PI 2019) ; this range will be employed in this clinical study.    
Similarly, MMF  or equivalent , at a dose of 1.0 g BID will be utilized per label (e.g., CellCept PI 
2019). 
For CS, all s ubjects  should receive a  minimum of  5.0 mg/d (prednisone or equivalent) from Day 0 
until Month 12 with administration according to local practice.   The use of immediate -release generic or equivalent medications for  TAC and MMF are all owed 
in the TCD601B102 study, however, substitution is not allowed for the first 12 months 
post-transplant.  All subject s who start on brand or a specific generic TAC and M MF are to be 
maintained on the same brand or generic for the duration of this trial.   For subject s who are inadvertently switched, or in the event of a drug shortage need to change  to 
another manufacturer , ITB-MED  is to be informed and the site should consider more intense 
therapeutic drug monitoring ( TDM ) to ensure the subject  achieves similar TAC con centrations.  
4.4 Purpose and Timing of Interim Analyses/Design Adaptations 
During the conduct of this study, ITB-MED and the DMC will review safety, PK and PD result s 
of the trial on an ongoing basis. A regular review of cumulative safety data, including as well as 
EBV -viral load and PTLD surveillance results, including clinically relevant changes on physical 
exam and clinical laboratory assessments  and ad hoc  imaging , biopsy proven acute rejection 
(BPAR), graft losses deaths, and key safety endpoints, will be conducted by ITB -MED . In the 
event safety endpoints or the acute rejection rate exceeds a clinically relevant threshold set forth 
in the protocol and DMC charter, or  the a priori  defined Stopping Rules  as outlined in 
ITB-MED   Page 38 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Section  9.1.1 are met, enrollment will be suspended to allow for the early termination of any 
treatment cohort where the benefit/risk of siplizumab  is deemed unacceptable.  
Formal  analyses to assess  PK, PD as well as safety will be performed as foll ows: 
• Escalation analysis:  After the first 4 siplizumab treated subjects  who have been enrolled 
in each cohort reach 28 days after the last  siplizumab infusion. 
• Interim analysis:  Once 50% of subjects assigned to the two treatment Cohorts complete 
their 6-month study assessment . 
The purpose of the Day 28 escalation  analy sis is to confirm progression to the next cohort  while 
the 6 -month interim analysis is to support PK/PD modeling activities  and clinical trial and dose 
escalation planning.  
4.5 Risks and Benefits 
The risk s and benefits are expected to be broadly similar to that of ATG in combination with SoC 
immunosuppression. In particular , the risk of increased infections  and first dose effect , will be 
minimized by adherence to the inclusion/exclusion criteria, premedication, close clinical 
monitoring and minimization of protracted siplizumab  exposure during treatment period. Infection 
risk will be mitigated by following applicable national vaccination guidelines and by use  of 
prophylaxis (See Section 6.5). Similarly, the risks of SARS -CoV- 2 will be minimized by following 
local, national and international guidelines for immunosuppressed and solid organ transplant 
patients (See Section 4.5.3).  
The risks of insufficient efficacy (higher rate of acute rejection -tBPAR than SoC ) will be 
minimized by enrolling a moderate immunologic risk patient population, frequent monitoring of clinical labs and signs and symptoms suggesting BPAR and the early discontinuation of any treatment arm that is unsafe or ineffective according to the Stopping Rules  detailed in 
Section  9.1.1.   
The below sections list the possible risks related to siplizumab  treatment. For further details please 
refer to Section 7 of the current IB.  
Information and guidance for the SoC treatment used in this study is provided in the local labelling 
information and should be strictly followed. 
4.5.1  S iplizumab  
Risks of siplizumab  administration include those generally associated with administration of a 
monoclonal antibody in humans. These include the possibility of a hypersensitivity reaction 
characterized by acute or delayed allergic reaction, anaphylaxi s, urticaria, rash, dyspnea, 
hypotension, fever, chills,  and immunogenicity. A serious infusion reaction that results in 
anaphylaxis is a rare event in monoclonal antibody therapy. S iplizumab  is a fully humanized 
monoclonal antibody of the IgG1 class. This  class of antibody is normally abundant in humans. 
Therefore, the antibody itself is expected to be less immunogenic in humans compared to chimeric or other humanized antibodies.  
Assays to detect a putative antibody response to siplizumab  are included in the study design. 
ITB-MED   Page 39 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
In consideration of the clinical  and non -clinical toxicology study results for siplizumab 
(MEDI -507) as well as clinical studies with antibodies that target CD 2, the potential risks of 
siplizumab  in humans may include: 
• Infusion reactions, inflammatory reactions  and cytokine release 
• Immunosuppression and infections 
• EBV -associated lymphoproliferative disorders  
• Other hypothetical risks 
These risks and an overall risk mitigation strategy are discussed below.  
4.5.1.1  Infusion and Inflammatory R eactions  and Cytokine Release  
Cytokine Release  
Siplizumab  is a non- activating humanized mAb that binds to CD2+ immune cells and rapidly 
eliminates them via ADCC therefore cytokine release syndrome may be observed  after 
administration. Cytokine release syndrom e is an acute clinical syndrom e and  has been te mporally 
associ ated with the ad ministr ation of  certain T-c ell depleting a ntibo dies, particularly  the murine 
anti-CD3 antibody, muromonab- CD3 ( Orthoclone- OKT3 ). Similar effects are noted with B -cell 
depleting antibodies such as rituximab ( Rituxan) . This syndrom e has been attributed to the release 
of cytokines by  activated ly mphocytes or monocytes. The clinical m anifestations have ranged from  
a more frequ ently repo rted m ild, sel f-limited, “ flu-like” illn ess to a less frequently reported s evere, 
life-threatening, shock-li ke reaction, which m ay include serious cardiovascular, pul monary and 
central  nervous system  manifestations. The syndrom e typically begins approxi mately 30 to 60 
minutes after ad ministr ation (but m ay occur later) and m ay persist for several hours. The frequency 
and severity of thi s symptom co mplex is usually greatest with the fir st dose. With each succes sive 
dose, both the inci dence and severity  of the syndrom e tend to di minish. Increasing the a mount of 
a dose or resu ming treat ment after an interruption m ay result in a reappearance of the syndrom e.   
A cytokine release event has not been reported in any subjects receiving s iplizumab  alone and in 
combination with other immunosuppressants to da te. However due to the target cell population, 
CRS remains a hypothetical risk . 
Infusion Reactions  
Infusion- related reactions, such a chills, pyrexia, and fatigue, have been commonly seen in 
siplizumab ( MEDI -507) treated patients with cancer, GvHD , psoriasis and following organ 
transplantation . These events have been m ild to m oderate in severity, tra nsient in n ature, and have 
not recurred  with re -challenge. Other associated events included nausea, vom iting, and 
hypotension. In the cancer studies, as prophylaxis for infusion type r eactions, patients have been  
premedicated with acetaminophen and diphenhydra mine before each siplizumab  infusion. 
Demerol has been  administered for treatment of patie nts with rigors. Chills without rigors have 
been ma naged with warm  blankets. 
ITB-MED   Page 40 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Inflammatory  Reactions 
Allergic reactions may present as mild pruritic rashes  or they may be severe such as erythroderma, 
Stevens -Johnson syndrome, vasculitis, delayed hypersensitivity or anaphylaxis.  
Anaphylactic reactio ns (anaphylaxis) are serious and occa sionally fatal hypersensitivity reactio ns. 
Aller gic reactions including anaphylaxis may occur when any fore ign protein is injected into the 
body. They m ay range from  mild manifestations such as urticaria or rash to lethal syste mic 
reactions. Anaphylactic reactions occur soon a fter exposure, usually within 10 minutes. Patients 
may experience paresthesia, hypote nsion, laryngeal ede ma, mental  status changes, facial or 
pharyngeal angioede ma, airway  obstruction, bronchospas m, urticaria and pruritus, serum sickness, 
arthritis, allergic  nephritis, glomerulonephritis, temporal arteritis or eosinophilia.  
Serious allergic events including anaphylactic or anaphylactoid reactions have been reported in 
patients re -exposed to antibodies derived from  foreign protein such as OKT3 or ATG. Since it can 
be very difficult to distinguish between cytokine release syndrome and anaphylaxis, extra caution must be ta ken. Reactions occurring within 10 mi nutes of the start of an infusion are usually 
anaphylaxis and  should preclude re -administration of the antibody. Vasculitides m ay occur, most 
commonly leukocytoclastic vasculitis or palpable purpura. 
4.5.1.2  Immunosuppression and Infections  
Siplizumab  is being developed for its expected immunomodulatory and T -cell depleting activity. 
CD2 ligation is linked to the functional activity of T -cell activation and co -stimulation.  T- cell 
depleting antibodies m ay be im munosuppressive and prolonged immunosuppression m ay increase 
the risk of infection, including opportunistic infections. Administration of es calating doses of 
siplizumab  is expected to result in general immunosuppression due to T - and NK-cell depletion 
when full receptor occupancy has been achieved.  Siplizumab induction will be combined  with 
background, CNI -based triple -therapy immunosuppression in renal transplant pa tients.  Subjects 
treated with siplizumab  may present with an increase  in the overall degree of immunosuppression 
from days to weeks depending on the dose and regimen as intended in induction treatment with 
SoC T -cell depleting antibodies.  During this time of immunosuppression subjects may be at a 
higher risk for infection.  
Vaccination of human subjects during treatment with siplizumab  and prior to clearance of the 
antibody is likely to result in ther apeutic failure ( i.e., non- protective antibody tite rs) (see 
Section  6.5) Administration of live attenuated agents should be avoided while receiving 
siplizumab  treatment and for up to 6 months thereafter, depending on the dose and time for 
reconstitution of immune function. In completed clinical trials with siplizumab there is n o clear evidence for a higher rate of infections 
associated with treatment administration.  Infections w ere com mon in Post- HSCT patients with 
Garde II- IV aGvHD where an increased risk of immunosuppression related opportunistic 
infections, including viral reactivation, is common.  In study MI-CP046 (adult GvHD), infections 
were common in both MEDI -507 (19 [90%]) and plac ebo control arms (12 [92%]). When the 
investigator’s assessment of relatedness is considered, all of the infection events are consigned to background. In oncology studies, infec tions occurred in 3/19 (16%) T-cell lymphoma patents 
ITB-MED   Page 41 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
(MI-CP099), with 5 patients (26%) testing positive for CMV antigen; three of whom discontinued 
treatment per protoc ol. In Study MI -CP107, 4 infection -associated SAEs (infection, respiratory 
syncytial virus, sepsis, and staphylococcal bacteremia) were reported in 4/22 (18.2%) of patients. 
One event (infection)  was judged by the Investigator as being related to MEDI -507. In the CD2+ 
T-cell lymphoma patient pool, there was no dose related increase in infection rates between arms, 
although there was an increase in EBV -related events; EBV -associated lymphoproliferat ive 
disease was reported in 9 patients treated across the T -cell lymphoma and aGvHD populations; 
see Lymphoproliferative Disorders and other Malignancies  in Section 4.5.1.3 for details .  
Assessing the rates of treatment emergent infections in a relatively healthy population, psoriasis, the placebo group was higher as compared to the siplizumab treated group.   
While the sample size in the renal transplant pool is limited, the reported infections were as 
expected , and none were suspected by the investigator to be due to siplizumab administration as 
presented in Table 4-1 below. 
Table 4-1 Renal transplantation pooled analysis: O pportunistic infections  
Standard or Custom MedDRA Query  
  Preferred  Term  IV: ≤ 0.12 mg/k g 
(n=13)  IV: > 0.12 mg/kg  
(n=10)  Total  
(N=23)  
Opportunistic Infection (CMQ)    2 (15.4%)    4 (40.0%)    6 (26.1%)  
Clostridium difficile colitis    0   2 (20.0%)    2 (8.7%)  
Gastritis    1 (7.7%)    1 (10.0%)    2 (8.7%)  
Gastroenteritis    0   1 (10.0%)    1 (4.3%)  
Herpes esophagitis    1 (7.7%)    0   1 (4.3%)  
Urinary tract infection    0   1 (10.0%)    1 (4.3%)  
Viral infection    0   1 (10.0%)    1 (4.3%)  
Source: Table 2.1.5.5 (Listing ADVERSE_EVENTS in CP027 study, ListingAE_LAA in NKD03 study, listing16_2_7_1 
in ITN036 study.; Abbreviations: CMQ = Custom MedDRA Query; SMQ = Standardized MedDRA Query; Note: 
MedDRA Version 22.1.  
4.5.1.3  Lymphoproliferative Disorders  
In patients at a hig h risk of lymphoproliferative disorders participating in studies with MEDI -507, 
specifically patients with CD2+ T -cell lymphoma and patients with ongoing acute GvHD 
following a bone marrow transplant, EBV -associated lymphoproliferative disorder ( LPD ), PTLD , 
and lymphoma have been reported. In the T- cell lymphoma trials (MI -CP099 and MI -CP107), 
EBV -LPD was reported in 5/51 (9.8%)  patients including large granular lymphocytic leukemia 
(LGL ; n=2), cutaneous T -cell lymphoma (n=1),  peripheral T -cell lymphoma  (n=1), and adult 
T-cell lymphoma (A TL; n=1) . In the aGvHD studies  EBV -LPD  (n=1), P TLD  (n=1) and 
EBV -related lymphoma  (n=2) was reported in 4/48 (8.3%) patients . In addition, t hree cases of 
LPD have been reported in Investigator -initiated and compassionate use studies of MEDI -507 in 
patients following bone marrow transplantation.   
All of the LPD  cases reported with MEDI -507 have been limited to two unique patient populations , 
both of whom had a history of malignancies and increased risk factor s for EBV -LPD, 
notwithstanding their primary T- cell lymphoma and a GvHD following BMT .  While rare, 
EBV -associated secondary hematological malignancies are not unexpected in the setting of 
profound immunosuppression associated with T -cell lymphoma where B -cell lymphoma rates vary 
ITB-MED   Page 42 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
from 2 -15% based on patient age, ethnicity and immune status ( Dojcinov et al 2018).  In the setting 
of HSCT, especially in patients who present with multiple risk factors ( Curtis et al 1999;  Uhlin et 
al 2014), PTLD, rates of 8% up to 40% have been reported ( Juvonen et al 2003).    
In the setting of renal transplantation, siplizumab use is not expected to increase the risk of 
EBV -LPD/PTLD o ver ATG- based induction in combination with background 
immunosuppression.  Independent adjudication of all 9 EBV -LPD cases was conducted to assess  
the overall risk of EBV -LPD in the setting of renal transplantation.  While a notable risk of 
EBV -LPD  in the setting of T -cell lymphoma was assessed by the committee  it was stated that 
experience to date does not demonstrate that this risk exceeds that as sociated with ATG . 
This rate in the US has been reported to be 1.03% ( Hart et al 2020 ) and as high as high as 2.4% 
with ATG induction (Thymoglobulin PI 2020).  The rate of EBV -LPD is known to be higher in 
patients who are EBV -seronegative with a relative risk up to 33- fold that of EBV+ recipients 
(Marks et al 2011).   Therefore, all recipients will be screened prior to administration of siplizumab,  
and EBV -seronegative subjects excluded from participating in the TCD601B102 clinical trial. In 
addition, clinicians who specialize in transplant immunosuppression, and are aware of the risks for 
EBV -LPD , will be managing patients enrolled in this study.  Regular assessments of hematology, 
EBV -viral load  as well as PTLD surveillance including full physical exams at each visit as well a s 
monitoring of clinical signs and symptoms will be conducted during the 12-month study. 
4.5.1.4  Other Hypothetical Risks  
Renal Dysfunction  
In two renal transplant tolerance studies, NKD03/ITN010ST (n=5) and ITN036ST (n=5) , a 
transient, acute kidney injury ( AKI) -like syndrome was reported in a majority (9/10) of patients 
early in the post -transplant course . The syndrome was associated with recovery of host 
hematopoietic cells and rapid loss of donor chimerism at approximately two weeks post -transplant 
and is better described as Chimeric Transition Syndrome (CTS). Patients in these two trials 
received siplizumab ( 0.6 mg/kg MEDI -507 on D ays -1, 0 and 1) in combination with a 
non-myeloablative, cyclophosphamide- based , conditioning regimen, thymic irradiation and 
rituximab pre - and post -transplant.  Patients also received a combined haploidentical bone marrow 
cell infusion to induce transient chimerism and a renal allograft from the same donor on Day 0.   
Patients with CTS presented with a significant increase in s erum creatinine (SCr) with onset 
around post-transplant day 10-14 that peaked ( SCr range 3.5 to 15.4 mg/dL) between days 10-20; 
resolving by day 30.  Renal biopsies taken during the CTS event were negative for T -cell mediated 
rejection but showed capillary endothelial injury with cellular infiltrates (CD8+ / CD68+ cells) in the peritubular and glomerular capillaries.  
Overall, 78% (7/9) of patients recovered normal renal function following the CTS event; 3 patient s 
recovered with minimal intervention (corticosteroid pulse) while 4 patients required treatment (Intrave nous Immunoglobulin ( IVIG ), ATG and/or plasma exchange).  The two remaining patients 
failed to recover full renal function; this include d one patient who lost their graft at day 10 due to 
severe antibody mediated rejection as well as a patient who presented with subsequent CNI toxicity 
and later progressed graft loss associated with thrombotic microangiopathy at Month 7. 
ITB-MED   Page 43 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Renal dysfunction, including significant changes in serum creatinine or eGFR has not been 
reported in other patient populations receiving siplizumab  alone or in combination with SoC 
immunosuppression , including 13 patients enrolled in study MI -CP027 following renal 
transplantation.  Patient’s serum creatinine, serum cytokines and renal injury makers will be 
measured frequently in the first few weeks post-transplant with a focus on renal injury and 
dysfunction.  I n addition, urinary injury biomarkers will be collected for future analysis and 
biopsies will be evaluated for CTS in the event patients present with BPAR.     
Maligna ncies 
Prolonged and sustained immunosuppression may result in an increased risk of developing certain 
types of cancer.  
In the T- cell lymphoma trials one patient with LGL developed a secondary leukemia (M4 type 
leukemia) one year after completing MEDI -507 therapy was reported . In the GvHD studies  a case 
of acute my eloid leukemia  relapse was reported.  
In the study of renal transplant patients, one patient experienced a basal cell carcinoma of the skin on an area of actinic exposure reported during long- term follow -up.  
Two patients in the psoriasis studies had secondary malignancies (squamous cell carcinoma of the skin and myelodysplastic syndrome ) following treatment with MEDI -507. Both patients had a 
prior history of these respective conditions and were entered into a MEDI -507 psoriasis study in 
violation of protocol entry criteria that excluded patients with a history of cancer (although in the latter case the condition was not disclosed at study enrollment).  
Adjunct Immunosuppression  
The combination of escalating doses of siplizumab  in the presence of adjunct immunosuppression 
with T AC, MMF , and CS is  not known. Please refer to the local labeling for the other agents for 
full disclosure of the expected risks associated with use in the setting of de novo  renal 
transplantation for the investigational arms.  
4.5.2  Risk s of ATG  Induction Therapy  
The following summary is taken from the most recent US FDA -approved labelling of ATG  
(Thymoglobulin, Genzyme, 20 20). For the most recent guidance refer to the most recently 
approved local labeling from the appropriate authority. Immune -Mediated re actions  
Serious immune -mediated reactions, including anaphylaxis or severe cytokine release syndrome 
(CRS), have been reported with the use of ATG. Fatal anaphylaxis has been reported. If an 
anaphylactic reaction occurs, terminate the infusion immediately  and p rovide emergency treatment 
as indicated  per local practice and clinical expertise .  
ITB-MED   Page 44 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Infusion- Associated  Reactions (IAR) (including Cytokine Release Syndrome)  
Cases consistent with cytokine release syndrome (CRS) have been reported with rapid infusion 
rates. CR S is attributed to the release of cytokines by activated monocytes and lymphocytes. 
Severe acute CRS can cause serious cardiorespiratory events and/or death . Close compliance with 
the recommended dosage and infusion time may reduce the incidence and severity of infusion- associated reactions (IARs). Slowing the infusion rate may minimize many of these IARs.   
Local r eactions at the infusion site may include pain, swelling, and redness of the skin.  
Hematologic Effects  
Low platelet and white blood cell (WBC)  counts, including low counts of lymphocytes and 
neutrophils, have been identified and are reversible following dose adjustments. Total white blood 
cell and platelet counts should be monitored. 
Infection s  
ATG is routinely used in combination with other immunosuppressive agents. Infections (bacterial, 
fungal, viral and protozoal), reactivation of infection (particularly cytomegalovirus) and sepsis 
have been reported after ATG administration in combination with multiple  immunosuppressive 
agents. These infections can be fatal.  
Malignancy  
Use of immunosuppressive agents, including ATG, may increase the incidence of malignancies, including lymphoma or lymphoproliferative disorders. These events have been associated with fatal outcome . 
Immunizations  
The safety of immunization with attenuated live vaccines following ATG  therapy has not been 
studied; therefore, immunization with attenuated live vaccines is not recommended for patients who have recently received ATG.  
Laborat ory Tests  
ATG may interfere with rabbit antibody- based immunoassays and with crossmatch  or 
panel -reactive antibody cytotoxi city assays.  ATG has not been shown to interfere with any routine 
clinical laboratory tests that do not use immunoglobulins.  4.5.3  Risks of SARS -CoV-2 (COVID -19) 
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS -CoV- 2), can 
spread rapidly within healthcare settings and communities and poses a special challenge for organ 
transplantation. Ongoing community transmission has been noted on all continents except 
Antarctica. Person -to-person transmission of SARS -CoV- 2 occurs during close exposure 
ITB-MED   Page 45 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
(< 2 meters) to an infected person, primarily via respiratory droplets produced when the infected 
person coughs or sneeze s. COVID -19 disease is a respiratory illness caused by the SARS -CoV- 2 
virus with variable presentation from asymptomatic to severe. Shedding of high viral titers has 
been documented from the respiratory tract, including shedding before the onset of symptoms, and results in droplet transmission of SARS-CoV-2 ( Zou et al 2020). Transmission via droplet spread 
can occur from both symptomatic and asymptomatic individuals ( Arons et al 2020) and it appears 
that patients with COVID -19 have the highest viral loads early in the course of their infection. 
Thus, a reliance on symptom -based screening strategies alone is not sufficient to prevent or 
diagnose infection; consideration of symptoms and exposure history, along with PCR -based 
testing is imperative.  
COVID -19 Disease:  
Case series on COVID -19 disease in transplant recipients have been published, however data 
remains very limited. Imaging demonstrates pneumonia in the majority of patients that are 
hospitalized (75- 100%). Patients with less severe infections may have lower rates of clinical 
abnormalities. Mild infections are common, however preliminary experience suggests that infection, once acquired by immunosuppressed transplant recipients , may be of greater severity 
than in normal hosts after the initial incubation period. Experience with other viruses including prior outbreaks of coronaviruses, also suggests that severe infections will occur in some transplant recipients.  
At this time, the risk factors for severe disease have been characterized by observational studies. An initial report by ( Pereira et al 2020 ) showed that advanced age was associated with severe 
disease in their transplant cohort, which is not different from the disease profile in the immunocompetent population ( Kates et al 2020 ) reported age >65, chronic lung disease, 
congestive heart failure, and obesity were independently associated with poor outcomes of COVI D-19 in solid organ transplantation. It is anticipated that transplant recipients may have a 
greater viral burden and shedding resulting in greater infectivity and potential spread to other individuals.  
Limited data are available on optimal treatment protocols, and none have been clearly 
demonstrated to optimize outcomes. When considering potential therapies, clinicians should consider the need for immunosuppression reduction and presence of potential drug-drug interactions that may result in toxicity or therapeutic failure, e.g., beta interferon or CYP3A inducers/inhibitors.  
The risk of a COVID-19 infection from an infected organ donor is unknown at this time. To date, 
there has been one documented case ( Kaul et al 2021) of donor -derived disease transmission in a 
bilateral lung transplant recipient. Transmission from blood banks has not been documented at this time.  
Guidelines on the risks and management of SARS -CoV- 2 in the setting of clinical trials as well as 
that of renal transplant patients have been published by the European Medicines Agency (EMA), US National Institutes of Health (NIH), Transplantation Society (TTS) and American Society of Transplantation (AST). Treatment guidelines on the use in immunocompromised and transplant recipients are updated periodically as knowledge of COVID -19 disease management evolves. 
ITB-MED   Page 46 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Cumulative cases and incidence rates are tracked and published by the World Health Organization 
(WHO) and other public and private entities and should be  used to guide local management of 
patients.  
With active circulation of SARS -CoV- 2 in the community, it is appropriate to counsel all 
candidates about the risk for acquisition from the community and hospital environment. 
Candidates should be educated about preventive strategies such as social distancing, masking when in proximity to non- household contacts, frequent hand washing, and avoidance of travel to 
high- risk areas.  
A compendium of global guidance documents is maintained by the NOTIFY library and can be found at the following URL: 
 https://www.notifylibrary.org/background-documents#SARSCoV-2.  
4.5.4  Risk Mitigation Strategy  
Safety and tolerability data for doses up to 15 mg/kg IV have been collected in patients with T- cell 
lymphoma with good tolerability.  With initial administration of a biologic, the first 4 hours of 
exposure are most critical with most infusion reactions (including hypersensitivity, cytokine 
release, anaphylaxis) occurring within the first 2 hours of exposure ( Tabrizi and Roskos 2007). No 
cytokine release has been detected with IV or s.c. sipliz umab ( MEDI -507) administration i n the 
completed patient studies . Cytokine release or anaphylaxis ha ve not been reported with similar 
compounds specifically targeting the CD 2 receptor. A mild infusion reaction has been described 
in primates as well as clinical studies with siplizumab following the first do se.  This first -dose-
effect  presents as mild  and transient  pyrexia with chills, nausea and fatigue . These infusion 
reactions are self-limiting  and respond well to premedication with acetaminophen and 
diphenhydramine. Subjects will receive their first dose of siplizumab  in the pre - to inter -operative 
time period, a t a time whe n patients are under the close supervision of clinical staff in a hospital 
environment. Any infusion related reactions can be managed at that time in accordance with local protocols .  In the TCD601B102 study all subjects  will rec eive premedication prior to each dose of 
siplizumab  to mitigate any infusion reactions. 
Infections are a common risk for all transplant recipients. Subjects  will be regularly evaluated 
while hospitalized  and upon return to the clinic for signs and symptoms  which might indicate a 
severe infection, i.e., fever, nausea, myalgia, headache, arthralgia, chills, diarrhea, stiff neck, and malaise, and will be treated as appropriate per local practice depending on the infectious agent. 
Subjects will be informed to r eport any of the aforementioned symptoms to the clinical staff to 
assure proper assessment and care can be administered in a timely manner.  
Considering the expected immunosuppressive nature of the compound, subject s will be screened 
for a history of latent infections . Viral reactivation will be assessed for CMV and BK virus  
according to local practice on a regular basis.  Prophylaxis for CMV and pneumocystis pneumonia 
(PCP) will be administered to all subject s during the trial according to local practice.  A negative 
test result for TB  performed within 6 months of randomization will be required prior to enrollment. 
If there is suspicion of TB, a chest x- ray may be performed in accordance with local guidelines; 
subjects  with a positive test will be excluded from participation.   
ITB-MED   Page 47 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
EBV  serology will serve as a key inclusion criterion, where EBV -seronegative subjects will be 
excluded  from participation . EBV viral loads via EBV -PCR will be collected from all subject s 
throughout the trial and will be analyzed centrally to minimize inter -laboratory variation .  Positive 
results that demonstrate an increase over time will be communicated to the investigator for 
additional follow-up and per-protocol PTLD surveillance as described in Section 8.4.5.  
The ongoing SARS -Cov- 2 pandemic represents a challenge for all renal transplant candidates and 
recipients. Due to the dyna mic nature of COVID -19 infection rates, centers should continue to 
follow local and national guidelines and set policies based on the local incidence and prevalence 
of infections as well as hospital and staffing resources. This includes decisions to conduc t or defer 
solid organ transplant procedures as well as the ongoing management of donors and recipients. 
Subjects eligible for the TCD601B102 study will be randomized from the pool of active candidates 
who are currently undergoing transplantation and will be receiving T -cell depleting induction and 
standard of care immunosuppression. All eligible subjects will be informed of the risks of 
SARS -COV- 2 during the consent process. To decrease the risk to study subjects, all candidates 
will be screened for SARs -CoV-2 prior to enrollment and excluded if positive. 
Ongoing surveillance per standard of care will occur thereafter based on local conditions and signs and symptoms. In renal transplant patients who experienced COVID -19 disease, common 
presenting symptoms were fever, dry cough, and diarrhea, with most patients exhibiting lymphopenia and elevated C -reactive protein (CRP) ( Fung and Babik 2020). Subjects will be 
counseled to report any of these physical symptoms to the clinical staff. Clinicians should also consider the common laboratory changes when assessing the potential for COVID- 19 disease.  
Subjects who may be exposed to SARS -CoV- 2 or contract active disease will be managed per 
local practice and international guidelines including recommendations for seeking treatment or self-quarantine. As with all infection events, SARS-CoV-2 positivity and COVID- 19 disease will 
be captured in the safety database and will be evaluated by the DMC during their periodic dose escalation and ongoing safety review. Within the clinical trial setting, subjects may be required to attend in -person study visits in excess of those based on standard of care for clinical laboratory 
assessments as well as PK/PD sample collection; this may increase their risk o f SARS -CoV- 2 
exposure. To minimize the time patients,  spend indoors and within the clinic for these assessments, 
phone contact or virtual / telehealth technology will be utilized where appropriate by the site staff. In addition, patients will be counseled on the importance of following proper hygiene, masking 
and social distancing practices to minimize community and hospital exposure during their standard 
of care and study specific visits. 
SARS -CoV- 2 vaccines (i.e., mRNA, adenoviral vector) are under development or have been 
authorized for clinical use globally. The effectiveness of these vaccines in immunocompetent 
adults is between 76- 95%, however the effectiveness in solid organ transplant recipients is 
unknown (See Section 6.5). Based on current vaccination guidelines, it is recommended that all transplant candidates and their household members receive SARS -CoV- 2 vaccination when it 
becomes available. Ideally, transplant candidates should be targeted for vaccination while they are awaiting transplant or 3-6 months post-transplant in this trial, based on T- cell recovery.  
Subjects  will be hospitalized for several days  post-transplant . Following discharge from the 
hospital, subjects will return to the clinic  for routine assessments  frequently during the first 
ITB-MED   Page 48 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
3-6 months per standard of care.  During these visits , safety  and PK/PD assessments will be 
collected. Standard safety assessments will include vital signs, physical examinations, c linical 
laboratory evaluations (hematology, blood chemistry and urinalysis), AE and SAE monitoring as 
outlined in the  Schedule of Assessments. In addition to standard clinical laboratory assessments, 
subjects will be monitor ed regularly for signs and symptoms of infectious, inflammatory, 
hematologic or renal toxicity / rejection .  
Subject ’s serum creatinine will be assessed  frequently in the first few weeks post -transplant and 
thereafter with a focus on renal injury and dysfunction.  Changes in renal function will be assessed 
via serum creatinine  and estimated glomer ular filtration rates ( eGFR ) using Modification of Diet 
in Renal Disease  (MDRD)  formula .  In the event subjects  present with a significant increase in 
SCr and/or BPAR  for-cause biopsies are to be collected  for evaluation according to the standard 
Banff histology system.      
   
Immunophenotyping via fluorescence- activated cell sorter  (FACS ) analysis  will be conducted 
frequently during the study to assess the potential for an increased risk of infection, changes in 
leukocyte subsets and recovery following depletion anticipated with all siplizumab  dosing arms.  
Coagulopathy will be assessed using standard hematology (platelets) and coagulation studies, 
including international normalized ratio  (INR)/prothrombin time (PT) and activated partial 
thromboplastin time (aPTT) according to local practice.  
Finally, considering the open- label study design, ITB-MED  and an independent DMC will review 
study data, including safety events and AEs of special interest, regularly and on an ad hoc  basis . 
Furthermore , a priori  defined stopping criteria, infection surveillance  and pharmacovigilance by 
ITB-MED  as well as ongoing clinical assessments by Investigator and site staff  will be employed 
to protect individual subject  safety during the trial.  
Overall, the non- clinical an d clinical safety results with siplizumab in human, as well as the 
comprehensive monitoring plan, a priori  defined study stopping criteria and ongoing review by an 
independent DMC support the continued development of this immunomodulatory compound and conduct of further investigational studies .  Moreover, in consideration of the ongoing 
SARS -CoV- 2 pandemic, each center will manage their ongoing transplant program and enrollment 
of patients in this trial based on the Investigator’s clinical judgement and individual patient risk assessment in consideration of both local and per protocol risk mitigation plans.  
The overall benefit -risk assessment including the aforementioned mitigation strategies and 
monitorable and manageable risks of administering siplizumab in this patient population is positive 
and support the conduct of this clinical trial. 

ITB-MED   Page 49 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
5 Population 
This multicenter study will be conducted in up to 8 centers worldwide. The study population will 
consist of approximately 24 male and female de novo adult renal transplant patients.  The 
Investigator must ensure that all subjects being considered for the study meet the following 
eligibility criteria. Subjec t selection is to be established by checking through all 
inclusion/exclusion criteria at screening  and confirmed prior to randomization. A relevant record 
(e.g., checklist) of the eligibility criteria must be stored with the source documentation at the stu dy 
site. 
Deviation from any entry criterion excludes a subject from enrollment into the study. 
5.1 Inclusion Criteria 
Subjects eligible for inclusion in this study have to fulfill all  of the following criteria:  
1. Able to understand the study requirements and p rovide written informed consent before 
any study assessment is performed . 
2. Male or female patients ≥ 18 to 70 years  of age. 
3. Recipients of a de novo  renal allograft from a heart -beating deceased, living unrelated or 
non-HLA identical living related donor. 
4. Recipients of a kidney with a cold ischemia time (CIT) < 30 hours ; hypothermic machine 
perfusion within the same timeframe  is acceptable .  
5. Subjects who test negative for SARS-CoV- 2 test via molecular testing (PCR)  
5.2 Exclusion Criteria 
Subjects meeting any of the following criteria are not eligible for inclusion in this study. 
1. Transplant recipients sero -negative for Epstein -Barr virus (EBV). 
2. Multi-organ transplant recipients. 
3. Subjects who have received a kidney allograft previously e.g., re -transplant. 
4. Recipien t of a  kidney from an HLA identical living related donor. 
5. Recipient of a kidney from a donor after cardiac death . 
6. Subjects at high immunological risk for rejection as determined by local practice [(e.g., 
presence of pre -existing DSA , recipient of high Kidney Donor Profile Index ≥ 85 kidney 
(where assessed) ]. 
7. Subjects with donor specific anti -HLA antibody as measured by complement-dependent 
cytotoxicity assay (CDC) , enzyme- linked immunosorbent assay ( ELISA ), or flow 
cytometry within 90 days prior to transplant or as performed per the center’s local practice . 
8. Complement-dependent cytotoxicity (CDC) crossmatch positive transplant (isolated 
positive B cell crossmatches are not an exclusion criterion). 
9. ABO incompatible recipient  
10. History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix. 
ITB-MED   Page 50 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
11. Subjects with clinically significant laboratory abnormality that would preclude 
participation in the study (e.g., >2.5 x Upper Limit of Normal ( ULN) values for (a) liver 
function chemistries (ALT, AST, ALP), (b) bilirubin, (c) coagulation studies ( INR/ PT, 
aPTT) . 
12. Patient with any of the following:  
• hemoglobin (Hgb) < 8 mg/dL 
• WBC count ≤ 2,000/mm3  
• platelet count ≤ 75,000/mm3. 
13. Sero-positive for  Human  Immunodeficiency  Virus  (HIV) or Hepatitis B Surface Antigen 
(HBsAg ). Subjects who are sero -positive for Hepatitis C  virus (HCV)  are excluded without 
proof of sustained viral response (SVR) after anti- HCV treatment . 
14. Recipient of a kidney from a donor  who tests positive for HIV, HBsAg/HBc positive or 
HCV.  
15. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes 
(e.g., siplizumab , ATG, TAC , MMF, CS). 
16. Any additional contraindication to the use of TAC or MMF according to the national 
labeling information of these products ( refer to the local product label).  
17. Evidence of TB  infection (after anti -TB treatment, patients with history of latent TB may 
become eligible according to national guidelines).  
18. Patient with severe systemic infections, current or within the two weeks prior to randomization. 
19. Subjects with any other clinically significant medical condition, active infection or laboratory abnormality that w ould, in the judgment of the investigator, interfere with the 
subject’s ability to participate in the study.  
20. Subjects who, in the opinion of the investigator, are not capable of giving informed consent for the study or who are unable or unwilling to adhere  to the study requirements outlined 
in the protocol. 
21. Use of other investigational products or enrollment in another investigational drug study within 30 days of screening or 5 half-lives of the medication, whichever is longer. 
22. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. 
23. Women of child- bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 24 weeks  after the study medications have been stopped. Highly effective 
contraception methods include: 
• Female sterilization  (have had surgical bilateral oophorectomy with or without 
hysterectomy), or tubal ligation at least six weeks before taking study treatment. In case 
of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. 
ITB-MED   Page 51 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
• Male sterilization (at least 6 months prior to screening). For female subjects on the 
study, the vasectomized male partner should be the sole partner for that subject. 
• Any of the following: 
a. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example, hormone vaginal ring or transdermal hormone contraception. 
b. Placement of long- acting reversible contraceptives an intrauterine device or 
intrauterine system. 
In case of use of oral contraception women should have been stable on the same brand (or generic equivalent) for a minimum of 3 months before taking study treatment. 
Additionally, total abstinence, when in line with the pref erred and usual lifestyle of the subject 
may be an acceptable form of contraception.  Period abstinence is not an acceptable form of 
contraception ( e.g., calendar, ovulation, symptothermal, post -ovulation methods) and withdrawal ).  
Women are considered post -menopausal and not of childbearing potential if they have had 
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks  prior . In the case of oophorectomy 
alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment i f she considered not of childbearing potential.  
6 Treatment s 
6.1 Method of Treatment Assignment 
Approximately 24 subjects will be randomly assigned to 1 of 2 treatment Cohorts and then, within 
each Cohort, randomized to one of two treatment arms; siplizumab or rATG  active control arm in 
an 8:4 ratio as noted in the table below.   
Table 6-1 Treatment Assignment  
Cohort  Arm Subjects (n)  Product  Dosing Regimen  
Cohort A  Arm 1  8 Siplizumab  0.2 mg/kg (Days 0 and 4)  
Arm 3 4 rATG  1.5 mg/kg (Day 0, 1 and 2)  
Cohort B  Arm 2  8 Siplizumab  0.6 mg/kg (Days 0 and 4)  
Arm 3 4 rATG  1.5 mg/kg (Day 0, 1 and 2)  
The randomization schedule will be generated and verified by independent statisticians. 
Prior to surgery, on Day 0 (Day of Transplant), the Investigator or his/her designee will confirm 
that the subject meets eligibility for randomization within the EDC system.  The randomization mechanism for the study will be deployed by an internet -based Interactive Web Response System 
(IWR S) and accessible 24 hours a day to authorized users.  Designated study personnel will access 
the IWRS to execute each randomization after a subject  has met all prerequisites for randomization 
ITB-MED   Page 52 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
and has completed all necessary screening procedures and eligib ility for the study has been 
confirmed.  
The EDC/IWRS will provide a notice and assign a unique randomization number to the subject  
being assigned to Cohort A or B  and randomized to receive either siplizumab or rATG (in one of 
3 treatment arms)  
The randomization number will be linked to the subject’s assigned treatment Cohort and Arm.  
After a subject is assigned a randomization number, the number will not be reused even if the 
subject withdraws before receiving any investigational product. 
6.2 Investigational Product  
6.2.1  Identification of Investigational Product  
Siplizumab  is a humanized IgG1κ  class monoclonal antibody, supplied as  
 for solution.  S iplizuma b 
will be supplied in 6 mL vials containing 60 mg and supplied at a concentration of 10 mg/mL.   
6.2.2  Management of Investigational Product  
Investigational product will be provided as open -label, bulk medication.  P roduct packaging and 
labeling will be performe d by Klifo, Glostrup, Denmark. Medica tion labels will be in the local 
language and comply with the legal requirements of each country.  
Investigational product must be received at the study site by the Investigator or his/her designee.  
The Investigator or his/her designee must acknowledge receipt of the investigational product 
within the EDC/IWRS .  Confirmation of product receipt and condition will be logged into the 
system  and any documentation of receipt maintained in the site’s study file.   
Following confirmation of  receipt, all investigational product must be stored i n an appropriate 
secure area (e.g., a locked room or a locked refrigerator) and within an adequately monitored 2 - 8 °C refrigerator.   Temperature logs must be maintained to document the daily minimum, 
maximum, and actual temperature to confirm the absence or presence of a temperature excursion.   
Access to the storage area and/or storage refrigerator must be limited to those persons authorized by the Investigator.  The Pharmacy Manual should be referenced for additional handling and storage details as well as expectations for reporting temperature excursions to ITB- MED.  
The Investigator must maintain an accurate record of the dispensing of all study product in a drug accountability log.  A copy of the log(s) must be  maintained  by the Investigator , Pharmacy st aff, 
or designee.  ITB -MED will retrieve copies of the logs periodically or at the end of the study for 
maintenance in the electronic trial master file ( eTMF ). Additionally, Investigational Product  
accountability will be noted by the Monitor during site vi sits and/or at the completion of the trial.  
All investigational product  supplies are to be used only for this protocol and not for any other 
purpose. Unless  specifically instructed by ITB -MED, the Investigator must not destroy any drug 
labels, or any partly used or unused investigational product supply. 
Only after receiving a written authorization by ITB -MED, the Investigator/designee will : (i. send 
all the unused and partly used drug supplies as well as the empty containers to the address provided 

ITB-MED   Page 53 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
at the t ime of authorization for destruction, or ii.) have the unused and partly used drug supplies 
as well as the empty containers destroyed by the site’s pharmacist or designee, providing a drug 
destruction certificate.  
Detailed i nstructions for the receipt, sto rage, accountability , and return or destruction will be 
described in the ITB-MED provided Pharmacy Manual.  
6.2.3  Investigational Product  Dosing Regimen  
The starting dose for s iplizumab  will be 0. 2 mg/kg with escalation to 0.6 mg/kg. 
The planned duration of investigational treatment is 5 days. Subjects will receive a total of two 
doses of siplizumab: pre- or intra-operatively on Day 0 and on Day 4. Subjects may be 
discontinued from treatment earlier at the discretion of the investigato r or upon request of the 
subject.  
Siplizumab  dose adjustments and/or interruptions for a given subject are not permitted .  The 
siplizumab  infusion rate may be changed in the event of an infusion reaction. 
6.2.4  Preparation of Siplizumab  
As per the treatment assi gned to the subject upon randomization, the Investigator or his/her 
designee will obtain the investigational product to be administered to the subject.  The dose of 
siplizumab  must be prepared by and administered by the Investigator or his/her designee  who is  
properly trained in the handl ing and aseptic preparation of IV infusions. The subject will be 
weighed  within 24 hours of each infusion administration and this weight will serve as  the basis for 
final dose calculations and compounding. 
The dose will be calculated by the following formula:  Dose (mg) = [subject  weight (kg) x dose 
level (mg/kg )].  60 mg siplizumab/ vial  
Example 1:  A subject whose weight is 70 kg in Cohort A (0.2 mg/kg) should receive 14 mg of 
siplizumab  (70 kg x 0.2 mg/kg = 14 mg ) and would require 1 vial of siplizumab . 
Example 2:  A subject whose weight is 70 kg in Cohort B ( 0.6 mg/kg) should receive 42 mg of 
siplizumab  (70 kg x 0.6 mg/kg = 42 mg) and would require 1 vial of siplizumab . 
Upon confirmation of subject dose, the product will be prepared from vial(s), using aseptic 
technique and administration to the subject via IV infusion using a syringe or infusion pump.   
Detailed instructions on the preparation and administration of the investigational product will be 
provided in the Pharmacy Manual and must be referenced prior to administration of product to any 
study subject. 
6.2.5  Premedication for Siplizumab Infusion  
Prior to each infusion of siplizu mab, subjects  should receive premedication with 650-1000 mg 
acetaminophen  (paracetamol ) and an H1-antagonist ( antihistamine  e.g., 25 mg diphenhydramine ) 
to minimize signs and symptoms of an infusion reaction. Premedication administration  should 
occur  at least 1 hour and no more than 5 hours prior to the start of the infusion.   
ITB-MED   Page 54 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
6.2.6  S iplizumab  Administration 
Siplizumab  will be administered by IV infusion to the subject by authorized site personnel  on 
Day 0 and Day 4.  
The first dose of siplizumab  will be administered over an hour (±5 min) by IV infusion. The 
infusion should be administered pre- or intra-operatively  and timed so that the completion of the 
infusion is no earlier than 4 hours prior to revascularization and perfusion of the allograft. When 
administered intra -operatively, the infusion must be completed prior to revascularization. This 
ensures both donor and alloreactive T -lymphocytes are suppressed and depletion is initiated in the 
hours and days post -transplant. The second and final dose will be administered by IV infusion over 
an hour on Day 4.  
The compatibility of siplizumab with other IV medications is not known and must not be combined 
with other infusions or medications.  
The infusion may be given directly into a peripheral vein or a separate lumen in an indwelling, 
multi- lumen, central catheter  and not administered concurrently with any other medications.   
The date, start time, completion time and volume of siplizumab  administration  must be recorded  
in the subject’s source documentation and applicable eCRF.  
For all subjects , regardless of the timing of the Day 0 infusion, the Day 4 infusion  will be 
administered between 0800 and 1000 to facilitate future sample collection and study visits.  
No dose adjustments beyond changes based on the subject ’s actual weight are permitted to the 
siplizumab  dose during the study.  
In case of notable AEs and /or SAEs, including loss of efficacy and/or associated PK/PD data 
collected during the study, changes to the next planned dose level across the study may be 
considered and implemented via a protocol amendment.  
6.2.7  Provisional Dose Levels  
Table 6 -2 describes the starting dose and the dose levels that may be evaluated during this trial. 
Table 6-2 Provisional dose levels  
Dose level  Proposed daily dose*  Increment from pr evious dose  
1  0.2mg/kg  (starting dose)  
2 0.6 mg/kg  ½-log 
*It is possible for a n intermediate dose level (s) to be added during the course of the study . Cohorts may 
be added at any dose level below the maximum tolerated dose in order to better understand safety, PK 
or PD.  
6.2.8  Dose Escalation Guidelines  
Before escalat ing to the next dose level, an interim review of all available safety/tolerability (e.g., 
AEs, SAEs , clinical laboratory assessments, vital signs), PD (immunophenotyping), receptor 
occupancy and PK data ( if available ) up to a minimum of approximately 28 days post dose for at 
least 4 siplizumab treated subjects in the lower dose arm will be performed.  
ITB-MED   Page 55 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
This 28- day s afety period allows sufficient time for subjects to reach full -receptor occupancy, 
maximum pharmacodynamic activity and for the presentation of acute, drug related, toxicities.  
For treatment cohorts where receptor occupancy at the 28 -day assessment cut -off is >99% in at 
least 2 subjects, dose escalation decisions will be deferred by a minimum of approximately 14 days 
until results of the next PD assessment have been analyzed and reviewed. If the CD2 receptor occupancy remains at >99% in at least 2 subjects at the s econd assessment time point, reevaluation 
of receptor occupancy on an approximately 14- day schedule may continue until a decision to 
escalate has occurred or stopping criteria have been satisfied.  
Where siplizumab  concentrations are not quantifiable, i.e., with low doses, rapid clearance or assay 
limits, receptor occupancy or lymphocyte recovery will serve as the only measure of 
investigational treatment exposure for dose escalation  decisions.  
In order to escalate to the next dose level, the data at the aforementioned review must be assessed 
as satisfactory or not clinically significant. The decision to escalate to the subsequent dose cohort  
will be made jointly between ITB -MED and the Investigator(s)  following a revi ew of all relevant 
safety and PK/PD dat a.   
To assure subjects are not exposed to a prolonged duration of T- cell depletion and/or sustained 
receptor occupancy and consequent immunomodulation / immunodeplet ion, the selection of the 
next highest dose will be guided by the following criteria:  
• Escalation will not proceed if the dose is not considered safe, regardless of the duration of target suppression or PD activity 
Siplizumab  dose escalation will be stopped when: 
1. An average of ≥ 24 weeks (168 days) duration of T-cell depletion has been measured 
(defined as <10% of baseline (i.e., 90% depletion) in ≥2 subjects or  
2. An average of ≥ 24 weeks (168 days) duration of >99 % peripheral CD2 receptor occupancy 
has been measured in ≥2 subjects or  
3. An average of >36 weeks  (252 days)  duration of >99% CD2 receptor occupancy and T- cell 
depletion is accurately predicted using PK/PD modeling for the next dose escalation. 
Additionally, based upon the outcome of safety and PK/PD data review during and prior to dose 
escalation, or in the case of notable adverse even ts or safety concerns, the following changes to 
the next planned dose level may be considered: 
• Administration of a dose level  below the starting dose  
• Administration of an intermediate dose  strength between the current and preceding dose  
• Repeated  administration of the current dose strength   
• Termination of any further dose escalation 
Any change in dosing or clinical conduct of the study will be implemented via an amendment and approved by the ethics committee responsible for initial approval of this study. The local heath authority will also be informed of any Suspected  Unexpected Seri ous Adverse Events ( SUSARS ) 
and study changes. 
ITB-MED   Page 56 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
6.3 ATG: Standard of Care Control 
6.3.1  ATG  Dose and Duration 
rATG  will be given at a dose of 1.5 mg/kg on Days 0, 1 and 2 for a total of three doses. rATG  dose 
adjustments and/or interruptions for a given subject are not permitted  unless warranted (see 
below).   
6.3.2  Preparation of ATG  
As per the treatment assigned to the subject upon randomization, the Investigator or his/her 
designee will prepare the investigational product to be administered to the subject.  The dose of 
rATG must be prepared by and administered by the Investigator or his/her designee who is 
properly trained in the handling and aseptic preparation of IV infusions. The subject will be weighed within 24 hours of each infusion administration and this weight wi ll serve as the basis for 
final dose calculations and compounding. 
6.3.3  Premedication for ATG  Infusion  
Prior to each infusion of rATG , subjects should receive premedication with corticosteroids , 
acetaminophen /paracetamol and/or an H
1-antagonist (antihistamine) to minimize signs and 
symptoms of an infusion reaction. Premedication administration should occur 1 hour prior to the 
start of the infusion.   
6.3.4  Administration of ATG  Infusion  
rATG  will be administered on Day 0, Day 1, and Day 2 per local label or as outlined in the 
pharmacy manual.  
6.3.5  Management  of ATG  Therapy  
Patients should be monitored for adverse reactions during and after infusion. The  total white blood 
cell and platelet counts should be monitored during and after rATG  therapy. T he rATG  dose should 
be reduced  by one -half if the white blood cell (WBC) count is between 2,000 and 3,000 cells/mm3 
or if the platelet count is between 50,000 and 75,000 cells/mm3. rATG  treatment may need to be 
stopped if the WBC count falls below 2,000 cells/mm3 or if the platelet count falls below 
50,000 cells/mm3.  
6.4 Concomitant Immunosuppression 
The following medications will be used in this study and will be administered in accordance with 
this protocol, SoC  practices at t he institution, and where applicable, current local labeling. Not all 
dosage forms listed are available in each country, dependent on local approval status and regulations.  
The use of immediate release generic TAC and MMF are allowed in this study.  Subjects should 
remain on the same concomitant immunosuppression medication throughout the duration of the 
study (12 months), i.e. If the subject starts with brand Prograf
® or CellCept®, the subject should 
ITB-MED   Page 57 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
remain on brand and not switch to a generic at any point throughout the 12-month study period; if 
the subject starts with generic, the subject should remain on the same generic throughout the study.  
Special attention must be taken to avoid concomitant administration of drugs, food, or beverages which are known to be a strong inducer or inhibitor of CYP3A4, as outlined in Appendix 5.   
All dos es of TAC, MMF, and CS along with dose changes during the study must be recorded, with 
reason for administra tion, on the corresponding eCRF.  
In general, symptomatic treatment should be considered first to treat subjects  who have difficulties 
tolerating their immunosuppressive regimen. However, for subjects  who are still unable to tolerate 
the protocol -specified  study treatment, dose adjustments, route adjustments, and interruptions of 
study drugs may be permitted in order to keep the subject on study treatment.  Concomitant medications will be supplied locally and used according to the local label and will 
inclu de: 
• Immediate release TAC as 0.5 mg, 1.0 mg, or 5.0 mg capsules 
• MMF 250 mg or 500 mg film-coated tablets, or 250 mg capsules, or 500 mg vial for IV 
• CS for oral and IV administration 
Pre-transplant immunosuppression may be administered according to center practice, but such 
practice must be applied consistently to all subjects at a given center. At randomization/enrollment, all subjects must follow the assigned regimen.  
6.4.1  MMF Administration 
MMF  will be administered p.o. twice per day ( BID) as 2 - 500 mg tablets , 4 - 250 mg capsules , or 
where oral administration is not feasible, as 1000 mg via IV administration (2 – 500 mg vial for 
IV administration ). For subjects  who remain intubated >24 hours post -transplant and/or are 
otherwise unable to swallow oral medication, IV MMF may be substituted 1:1 until oral conversion 
is possible. 
The first dose of MMF will be administered no later than 24 hours after graft reperfusion of the 
allograft.  
Dose adjustment/interruption guidance for MMF is provided in Appendix 5. All MMF doses and 
changes must be recorded on the applicable electronic case report form  (eCRF ).  
ITB-MED   Page 58 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
6.4.2  T AC A dministration  
TAC will be administered as capsules  or tablets p.o. BID and adjusted to maintain serum trough 
(C0) concentrations within the target range of 4- 11 ng/mL. If oral administration is not feasible  or 
practical IV TAC  containing the equivalent of 5 mg/ mL tacrolimus  administration by continuous 
intravenous infusion c an be substituted  per label . 
TAC should be initiated as soon as possible in the peri -transplant period and may follow local 
practice but must be initiated no later than 24 hours after reperfusion of the allo graft. The lowest 
permitted dosing of T AC in this study is 0.5 mg BID or IV equivalent. If TAC  is discontinued for 
more than 14 consecutive days, and the study regimen cannot be maintained, the subject ma y 
remain in the trial, however the new immunosuppressive regimen must be documented in the 
concomitant medications eCRF , including doses and trough concentrations where applicabl e. 
Subjects who discontinue their study regimen are expected to remain in the study on the local SoC 
until M onth 12.  
TAC dosing will be modified by Investigators as needed and recorded on the applicable eCRF at 
each visit. In the event of T AC intolerance (e.g., nephrotoxicity, neurotoxicity) dose reduction of 
TAC may be necessary. If it occurs that the T AC trough concentration is outside the required 
target, then the Investigator will be asked to confirm the intended T AC trough and to record the 
start date  and reason for dose reduction on the applicable eCRF.  
TAC is a substrate for CYP3A  metabolism and therefore susceptible to drug-drug interactions that 
can raise or lower systemic concentrations , leading to toxicity or therapeutic failure.  The 
co-administration of drugs known to interfere with T AC metabolism ( Appendix 6) should be 
avoided if possible. If these drugs are required, the Investigator should carefully monitor TAC 
trough concentrations and adjust them accordingly during and after the use of the interacting 
treatment.   
On days when trough concentrations are monitored, t he subject  will be instructed to record the 
time of the last dose on the day prior to the blood draw and to bring the morning dose to the visit 
so it may be administered after the blood sampling is completed.  
6.4.3  Corticosteroid A dministration  
CS should be administered  at a minimum of 5 .0 mg/day (prednisone or equivalent) from Day 0 
until Month 12 and per  local standard practic e in a way that is consistent in all subjects  enrolled at 
the site. Dosing of CS should be recorded in the Concomitant Medications eCRF. 
6.5 Infectious Prophylaxis Treatment 
All medications administered after the subject was enrolled into the study must be recorded on the appropriate eCRF. ITB -MED will provide eCRF completion guidelines with additional detail for 
recording concomitant medications. 
CMV  
CMV prophylaxis, with IV ganciclovir or oral valganciclovir, will be used in subjects  (CMV 
positive and CMV negative) as per local medical practice.  
ITB-MED   Page 59 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Pneumocystis jirovecii  (Pneumocystis carinii) pneumonia (PCP)  
All subjects  will be started on sulfamethoxa zole- trimethoprim, starting when oral medication can 
be tolerated and continued per standard institutional/local practice. The same regimen should be 
administered to all subjects  at a given study center. For subjects unable to tolerate 
sulfamethoxazole- trimethoprim, atovaquone plus levofloxacin (or equivalent fluoroquinolone), 
aerosolized pentamidine or dapsone may be administered.  
Hepatitis B  Virus  (HBV)  
Prophylaxis for HBV reactivation during the course of this study is allowed and will be 
administered a t the discretion of the Investigator.  
BK Virus  
Subjects  with BK viremia or viruria should be treated according to local practice. If treatment is 
given or dose adjustments are made, e.g., M MF dose reduction, they should be recorded on the 
Concomitant Medi cations eCRF.  
Oral Candida  
For oral thrush (Candida), Nystatin may be used in a swish and swallow regimen; alternatively, 
clotrimazole (Mycelex®) lozenges/troches may be used. Routine use of systemic agents, e.g., itraconazole, voriconazole and fluconazole, will not be allowed unless subjects  are systemically 
infected since azole antifungal agents may increase blood concentrations of TAC.  
Systemic therapy will be based on center practice and at the Investigator’s discretion. Treatment 
should be recorded on the Concomitant Medications eCRF.  
Immunization  
Immunization of transplant candidates for vaccine preventable diseases is recommended more than 
2 weeks prior to transplantation or starting at 1- 6 months after transplantation If given prior to 
transplanta tion, the full immunization series should be completed before the transplant procedure. 
In certain situations, it may be appropriate to wait until 3 or more months after transplantation to vaccinate, such as following T - or B-cell depletion therapy. Waning vaccine titers to other routine 
immunizations have been well documented after transplantation. Lower seroconversion rates to influenza vaccination are well documented in the setting of mycophenolate mofetil and tacrolimus use ( Danziger -Isakov et al 2019). Vaccination during treatment with siplizumab and prior to 
clearance of the antibody and pharmacodynamic effects are likely to result in therapeutic failure (i.e., non- protective antibody titers). Administration of live attenuated agents should be avoided 
while receiving siplizumab treatment and for up to 6 months thereafter, depending on the dose and time for reconstitution of immune function. 
ITB-MED   Page 60 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
6.6 Other Concomitant T reatments 
The Investigator should instruct the subject to notify the study site about any new medications 
taken  after enrollment into the study.  All medications, procedures , and significant non-drug 
therapies (including physical therapy and blood transfusions) administered after the subject was enrolled into the study must be recorded on the appropriate eC RF. ITB -MED will provide eCRF 
completion guidelines with additional det ail for recording concomitant medications. 
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited medication. If in doubt the investigator should contact the ITB -MED medical monitor or designee 
before randomizing a subject or allowing a new medication to be started. If the subject is already enrolled, contact ITB-MED to determine if the subject should continue participation in the study. 
No other immunosuppressive medications should be administered, other than as per p rotocol.  
6.7 Treatment of Adverse Events 
Following are recommended guidelines for the management of AEs. Medication s used to treat 
AEs must be recorded on the appropriate e CRF.  
6.7.1  Treatment of Acute Rejection Episodes  
In all suspected acute rejection episodes, regardless of initiation of anti -rejection treatment, a renal 
biopsy should be performed within 48 hours.  Acute rejections should be treated with bolus methylprednisolone (other CS are acceptable at an 
equivalent dose) according to local practice. Recommen ded treatment is at least 3 boluses of IV 
methylprednisolone with a minimal dose of 250 mg/bolus or at least 2 boluses of IV methylprednisolone with a minimal total dose of 750 mg. 
Subjects  who experience steroid -resistant rejections, vascular rejections , or rejections with a Banff 
grade ≥ 2B (Appendix 6Appendix 6Appendix 6Appendix 6Appendix 6Appendix 7) may be treated 
with other anti-rejection therapies (i.e., antibody therapy).  It is important to note that the  combination of siplizumab  and other T -cell depleting antibodies, 
e.g., ATG, alemtuzumab, mT OR inhibitors (sirolimus or everolimus), IVIG or costimulatory 
blockade (belatacept ) have not been investigated and may result in overlapping pharmacology. In 
the setting of an acute rejection episode, the selection and use of one or more of these agents in 
combination with siplizumab  is at the investigator’s discretion based on their experience.   
All episodes of acute rejection , and any medications used for suspected or confirmed acute 
rejections , must be entered on the corresponding eCRF, preferably within 24 hours. 
6.7.2  Management of BK V iremia  
BK Polyoma virus (BKV) screening generally utilizes plasma (or whole blood) viral load (VL) molecular assays. Urine studies (cytology for “decoy cells,” BKV DNA or VP -1 mRNA) are less 
specific. Decoy cells are shed infected tubular and ureteric epithelial cells with an enlarged nucleus with a large basophilic intranuclear inclusion by urine cytology. Cytology cannot distinguish BKV from adenovirus and false negative tests also occur. A urinary test for BKV (cytology for decoy 
ITB-MED   Page 61 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
cells or urine BKV loads over 7- log geq/mL) is adequate for screening; if negative, the risk for 
polyoma virus associated nephropathy (PVAN) is low.  
Quantitative cutoffs for presumptive diagnosis of BKV nephropathy include plasma DNA VL 
>10,000 copies/mL (whole blood polymerase chain r eaction (PCR)  VL >1500–3500 copies/mL), 
urine VP1 mRNA load >6.5 X 10e5 copies/ng total RNA, or urine DNA load >10e7 copies/mL; higher viral loads are increasingly predictive of PVAN.  
World Health Organization (WHO) standards  will be utilized in the perfo rmance of BKV 
quantitative nucleic acid testing (QNAT) to ensure minimization of  interlaboratory variability .  
Biopsy is suggested for confirmation if creatinine is elevated. Renal histopathology provides 
definitive diagnosis of PVAN ( Fishman 2017).  
If a subject  is found to have BK Viremia or PVAN, the event should be recorded in the appropriate 
eCRF as an AE or SAE,  and they should be managed as per local center practice.  
6.7.3  Management of Delayed Graft Function (DGF)  
DGF for t his trial is defined  as the need for dialysis  performed within 7 days of transplant.  
However, in the event that a subject experiences DGF and does not undergo dialysis , DGF must 
still be reported as an AE in these subject s.  
NOTE: Patients who require dialysis (up to two sessions), with the purpose of correcting electrolyte abnormalities in the immediate post- transplant time period, would not meet the 
definition of DGF for purposes of this study. 
In case DGF is reported as an AE and dialysis is also reported, the end of DGF is considered the 
day the last dialysis session ends.  Fo r all other subject s it is when the renal dysfunction is 
considered resolved by the investigator. 
In case a subject  experiences DGF, the DGF is by def inition starting at reperfusion after the 
transplantation procedure. If the graft dysfunction is starting later according to the Investigator, 
then this condition is considered secondary graft dysfunction.  
In case of DGF, treatment will be according to local practice. DGF treatments must maintain 
sufficient immunological coverage for the graft and may include maintaining, interrupting, or 
reducing the dose of study treatment  and the use of rATG . If a polyclonal antibody or rATG  is 
used prior to Day 4, the investigational product  must be discontinued, and the subject will be placed 
on SoC per local practice.  
6.7.4  Primary Graft Non -Function (PGNF)  
PGNF is defined as dialysis start ing after transplantation with a continuous record of 
post- transplant dialysis until either transplantectomy , re-transplantation or death . PGNF should be 
reported on the Graft Loss eCRF. 
If a subject is placed on permanent dialysis (or re -transplanted), the Graft Loss and AE  eCRFs 
should be completed, and an SAE of graft loss reported.  
ITB-MED   Page 62 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
6.7.5  Management  of EBV -PTLD  
EBV -PTLD is a serious disease.  Transplant clinicians managing suspected and confirmed PTLD 
should follow local institutional guidance on the diagnosis and management of EBV -PTLD , 
including consulting with transplant infectious disease and hematology- oncology clinicians  where 
relevant.    
In patients diagnosed with EBV -PLTD , therapy must be individualized.  rATG and s iplizumab 
doses planned for this trial ar e expected to result in T - and NK -cell depletion and minimal to no  
modulation of the B -cell compartment , respectively .  Clinicians should refer to the siplizumab IB  
or local labelling for rATG when considering therapeutic options  for the treatment of EBV -PTLD . 
Consensus guidelines on the diagnosis and management of E BV-LPD and PTLD in the setting of 
solid organ transplantation have been published and may be referenced  (Allen and Preiksaitis 2013  
and Parker et al 2010 ). 
6.8 Treatment Exposure and Compliance 
Following discharge from the hospital, the Investigator or designee will dispense the appropriate 
amount of  concomitant study treatment per SoC . Drug accountability will be  performed to assess 
compliance at each study visit. The Investigator should promote compliance by instructing the 
subject  to take their study drugs exactly as prescribed and by stating that compliance is necessary 
for the subject ’s safety and the validity of the study. The subject should be instructed to contact 
the Investigator if he/she is unable for any reason to take the study drugs as prescribed. 
All drug trough concentrations assessed in this study ( siplizumab , TAC) will be measured per the 
Schedule of Assessments  and the Laboratory Manual.  For all samples sent for central analysis, 
the exact time  and the date of sampling, together with the exact time and date of the last study 
medication dose prior to the sampling must be accurately recorded on the central laboratory 
request form (refer to the separate Laboratory Manual). S iplizumab  will be measur ed in serum  and 
TAC will be measured in whole blood.  On the day of a scheduled sampling, the subject  will be instructed not to take his/her morning dose 
of immunosuppressant medications, to record the medication dosage and time of last dose on the 
day prior to the blood sampling, and to bring all study drugs to the visit so that a dose may be administered upon completion of blood sampling.  
6.9 Prohibited Treatment 
Immunosuppressants and induction treatment  other than those specified in the protocol are NOT 
allowed after informed consent up to the  end of study.  If the use of any of these medications or 
other non- protocol immunosuppressants is discovered prior to randomization/enrollment, the 
subject must not be randomized and will be recorded as a screen failu re. If discovered after 
randomization/enrollment, no further doses are to be given, and the subject should continue on the randomized/assigned treatment regimen, noting the protocol deviation.  
The exception is for the treatment of acute rejection not resp onding to corticosteroids. 
The use of concomitant medications that may influence tacrolimus levels should be avoided, please 
refer to Appendix 6 and local prescribing information. 
ITB-MED   Page 63 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
7 Informed Consent Procedures 
Eligible subjects may only be included in the study after providing (witnessed, where required by 
law or regulation), Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) 
approved informed consent. 
If applicable, in cases where the subject's representative(s) gives consent (if allowed according to 
local requirements), the subject must be informed about the study to the extent possible given his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by personally signing and dating the written Informed Consent Form (I CF). 
Informed consent must be obtained before conducting any study- specific procedures . The process 
of obtaining informed consent must be documented in the subject source documents. 
ITB-MED  will prov ide to investigators in a separate document a proposed ICF  that complies with 
the International Conference on Harmonization Good Clinical Practice  (ICH GCP ) guidelines and 
regulatory requirements and is considered appropriate for this study. Any changes to the proposed 
consent form suggested by the investigator must be agreed by ITB-MED before submission to the 
IRB/IEC.  
A copy of the approved version of all consent forms must be provided to ITB -MED after IRB/IEC 
approval. 
8 Visit  Assessments   
The Schedule of Assessments is located in Appendix 1 and lists all of  the study assessments and 
when they are to  be performed . All data obtained from these assessments must be supported in the 
subject’s source documentation. While COVID -19 disease remains a risk, efforts to minimize the time a subject spends indoors at 
the clinic may be considered. These efforts could include use of virtual or telehealth technology, 
where appropriate, to remotely capture applicable study data (e.g., overall health status, assessment of medication compliance, review of adverse events). The intent is to allow centers to minimize in-person onsite clinic visit activities to those assessments that require the subject to be physically 
present (e.g., laboratory collections or physical assessments). In the event virtual or telehealth technology is utilized to facilitate data collection, it should be done per institutional practice and local regulations. Detailed documentation of all contact and informat ion collected virtually is to 
be recorded in the study records.  
This protocol defines 7 days to a week and 4 weeks (or 28 days) to a Study Month. For example, 
Week 2 is considered to start on Day 8 and Study Month 2 is considered to start on Day 29 (Start  
of Week 5) .  
Following is a description of study assessments/procedures.  For the full Schedule and when to collect for each subject, refer to Appendix 1. 
ITB-MED   Page 64 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
8.1 Subject Identification 
Each subject is identified in the study by a s ubject  identification  number (SID) that is automatically 
assigned by the EDC system once the subject has signed informed consent, ha s at least one study 
assessment or procedure completed, and the relevant data has been entered into the eCRF/EDC by 
the des ignated site staff. The SID  is retained as the primary identifier for the subject throughout 
his/her entire participation in the trial. The SID consists of the Site  Number (assigned by ITB -
MED to the investigative site) with a sequential subject number suffixed to it, so that each s ubject 
is numbered uniquely across the entire database.  
8.2 Screen Failure Assessments 
Subjects who sign an ICF and are subsequently found to be ineligible prior to randomization will be considered a screen failure. The reason for screen failure should be recorded on the appropriate eCRF. The demographic information, informed consent, and Inclusion/Exclusion pages must also be completed for screen failure subjects. No other data will be entered into the clinical database for subjects who are screen failures, u nless the subject experienced a SAE during the screening 
phase.  
It is permissible to re -screen a subject if s/he fails the initial screening; however, each case must 
be discussed and agreed with ITB- MED on a case -by-case basis.  
8.3 Efficacy / Pharmacodynamic Assessments  
All blood samples  will be taken by either direct venipuncture or an indwelling cannula. Please 
refer to the Laboratory Manual for a detailed description of central labor atory sample processing, 
handling, storage, shipment and analytical measure s. 
Immunophenotyping The effect of siplizumab  on circulating leukocytes and T -cells will be determined using flow 
cytometry FACS. Cell subpopulations that will be analyzed may include but are not limited to 
those bearing one or more of the following cell surface or intracellular markers: CD2, CD3, CD4, 
CD5, CD8, CD19, CD25, CD27, CD38, CD45RA, CD45RO, CD59, CD127, CD138, CD154, FoxP3 and HLA- DR.  
Lymphocyte CD2 Receptor Occupancy  
Peripheral CD2 receptor occupancy by siplizumab  will be determined by flow cytometry analysis, 
measuring free or total CD2 receptors on T- cells.  
8.4 Safety Assessments  
8.4.1  Physical Examination  
A com prehensive physical examination will be conducted at screening, on Day 7 and then at each 
study visit thereafter.  The examination will include a comprehensive assessment  of the subject’s 
general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen (including spleen  and l iver), back, lymph nodes , extremities  and vascu lature. The examination will 
ITB-MED   Page 65 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
also include a thorough neurological evaluation. If indicated , based on medical history and/or 
symptoms, rectal, external genitalia, breast, and pelvic exams will be performed.  
Physical examination findings will be entered in the applicable Physical Examination eCRF. 
Clinically relevant findings that are present before  the subject has had at least one invasive study 
procedure completed and/or performed  must be recorded on the appropriate Medical History 
eCRF. Significant findings discovered after the start of study procedures , which meet the 
definition , must be recorded as an adverse event . 
8.4.2  Vital Signs  
Vital signs (radial pulse rate, blood pressure , respiratory rate , and body temperature) will be 
recorded as indicated in the Schedule of Assessments . Attempts should be made to assess the blood 
pressure and pulse on the same arm each time of determination and after the subject has rested in 
the sitting position (may be supine if during hospitalization) for at least five minutes. Body 
temperature should be measured as per local practice – the same method to be used consistently 
for all subjects at each site.  
8.4.3  Height and Weight  
Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram [kg] ); in indoor clothing, 
but without shoes will be measured. 
Body mass index (BMI) will be calculated using the following formula:  
• BMI = Body weight (kg) / [Height (m)]2 
8.4.4  Laboratory Evaluations 
Samples for the laboratory tests noted below will be collected at the time points specified in 
Schedule of Assessments .  Refer to the Laboratory Manual f or detailed instructions  regarding the 
timing of central laboratory specimen collection  along with the handling, processing, storage,  and 
shipping of samples.  
In the case where a laboratory assessment that is listed in the inclusion/exclusion criteria is outside 
of a protocol -specified range at screening and/or at the initial baseline, the assessment may be 
repeated once prior to randomization. If the repeat value remains outside of protocol -specified 
ranges, the subject is excluded from the study. The Investigator must document in the source documents, the clinical considerations and medical 
relevance of any values outside of the reference range. (i.e., result was/was not clinically 
significant and/or medically relevant) for all laboratory values.  
Clinically relevant deviations of laboratory test results should also be evaluated for criteria 
defining an AE and reported as such if the criteria are met. Repeated evaluations are mandatory 
until normalization of the result(s) or until the change is no longer clinically relevant.  
Clinically significant abnormalities should be recorded on the relevant section of the Medical 
History/Current Medical Conditions/AE eCRF page as appropriate. 
ITB-MED   Page 66 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
8.4.4.1  Hematology  
Hemoglobin, hematocrit, red blood cell (RBC), MCV, MCH, Platelet Count, white blood cell 
(WBC) and differential count (% and abs).  
8.4.4.2  Clinical Chemistry  
Albumin, total bilirubin, calcium, creatinine, glucose, phosphorus, magnesium, potassium, A LT, 
AST, ALP , GG T, amylase, sodium, uric acid, and urea/ Blood Urea Nitrogen ( BUN) will be 
measured.  
8.4.4.3  Lipid Panel  
Cholesterol, triglycerides, LDL, HDL  will be measured.  
8.4.4.4  Urine Dipstick  
At a minimum, the  following parameters will be measured: pH, protein, blood, glucose, nitrite s, 
and leukocytes. 
In the event of positive findings, follow-up urinalysis should be performed per local standards.  
8.4.4.5  Pregnancy  
Serum or urine pregnancy testing will be required for females  of child- bearing potential, at 
timepoints as designated in the Schedule of Assessments . A serum or urine pregnancy test must 
be obtained up t o 72 hours prior to  time of transplant and the result must be available and negative 
prior to administration of investigational product.  8.4.4.6  Renal Func tion 
Renal function will be assessed by eGFR, using an automated calculat ion factoring  serum 
creatinine, demographics and the MDRD 4 formula.  
8.4.4.7  Coagulation Studies  
Coagulation studies will be performed, including international normalized ratio  
(INR) /prothrombin time (PT) and activated partial thromboplastin time ( aPTT) . 
8.4.4.8  EBV-DNA PCR  
All subjects will have quantitative EBV viral load measured in serum ( or whole blood) by a 
standardized PCR- based method. All  measurements will be conducted centrally by a laboratory 
utilizing World Health Organization  EBV international reference standards.  
There are currently no consensus guidelines on thresholds for EBV DNAemia or viral load  in adult 
renal transplant recipien ts, therefore any PCR positive  result that is increasing  from baseline or a 
previous assessment will be flagged to the investigator  for local follow -up per protocol, including 
a full physical and neurological exam with careful attention to the liver, spleen, allograft and lymph 
nodes.  In addition, ad hoc  abdominal and allograft ultrasound to screen for signs and symptoms 
of potential PTLD lesions  will be conducted.   
ITB-MED   Page 67 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Suspicion of PTLD in the setting of increasing EBV viral load should be further evaluated as 
outlined in Section 8.4.5.    
8.4.4.9  CMV DNA PCR  
All subjects will have quantitative CMV viral load measured by a PCR -based method, preferably  
calibrated in IU/mL .  The CMV titer  in blood should be recorded on the applicable eCRF.  No 
specific viral load cutoffs are available to initiate antiviral therapy. However, persistent low -level 
viremia (<2500 IU) suggests excess  immunosuppression or stimulation by other infections or  
processes ( e.g., rejection).  If PCR positive, then treatment should be initiated  per local practice. 
8.4.4.10  Donor Specific Antibodies (DSA ) 
Blood samples for DSAs  (antibodies directed against antigens expressed on donor organs) will be 
collected and evaluated locally.  8.4.4.11  Immunogenicity  
The presence of anti -siplizumab  antibodies will be determined using a bridging ELISA -based 
assay.  
8.4.4.12  Viral Testing and S urveillance   
All subjects will be screened/monitored for HBV, HCV, HIV, EBV, CMV,  and BK virus per local 
center practice unless more rigorous testing is required for EBV  and CMV monitoring, as noted in 
Section  8.4.4.8 and 8.4.5. Results of these assessments are to be transcribed into the appropriate 
eCRF pages.  
8.4.5  EBV-PTLD  Surveillance  
Clinical manifestations of EBV infection range from asymptomatic infection to clinically 
significant and potentially life -threatening disease in transplant recipients. EBV infection can be 
either primary (new infection occurring in an immunologically naïve subject) or secondary due to either reactivation of latent EBV in the transplant recipient under the pressure of immune suppression or reinfection with a new EBV strain. In general, secondary infection tends to be mild or even asymptomatic. Histologic evaluation is important in defining disease status of a subject with suspected PTLD; manifestations can evolve in individual subjects.  
The World Health Organization has provided standardized criteria for the pathologic evaluation of 
lesions associated with EBV in solid organ transplant recipients.  
The following signs and symptoms should guide the clinician in assessing the risk of and for 
EBV -PTLD ( Green and Michaels 2013):  
Signs 
• Pallor  
• Lymphadenopathy 
• Subcutaneous nodules 
ITB-MED   Page 68 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
• Tonsillar enlargement or inflammation  
• Hepatosplenomegaly 
• Focal neurologic signs 
• Mass lesions found on imaging obtained for other reasons 
 
Constitutional and systemic symptoms:  
• Unexplained fever or night sweats 
• Malaise  
• Weight loss and/or anorexia 
• Sore throat 
• Swollen glands 
• Headache or focal neurologic symptoms 
 Allograft -specific symptoms:  
• Liver: jaundice, abdominal pain 
• Intestine: abdominal pain, gastrointestinal bleeding, nausea and vomiting 
• Heart/lung: shortness of breath, cough, decreased lung function (lung alone) 
• Renal: kidney dysfunction 
 Laboratory tests: 
• Serial increase in EBV viral load from peripheral blood 
The following assessments may be considered as part of the diagnostic work- up for suspected 
EBV -PTLD ( Green and Michaels 2013):  
Routine:  
• CBC, differential, platelets  
• Serum electrolytes, calcium, BUN and creatinine  
• Liver function tests  
• Uric acid  
• Lactate dehydrogenase  
• Quantitative immunoglobulins  
• EBV serologies (anti- Epstein –Barr nuclear antigens (EBNA), viral capsid antigen (VCA) 
and early antigen (EA) 
• EBV viral load from peripheral blood 
• Stool : occult bleeding 
ITB-MED   Page 69 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
• Chest radiograph (anteroposterior and lateral) 
• CT or PET scan of neck/chest/abdomen/pelvis 
• Core needle or excisional biopsy of lesion(s) with f low cytometry of  lymphocytes (when 
possible)  
o EBER, CD20 histochemistry studies of pathologic samples 
In select patients, based on signs, symptoms and routine assessments, the following procedures 
may be considered:  
• Bone marrow biopsy 
• Bone scan  
• Brain CT/MRI  
• Gastrointestinal endoscopy 
• Lumbar puncture 
• Ultrasound assessment of abdomen and allograft  
Any diagnostic procedures or additional laboratory assessments that result in the diagnosis of  
EBV -PTLD must be captured on the relevant eCRFs. 
8.4.6  Imaging: PTLD Surveillance 
When warranted based on physical examination findings  and/ or EBV surveillance, subjects should 
have an ultrasound performed of the abdominal cavity and allograft to rule  out nodal and/or extra -
nodal EBV -LPD lesions. CT, MRI and/or PET imaging may be considered for staging and 
monitoring of biopsy confirmed PTLD.    
8.4.7  Renal  Biopsy  
Any biopsies performed according to local practice  must be recorded.  Biopsies will be read by the 
local pathologist according to local practice and the 2017 Banff criteria  (Appendix 7). The results 
of the biopsy read by the local pathologist will be listed on the applicable eCRF.  
Additionally, f or all suspected rejection episodes, regardless of initiation of anti -rejection 
treatment, a  renal  biopsy must be performed within 48 hrs. The results will be used for subject 
management for acute rejection.  
Please refer to the Laboratory M anual for details on biopsy handling and histology assessments. 
8.4.8  Treated Biopsy Proven Acute Rejection  
Treated biopsy proven acute rejection (t BPAR ) is any  condition in which the subject receiv es 
anti-rejection treatment and is  histologically diagnosed as acute rejection according to the 2017 
Banff criteria , including borderline rejections, as outlined in Appendix 7.  
8.4.9  Graft Loss 
The allograft will be presumed to be lost on the day the subject starts dialysis and is not able to 
subsequently be removed from dialysis. If the subject undergoes allograft nephrectomy prior to 
ITB-MED   Page 70 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
starting permanent dialysis, then the day of nephrectomy is the day of graft loss. The  reason for 
graft loss will be recorded on the applicable eCRF. Graft loss is considered a n SAE and should be 
reported on the AE eCRF (as  serious ), and the SAE reported to ITB -MED Safety within 24 hours. 
8.4.10  Death  
In the ev ent of subject death, the SAE leading to death should be reported to ITB -MED Safety 
within 24 hours.   
8.5 Pharmacokinetic Assessments  
Pharmacokinetics ( siplizumab  / anti- siplizumab  antibodies) 
PK samples will be obtained and evaluated in all subjects at all dose levels, as outlined in the 
Schedule of Assessments . The timing of the PK sample collection may be altered based on 
emergent data, but the total number of samples and total blood volume collected will not exceed 
those stated in the L aboratory M anual.   
Siplizumab  concentrations will  be determined by a valid ated ELISA method; the anticipated 
Lower Limit of Quantification (LLOQ) is  10 ng/mL  and c oncentrations will be expressed in mass 
per volume units . Concentrations below the LLOQ will be reported as “zero” and missing data 
will be labeled as such in the Bioa nalytical Data Report.  
The following PK parameters will be determined using the actual recorded sampling times and 
non-compartmental method(s): C max, Tmax, area under the curve ( AUC ) last, AUC inf, T1/2, Vz/F and 
CL/F from the serum concentration -time data.  
The linear trapezoidal rule will be used for  (AUC ) calculation. Regression analysis of the terminal 
plasma elimination phase for the determination of T 1/2 will include at least 3 data points after C max. 
If the adjusted R2 value of the regression analysis of the terminal phase will be less than 0.75, no 
values will be reported for T 1/2, AUC inf and CL. 
Follow instructions outlined in the Laboratory Manual regarding sample collection, numbering, processing and shipment. 
8.6 Asses sment of Treatment Exposure and Compliance 
PK parameters (measures of treatment exposure) will be determined in all subject s treated with 
study treatment.  TAC trough concentrations will be determined locally and recorded on the 
relevant trough level e CRF.  The local trough values will be used to adjust the TAC dosing as 
needed. 
Compliance with the subject’s treatment regimen will be assessed by the Investigator and/or 
designat ed site personnel at each study visit and info captured in the source and relevant eCRF.  
ITB-MED   Page 71 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
8.7 Exploratory Biomarker  Assessments  
 
 
    
  
 
 
 
  
 
9 Study Discontinuation and Completion 
9.1 Discontinuation 
9.1.1  Safety Stopping Rules  
The following stopping rules based on potential toxicities will serve as the basis for placing enrollment and dose escalation on hold.  
Although the stopping criteria do not incorporate an absolute requirement for causality, the 
potential relationship between an AE(s) and siplizumab  will be evaluated carefully on a case-by-
case basis between ITB -MED and the Investigator. Following a review of the AE(s), a decision to 
permanently discontinue enrollment or re -initiate dosing will be made by the DMC. Dose limiting 
toxicities (DLTs) will be assessed according to the standardized toxicity grading scale, the National Cancer Institute ( NCI) CTCAE  version 5.0 ( NCI 2017). 
• One (1) subject death or graft loss within the first month with the exception of technical failures .  
• One (1) subject presents with histologically * confirmed  EBV -PTLD . 
• One (1) subject with Grade 3 or higher cytokine release syndrome within 24 hours of any siplizumab  administration . 
• One (1) subject with any Grade 4 toxicity, considered drug related as determined by the 
Investigator within the first 28 days.  

ITB-MED   Page 72 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
• Two (2) subjects with sustained (> 7 days) Grade 3 neutropenia (neutrophil counts 200/mm3 
to < 500 to; 0.2 to <0.5 x 10e9/ L) considered related to siplizumab . 
• Two (2) or more subjects presenting with Grade 3 or higher toxicity considered drug related 
as determined by the Investigator, including infusion reactions , within 24 hours of any 
siplizumab  administration . 
• Three (3) or more subjects per cohort presenting with Grade IIA or higher BPAR ( T-cell 
mediated rejection ( TCMR ); central pathology) during the first 6 months post-transplant. 
*NOTE: in the case of suspected  PTLD lesions where a biopsy is not possible (e.g., CNS 
symptoms), radiographic and imaging (MRI) studies may be used to stage and assess the disease.  
In addition, safety data will be regularly reviewed by ITB -MED and an independent DMC. This 
regular review of cumulative data includes near real -time assessment of acute rejection (BPAR) , 
graft losses deaths , and key safety endpoints. In the event the acute rejection rate exceeds a 
clinically relevant threshold set forth in the protocol and DMC charter, or the a priori  defined 
stopping rules, enrollment will be suspended to allow for the early termination of any treatment 
cohort where the benefit/risk of siplizumab  is deemed unacceptable.  
9.1.2  Discontinuation of S tudy Treatment  
Discontinuation of study treatment for a subject occurs when study treatment is stopped earlier 
than the protocol planned duration. Discontinuation can be initiated by the subject , the investigator , 
or by ITB- MED . 
Possible reasons for study treatment discontinuation are: 
• AE, e.g., c ytokine release syndrome, PTLD,  CTS   
• Lack of Efficacy  
• Technical problem during transplant surgery 
• Primary non-function 
• Subject/Guardian Decision 
• Lost to follow-up 
• Pregnancy  
• Death  
• Graft Loss  
The Investigator  should discontinue a subject from their randomized treatment regimen if  he/she 
believes that continuation in the study would be detrimental to the subject’s well-being. 
Subjects who discontinue their study treatment should NOT be considered withdrawn from the 
study UNLESS they withdraw their consent to participating in all the elements of the study. Such subjects should remain in the study, if possible, and receive standard of care immunosuppression, according to local practice, and return for follow-up visits through Month 12.  
All randomized subjects are expected to continue in the study up to Month 12. If they refuse to 
return for these assessments or are unable to do so, every effort should be made to contact them to 
ITB-MED   Page 73 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
determine their health status, evaluate safety (SAEs) and to request a final study visit. 
Documentation of attempts to contact the subject should be recorded in the source documentation. If the subject is unable to return for a final study visit, every effort to obtain the subject and graft status should be made and documented within the subject chart. 
9.1.3  Withdrawal of  Informed Consent  
Subjects may voluntarily withdraw consent to participate in the study for any reason at any time. 
Withdrawal of consent occurs only when a subject  no longer wishes  to participate in the study and 
does not allow further collection of personal data. 
In this situation, the investigator should make a reasonable effort ( e.g., telephone, e -mail, letter) to 
understand the primary reason for the subject’s decision to withdraw his/her consent and record 
this information.  Study tr eatment must be discontinued, and no further assessments c ompleted . 
Further attempts to contact the subject are not allowed unless safety findings require communicating or follow-up. 
ITB-MED will continue to maintain , and use collected study information (including any data 
resulting from the analysis of a subject’s samples until the time of withdrawal) according to 
applicable law.  
All biological samples  collected  at the time of withdrawal, but not yet analyzed  for subjects 
enrolled within the US , may still be used for further testing/analysis in accordance with the terms 
of this protocol and of the ICF.   
9.1.4  Lost to F ollow -up 
For subjects whose status is unclear because they fail to appear for study visits without stating an intention to discontinue or withdraw, the investigator must show "due diligence" by documenting in the source documents steps taken to contact the subject, e.g., dates of telephone calls, registered 
letters, etc. A subject should not be considered as lost to follow -up until due diligence has  been 
completed  or until the EOS . 
9.1.5  Early Study Termination by the S ponsor  
The study can be terminated by ITB-MED at any time. Should this be necessary, the subject should 
be seen as soon as possible and treated as a prematurely withdrawn subject. The Investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the  protection of the subject’s interests. The  Investigator will be responsible for 
informing IRBs and/or ECs of the early termination of the trial.  
9.2 Study Completion 
Study completion is defined as when the last subject finishes their final s tudy visit (Month 12)  and 
any repeat assessments associated with this visit have been documented and followed-up appropriately by the Investigator or, in the event of an early study termination decision, the date 
of that decision.  
ITB-MED   Page 74 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Each subject will be required to complete the study in its entirety and thereafter no further study 
treatment will be made available to them (as applicable based on local regulations). Subjects who are prematurely withdrawn from the study should be treated according to local SoC per the 
Investigator’s judgment. The study will complete when the last subject completes their Study Completion V isit, and any repeat assessments associated with this visit have been documented and 
followed-up appropriately by the Investigator. 
9.3 Subject Replacement 
Replacement during Dose Escalation  
Subjects will not be replaced on study. However, if a subject is considered as non -evaluable, 
enrollment of a new subject to the current  cohort will be considered if there is less than the required 
number of evaluable subjects. Enrollment of new subjects may be considered until at least the minimum number ( 4) or at most the maximum number ( 8) of evaluable subjects is achieved within 
the co hort.  
Minimum and maximum numbers of evaluable subjects per cohort are defined in the guidelines for dose escalation and determination section. 
10 Safety Monitoring and Reporting 
10.1 Definition of Adverse Events and Reporting Requirements 
10.1.1  Adverse Events 
The Investigator is responsible for reporting all AEs that are observed or reported during the study, 
regardless of their relationship to study medication or their clinical significance.  Given the 
potential for protracted time between a subject providing informed consent and organ transplant, AE collect ion will commence once a subject has provided consent and has at least one invasive 
study procedure completed and/or performed (e.g., blood draw).  
An AE is any untoward medical occurrence in a study subject administered an investigational 
product which  does not necessarily have a causal relationship with the product. A n AE  can 
therefore be any unfavorable and unintended sign (including a new, clinical important abnormal 
laboratory finding), symptom, or disease, temporally associated with the product, whether or not related to the product.  
Pre-existing  diseases  or conditions will not be considered an AE  unless there is an increase in the 
frequency or severity, or a change in the quality of the disease or condition (w orsening of a 
pre-existing condition is considered an AE).   
The occurrence of AEs  must be sought by non- directive questioning of the subject at each visit 
during the study. AEs  also may be detected when they are volunteered by the subject during or 
between visits or through physical examination findings, laboratory test findings, or other assessments.  
ITB-MED   Page 75 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
AEs must be recorded under the signs, symptoms, or diagnosis associated with them, and 
accompanied by the following information: Assessment  and grade  according to the CTCAE  
criteria  (version 5.0 or higher) 
• Relationship to the study treatment  
If the event is due to lack of efficacy or progression of underlying illness ( i.e., progression 
of the study indication) the assessment of causality will usually be ‘Not suspected.’ The 
rationale for this guidance is that the symptoms of a lack of efficacy or progression of underlying illness are not caused by the trial drug, they happen in spite of its 
administration and/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by an analysis of cohorts, not on a single subject 
• Duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not 
resolved  
• Whether it constitutes a SAE and which seriousness criteria have been met  
• Action taken regarding with study treatment 
• Outcome 
AEs (including lab abnormalities that constitute AEs) should be described using a diagnosis 
whenever possible, rather than individual underlying signs and symptoms. 
AE monitoring should be continued for the duration of the study; in the event a subject does not 
complete the study for any reason, AE monitoring should continue for  6 months after the last 
administration of investigational product.  
Once an AE is detected, it must be followed until its resolution or until it is judged to be permanent 
(e.g., continuing at the EOS ), and assessment must be made at each visit (or more frequently, if 
necessary) of any changes in severity, the suspected relationship to the interventions required to 
treat it, and the outcome. 
Information about adverse drug reactions for the investigational drug can be found in the IB. 
Abnormal laboratory values or test r esults constitute AEs  only if they are considered clinically 
significant and/or require therapy or active management.  
10.1.2  Serious Adverse Events  
A Serious Adverse Event (SAE) is any untoward medical occurrence that:   
• Resul ts in death  
• Is life-threatening 
o Note : The term “life -threatening” in the definition of ‘serious” refers to an event 
in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it were more severe. 
• Results in persistent or significant disability/incapacity  
• Constitutes a congenital anomaly/birth defect 
ITB-MED   Page 76 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
o Note: Inpatient hospitalization is defined as 24 hours in a hospital or an overnight 
stay.  A n elective hospital admission to treat a condition present before exposure to 
the study drug, or a hospital admission for a diagnostic evaluation of an AE, does not qualify the condition or event as an SAE. Further, an overnight stay in the hospital 
that is only due to transportation, organization, or accommodation problems and without medical background does not need to be considered an SAE.  Routine treatment or monitoring of the studied indication, not associated with any deterioration in co ndition  that has not worsened since the signing of consent is not 
considered an SAE. 
• Is an important medical  event  
All reports of intentional misuse and abuse of the product are also considered SAEs  irrespective if 
a clinical event has occurred.  
10.1.3  Adverse Events of Special Interest  
The following AEs are selected as adverse events of special interest (AESI)  for surveillance and 
follow-up, both serious and non-serious, based on previous experience with siplizumab, a ll: 
• Serious Infections 
• Opportunistic Infecti ons, including EBV, CMV, BK virus  
• Malignancies , including LPD/ PTLD   
10.1.4  SAE Reporting 
Every SAE, regardless of causality occurring after the subject has provided informed consent and had at least one invasive study procedure performed and continuing until the final study visit , must 
be reported to the ITB-MED Safety  Department  or its designee. Reporting must take place within 
24 hours of learning of its occurrence  and is done by entering the SAE into the eCRF within 
24 hours of awareness. Additionally, all AESI whether serious or not should also be reported following the same procedure. 
Recurrent episodes, complications, or progression of the initial SAE must be reported as follow -up 
to the original episode, regardless of when the event occurs. This information must be submitted 
within 24 hours of the Investigator receiving the follow -up information. An SAE that is considered 
completely unrelated to a previously reported one should be reported separately as a new event. Information on all SAEs (either initial or follow up)  is collected and entered  in the eCRF (s). 
Information may also be  submitted in writing to  when important 
information or clinical updates are required that may not be feasible to provide within the eCRFs. 
Please refer to the Site Study Manual  for detailed instructions o n the reporting of SAEs.  
If the SAE is not previously documented in the IB  or Package Insert (new occurrence) and is 
thought to be related to the study treatment, ITB-MED Safety may urgently require further 
information from the investigator for health authority reporting. ITB -MED may need  to inform all 
investigators involved in any study with the same study treatment that this SAE has been reported.  

ITB-MED   Page 77 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Suspected  Unexpected Series Adverse Reaction s (SUSARs ) will be collected and reported to the 
competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 
172/01 or as per national regulatory requirements in participating countries. 
Any SAEs experienced after the Month 12 (EOS) visit should only be reported to ITB -MED Safety 
if the investigator suspects a causal relationship to study treatment. For subject s who terminate 
from the study prematurely, SAEs should only be reported if they occur within 6 months following 
the last administration of study treatment and a causal relationship is suspected . 
10.1.5  Pregnancy Reporting  
To ensure subject  safety, each pregnancy occurring while the subject  is on study treatment must 
be reported to ITB -MED Safety within 24 hours of learning of its occurrence. The pregnancy 
should be followed to determine outcome, including spontaneous or voluntary termination, details 
of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy follow -up should be repor ted to ITB -MED Safety and should include an assessment of 
the possible relationship to the investigational treatment to pregnancy outcome. Any AE or SAE 
experienced during pregnancy must also be reported . 
10.1.6  Early Phase Safety Monitoring  
The Investigator will  monitor AEs in an ongoing manner and inform ITB-MED  of any clinically 
relevant observations. Any required safety reviews will be made jointly between medically qualified personnel between ITB -MED  or it’s designee  and the Investigator (s). Criteria  pertaini ng 
to stopping the study/treatment or adapting the study design are presented above. 
ITB-MED  will advise the Investigator(s) at all sites in writing (e -mail) (and by telephone if 
possible) of any new, clinically relevant safety information during the conduct of the study in a 
timely manner.  
10.1.7  Reporting of S tudy Treatment Errors  
Medication errors are defined as potential, intercepted , or unintentional errors in the prescribing, 
dispensing, administration, or monitoring of a medicine while under the control of a healthcare 
professional, subject, or consumer . 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on the appropriate e CRF irrespective of whether or not associated with an AE/SAE and reported to Safety 
only if associated with an SA E; however , the ITB -MED study team should be notified 
immediately.  
11 Data Monitoring Committee  
This study will inc lude a DMC  which will function independently of all other individuals 
associated with the conduct of this clinical trial, including the site investigators participating in the study. The DMC will assess at defined intervals the progress of the clinical trial, safety data, and 
ITB-MED   Page 78 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
critical efficacy variables and recommend to ITB-MED  whether to continue, modify or terminate 
a trial.  
Specific details regarding composition, responsibilities, data monitoring and meeting frequency, 
and documentation of DMC reports, minutes, and recommendations will be described in a separate charter that is established between ITB-MED  and the DMC. 
12 Data Analysis and Statistical Methods  
This section describe s the statistical methods to be use d to analyze safety and efficacy.  These 
meth ods may be revised and updated due to reasons such regulatory requirements or need for 
further clarifications.  
The final analysis plan will be documented in a formal statistical analysis plan ( SAP) that must be 
finalized before database lock.  The SAP will include details on how variable s will be derived , 
how missing da ta will be handled, and how data will be presented as well as the details on statistical 
methods to be us ed for safety and efficacy analyses.  The final Clinical Study Report (CSR) will 
discuss deviations from the SAP, if any. Any data analysis carried out independently by the investigator must be submitted to ITB -MED  
before publication or presentation. 
12.1 Analysis sets  
The Full Analysis Set (FAS) comprises all subjects to whom study treatment has been assigned by 
randomization. According to the intent to treat principle, subjects will be analyzed according to the treatment they have been assigned to during the randomization procedure. 
The Safety Set includes all subjects who received at least one dose of study treatment. Subjects 
will be analyzed according to the study treatment received, where treatment received is defined as 
the randomized/assigned treatment if the subject took at least one dose of that treatment or the first treatment received if the randomized/assigned treatment was never received.  
The PK Analysis Set will include all subjects with at least one available valid (i.e., not flagged for exclusion) PK concentration measurement, who received any study drug and experienced no protocol deviations with relevant impact on PK data. 
The PD Analysis Set will include all subjects in the Full Analysis set  with available PD data and 
no protocol deviations with relevant impact on PD data. For all analysis sets, subjects will be analyzed according to the study treatment(s) received. 
12.2 Subject Demographics and other Baseline Characteristics  
All data for background and demographic variables will be listed by treatment group and subject. 
Summary statistics will be provided by treatment group.  
Subject demographics will include age, sex, race, ethnicity, height, weight and BMI. Other  baseline disease characteristics include relevant medical history, current medical conditions, 
ITB-MED   Page 79 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
resul ts of laboratory screens, transplant history, donor characteristics (e.g., age, sex, race, type, 
CIT) and any other relevant information.  
Summary statistics will be presented for the subjects in the FAS . Continuous variables will be 
presented with mean, median, 25th percentile, 75th percentile, standard deviation (SD), minimum 
and maximum, and the number of non-missing observations. Categorical data will be displayed via absolute and relative frequencies for each category 
(including a category labeled as “missing” when appropriate). 
12.3 Treatments 
The duration (days) of study medication administration will be summarized. This will be calculated by subtracting the date of the last administration of study medication from the date of first administration and then adding the dosing interval for s iplizumab , TAC, MMF or CS. In 
calculating the duration of treatment, days of temporary interruption of study medication for any reason will be included. Further, the frequency of dose changes (including temporary dose interr uption) will be presented by reason for the change. 
Average daily doses will be presented by treatment. “Zero” will be used for periods of temporary interruption of study medication for any reason. 
The number and percentage of subjects who prematurely discontinued study medication will be 
summarized by reason for discontinuation. 
Study treatment errors, including uses outside of what is foreseen in the protocol will be  
summarized.  AEs as a result of study treatment error will also be summarized.  
12.3.1  Concomitant Immunosuppressants  
The average daily dose of administered TAC, MMF,  and CS will be summarized by treatment arm 
for subjects on study medication. The dose of the induction agent will be summarized for each of 
days when it was administered. 
The dose of ant ibodies used for the treatment of acute rejection episodes will be recorded as well.  
12.3.2  Other Co-M edications 
Concomitant medications, other than immunosuppressants and CS mentioned above, will be 
summarized by therapeutic class and preferred term by presentin g the number and percentage of 
subjects using each medication for each treatment group. 
12.4 Analysis of the Primary Endpoint(s) 
12.4.1  Definition of P rimary Endpoint(s)  
All safety data, including laboratory assessments, vital signs  and AEs are considered primary 
endpoints.  
All information obtained on AEs  will be displayed by treatment and subject. The number and 
percentage of subjects with AEs  will be tabulated by body system and preferred term with a 
ITB-MED   Page 80 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
breakdown by treatment arm. A subject w ith multiple AEs  within a body system is only counted 
once towards the total of this body system. No formal statistical analysis will be done for the safety 
and tolerability evaluation.  
12.4.2  Statistical Model, Hypothesis, and Method of A nalysis  
All data will be  summarized and presented descriptively, no formal statistical analysis or 
hypothesis testing will be conducted on the analysis  sets. 
The use of the concurrent control group and supplementation with a historical control group to 
better  assess the incidence of AEs and SAEs reported with a T AC/MMF/CS based SoC treatment 
regimen  will be investigated .  Details  on the methodology for data selection  and analysis will be 
presented in the SAP. 
12.4.3  Handling of M issing Values/ Censoring/ Discontinuations  
The analysis will be made on the FAS population. The following imputation method will be 
applied for subject s with missing data: 
• Patients that lose their graft will be assigned a value of zero for their missing estimated glome rular  filtration (e GFR ) value.  
• Patients that die or are lost to follow -up with a functioning graft will have an imputed value 
using the last-observation- carried -forward (LOCF) method. 
• For subject s that discontinue randomized treatment , the eGFR will be considered missing after 
applying the windows defined in Section  12.1. 
Graft loss subject s do not have a functioning graft; hence the lowest possible GFR value (zero) 
will be assigned to such subject s. In contrast, subject s that die with a functioning graft, die for 
different reasons (e.g., suicide, car accident, cancer)  will have an imputed value assigned as 
described above.  
Patients who are lost to follow -up have renal function, but missing values for various reasons (e.g., 
moving from the area or not being able to make the site visit during the Month 6 or Month 12 visit 
window). Patients who have a functioning graft at the time of death or are Lost to Follow-up with a functioning graft will be analyzed via an imputation method that employs LOCF. 
12.5 Analysis of S econdary Endpoints 
12.5.1  Efficacy and/or Pharmacodynamic e ndpoint(s)  
Immunophenotyping 
These data will be summarized by treatment and subject.  
CD2 Receptor Occupancy  
The magnitude and duration of PD effect of siplizumab  will be as measured by peripheral blood 
CD2 -receptor occupancy. These data will be summarized by treatment and subject. Descriptive 
ITB-MED   Page 81 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
statistics will also be provided such as mean, median, SD , minimum and maximum, by time point 
and treatment.  
12.5.2  Safety Endpoints  
For all safety analyses, the safety set will be used. All listings and tables will be presented by 
treatment group. 
Safety summaries (tables, figures) include only data from the on- treatment period with the 
exception of baseline data which will also be summarized where appropriate ( e.g., change from 
baseline summaries). In addition, a separate summary for death including on treatment and post 
treatment deaths will be provided. In particular, summary tables for AEs will summarize only on-treatment events,  with a start date during the on- treatment period (treatment- emergent AEs).  
The on- treatment period lasts from the date of first administration of study treatment through the 
month 12 or EOS  visit.  
Adverse Events 
All information obtained on AEs  will be dis played by treatment group.  
The number (and percentage) of subjects with treatment emergent AEs  (events started after the 
first dose of study medication or events present prior to start of treatment but increased in severity based on preferred term) will be summarized in the following ways: 
• AEs by primary S ystem Organ C lass (SOC) and  Preferred Term   
• AEs rated to have relationship to study drug by SOC and P referred T erm 
• AEs by primary SOC, P referred T erm, and maximum severity 
• SAEs by SOC and P referred T erm 
• SAEs rated to have relationship to study drug by SOC and P referred T erm 
• Deaths by SOC and P referred T erm 
• AEs leading to discontinuation of a study drug by SOC and P referred T erm 
• AEs leading to dose adjustment or interruptions of a study drug by SOC and P referred T erm 
• Infections by type of infection (viral, bacterial, fungal, and others) and microorganism of 
infection  
• Serious infections by type of infection and micro-organism of infection 
• AEs by standardized MedDRA query (SMQ) levels (broad and narrow search) 
• AEs by SMQ and P referred T erm (broad and narrow search)  
Separate summaries will be provided for study medication related AEs , death, SAEs , other 
significant AEs  leading to discontinuation and AEs leading to dose adjustment. 
ITB-MED   Page 82 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
The number (and proportion) of subjects with AEs  of special interest/related to identified and 
potential risks ( e.g., serious infections, opportunistic infections, cytokine release s yndrome, 
malignancies)  will be summarized by treatment.  
Multip le Occurrences for Tables:  
In all tables about incidence rates of AEs / Infections, if a subject  has multiple occurrences of an 
AE, this subject  will be counted only once in the corresponding AE category. If a subject  has 
multiple AEs within a system organ  class, s/he will be counted only once for that class. If a subject 
has multiple severity ratings for an AE while on treatment, s/he is only counted under the 
maximum rating.  
Information pertaining to AEs noted during the study will be listed by subject , including the 
verbatim term given by the Investigator, the Preferred Term  and SOC given by the MedDRA 
dictionary, start and end date, causality, Grade and relationship to study drug as assessed by the 
Investigator. AEs which will be counted for a specific treatment period are those which are treatment emergent . 
These events are those with an onset after the start of the treatment period, or which were present 
prior to the start of the treatment period but increased in severity, changed from being not suspected to being suspected of study drug relationship, or developed into SAEs after the start of the treatment period.  
Vital Signs 
All vital sign data will be listed by treatment, subject, and visit/time and if ranges are available, abnormalities will be flagged. Summary statistics will be provided by treatment and visit/time.  
Clinical Laboratory Evaluations  
Abnormalities according to clinically notable criteria will be identified. A by -subject listing of 
individual subject  laboratory data will be generated. Values outside of the clinically notable limits 
will be flagged. Shift tables describing changes from randomization/enrollment based on the clinical notable criteria will be presented.  
Descriptive statistics (mean, SD , minimum, median and maximum) of quantitative laboratory 
variables, including change from randomization/enrollment, will be generated by visit. 
Other Safety evaluations  
BK-polyoma viremia and nephropathy  
The following variables will be analyzed descriptively:  
• occurrence of BK -polyoma viremia any time post-transplantation  
• occurrence of BK -polyoma virus nephropathy any time post-transplantation  
ITB-MED   Page 83 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
EBV and CMV Surveillance  
All quantitative and qualitative EBV  and CMV surveillance data (serology and DNA -PCR) will 
be listed by treatment, subject, and visit/time and if normal ranges are available, abnormalities will 
be flagged. Summary statistics including mean, SD, minimum, median and maximum  as well as 
change from baseline / previous assessment including s hift tables will be provided by subject and 
treatment by visit/time.  
Immunogenicity  
Anti-siplizumab  antibodies will be determined at specified time points. Immunogenicity data 
consisting of anti- siplizumab  antibodies information will be listed by subject  and visit. 
12.5.3  Pharmacokinetics  
Siplizumab  serum  concentration data will be listed by treatment, subject, and visit/sampling time 
point. Descriptive summary statistics will be provided by treatment and visit/sampling time point, including the frequency (n, %) of concentrations below the LLOQ and reported as zero. 
Summary statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and 
geometric), median, minimum and maximum. Concentrations below LLOQ will be treated as zero in summary statistics and for PK parameter calculations. A geometric mean will not be reported if the dataset includes zer o values. 
Table 12 -1 Non-compartmental pharmacokinetic parameters  
AUClast  The AUC from time zero to the last measurable concentration sampling time (tlast)  
(mass x time x volume -1) 
AUCinf  The AUC from time zero to infinity (mass x time x volume -1) 
AUCtau  The AUC calculated to the end of a dosing interval (tau) at steady -state (amount x time x volume -1) 
Cmax  The maximum (peak) observed plasma, blood, serum, or other body fluid drug concent ration after 
single dose administration (mass x volume-1)  
Tmax  The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after 
single dose administration (time)  
Lambda_z  Smallest (slowest) disposition (hybrid) rate con stant (time -1) may also be used for terminal 
elimination rate constant (time -1) 
T1/2 The elimination half -life associated with the terminal slope (λz) of a semi logarithmic concentration -
time curve (time). Use qualifier for other half -lives  
CL/F  The total body clearance of drug from the plasma (volume x time -1) 
Vz/F The apparent volume of distribution during terminal phase (associated with λz)  
(volume)  
If data permit, PK parameters will be calculated as described in Section 8.5 and Table 12 -1 and 
will be listed by treatment and subject. Concentrations below the limit of quantification will not be considered for the calculation of PK parameters. Descriptive  summary statistics will include 
mean (arithmetic and geometric), SD, and CV (arithmetic and geometric), median, minimum and maximum. An  exception to this is Tmax where median, minimum and maximum will be presented.  
ITB-MED   Page 84 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
A dose -independent, model -based analysis of the dose / concentration- exposure relationship 
should be derived using same the approach. Such analysis may be reported in a separate standalone 
report  
12.5.4  Biomarkers  
All biomarker data (e.g., renal injury markers, cytokine data) will be listed by treatment, subject, 
and visit/time. Summary statistics will be provided (mean, median, SD , minimum and maximum) 
by treatment and visit/time.  
In the summary tables, the frequency (n, %) of values below the LLOQ and above the upper li mit 
of quantification ( ULOQ ), respectively, will be included. 
In case of censored values (values below the LLOQ and/or values  above the ULOQ), the summary 
statistics (arithmetic mean, SD , geometric mean and CV% of geometric mean) will be calculated 
as the maximum likelihood estimates using a parametric model for data that can be right censored and left censored assuming the data being normally or log-normally distributed. 
12.5.5  PK/PD Relationships  
The relationship between siplizumab  concentration (PK) and PD variables will be explored 
graphically. Modeling of PK/PD data using a population approach may be performed as 
appropriate and may be reported in a separate standalone report. The broad principles outlined in 
the F ood and Drug Administration (F DA) Guidance for Industry: PPK  will be followed.  
12.6 Analysis of Exploratory Endpoints 
 
 
 
12.7 Interim Analyses  
A formal interim analysis  (IA) will occur once 50% of subjects assigned to the treatment Cohorts 
complete their 6-month study assessment. In consideration of the open -label nature of the study 
design and plan for descriptive statistical analysis , additional ad hoc  IA may be performed.  Results 
of the IA will inform decision making on safety, dose escalation and inclusion of additional doses 
to assure adequate profiling of the siplizumab PK and PD activity.   
Details of the IA  process and specific analysis will be presented in the SAP.   
In addition to the formal planned Interim Analys is, the AE and SAE rates will be monitored on a 
continuous basis to support the early discontinuation of any treatment arm that is unsafe and/or 
ineffective according to the Stopping Rules as outlined in Section 9.1.1.  

ITB-MED   Page 85 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
12.8 Dosing Decision  Data Review  
Prior to dose escalation to the next Cohort all available safety, tolerability , PK and PD data from 
the previous cohort(s) will be reviewed with the Investigators and a joint decision to escala te or 
terminate the arm will be made.  
Dose escalation from one Cohort to the next will be determined at least 28 days following the last 
investigational product administration in the 4th siplizumab treated  subject in each treatment 
cohort.   
The purpose of the Day 28 data review  is to confirm progression to the next cohort while the 6-
month IA is to support more PK/PD modeling activities  necessary to profile longitudinal 
siplizumab activity for more formal trial design and development decision making.   Results of the Dosing Decision data review  will be communicated to the DMC for information, 
consulting and/or decision purposes as  well as to participating investigators for information as 
deemed appropriate.  A separate, cumulative, data package will be provided to the independent 
DMC  as outlined in the DMC charter.  
12.9 Sample Size Calculation 
No formal sample size or power analysis has been performed. A sample size of 8 subjects for each  
treatment arm was chosen based on practical considerations , including the need to adequately  
characterize siplizumab PK and PD activity in renal transplant patients in the immediate 
post- transplant time period while balancing the overall exposure in a mechanistic profiling study. 
13 Study Conduct  
13.1 Sponsor Responsibilities 
ITB-MED is obligated to conduct the study in accordance with strict ethical principles .  ITB -MED  
will take action to ensure the accur acy and reliability of study data  by selecting qualified 
investigators and sites, by reviewing protocol procedures with the Investigator and relevant study personnel prior to study initiation, by conducting routine monitoring visits and by utilizing robust data management standards.  
13.2 Investigator Responsibilities 
The Investigator agrees to conduct this study in accordance with all laws, regulations, and 
guidelines of the pertinent regulatory authority.  While delegation of certain aspect s of the study 
to sub investigators  and research pers onnel is appropriate, the Investigator will remain  personally 
accountable for closely overs eeing the study and for ensuring compliance with the protocol and all 
applicable regulations and guidelines. Investigators should ensure that all persons who have been 
delegated study- related responsibilities are adequately qualified and informed about the protocol, 
study drugs and their specific duties within the context of the study. 
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the IRB/IEC for the trial protocol, written ICF, consent form updates, subject recruitment 
procedures (e.g., advertisements) and any other written information to be provided to subjects.  
ITB-MED   Page 86 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Prior to study start, the investigator is required to sign a protocol signature page confirming his/her 
agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to ITB -MED 
monitors, auditors, ITB -MED Quality Assurance representatives, designated agents of ITB -MED, 
IRBs/IECs, and regulatory authorities as required.  
If an inspection of the clinical site is requested by a regulatory authority, the investigator must 
inform ITB -MED immediately that this request has been made.  
13.3 Site Initiation 
Study personnel may not screen or enroll subjects into the study until after receiving  notification 
from ITB -MED or its designee that the study can be started.  Authorization to start the study will 
not occur until: 
• The study site has received the appropriate IRB/IEC approval for the study 
• A Clinical Trial Agreement has been executed  
• All pertinent study site personnel have received the appropriate protocol and study training  
• All regulatory/GCP documents have been submitted and approved by ITB- MED  
The regulatory documents must be received from the Investigator and reviewed and approved by 
ITB-MED or its designee before the study site can begin screening procedures and before 
ITB-MED can authorize shipment of investigational product to the site.  Copies of the 
Investigator’s regulatory documents must  be retained at the study site in a secure location.  It is 
the Investigator’s responsibility to ensure that copies of all re quired documents are organized, 
current and available for inspection. 
13.4 Data Quality Control 
13.4.1   Data Collection  
Designated investigator  staff will enter the data required by the protocol into the eCRFs  as soon 
as possible , but no later than 5 working days after a subject study visit . The eCRFs have been built 
using fully validated secure web- enabled software that conforms to 21 CFR Part 11 requirements, 
Investigator site staff will not be given access to the EDC system until they have been trained.  
The investigator/designee is responsible for assuring that the data entered into the eCRF is 
complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate. All data should be recorded, handled and stored in a way that allows its accurate reporting, interpretation, and verification. 
After final database lock, the investigator will receive copies of the subject data for archiving at 
the investigational site.  
13.4.2  Data  Management  
ITB-MED personnel or its designee will review the data entered by investigational staff for 
completeness and accuracy. Electronic d ata queries stating the nature of the problem and 
ITB-MED   Page 87 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data. 
Randomization codes and data about all study treatment (s) dispensed to the subject and all dosage 
changes will be tracked using an I WRS . The system will be supplied by a vendor, who will also 
manage the database. The data will be sent electronically to ITB -MED (or a designee) at specific 
timelines.  
13.4.3  Monitoring Procedures  
Before study initiation, ITB -MED or its  designee w ill review the protocol and data capture 
requirements with the investigators  and their study personnel. During the study, ITB -MED 
employs several methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The monitor will visit the site to check the completeness of subject records, the accuracy o f data capture / data entry, the adherence to the protocol and to GCP , the progress of 
enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist  the monitor during 
these visits. Continuous remote monitoring of each site’s data may be performed by ITB- MED or 
its designee.  
The investigator must maintain source documents /data  for each subject in the study. Source data 
is defined in International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use ( ICH) GCP (1.51) as all information in original 
records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data should be 
accurate, legible, contemporaneous, original, attributable, complete and consistent. 
All information within  the eCRFs must be traceable to these source do cuments in the subject’s 
file. Any data not requiring a separate written record will be defined before study start and will be 
recorded directly within the eCRFs.  The investigator must also keep the original ICF signed by the 
subject (a signed copy is given to the subject). The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. C onsistency of the source data with the e CRFs 
are performed according to the study- speci fic monitoring plan. No information in source 
documents about the identity of the subjects will be disclosed. 
In keeping with good clinical practice and guidance from the EMA, t he principal investigator must 
clearly define the intended location  of all source data by completing the Source Data Location 
Form  prior to subject recruitment.  This form  should be prepared by the site and should be signed 
and dated by the principal investigator or by a person whom the principal investigator has assigned 
this task.   The completed form should be filed in the Site Master File.  
13.4.4  Protocol Adherence  and Amendments  
This protocol defines the study objectives, the study procedures, and the data to be collected on 
study participants. Additional assessments required to ensure safety of subjects should be administered as deemed  necessary on a case-by- case basis. Under no circumstances , including 
ITB-MED   Page 88 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
incidental collection , is an investigator allowed to collect additional data or c onduct any additional 
procedures for any purpose involving any investigational drugs under the protocol, other than the 
purpose of the study. If despite this interdiction prohibition, data, information, observation would be incidentally collected,  the inve stigator shall immediately disclose it to ITB -MED and not use it 
for any purpose other than the study, except for the appropriate monitoring on study participants. 
Investigators should exercise  due diligence to avoid protocol deviations; however, should a 
deviation occur , the principal investi gator or their designee, must document the deviation from the 
approved protocol  and include an explanation for the deviation, including mitigation plans to avoid  
future occurrences .  
If an investigator feels a protocol deviation would improve the conduct of the study this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by ITB -MED 
and approved by the IRB/IEC and health authorities, where required, it cannot be implemented. Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by ITB -MED, health authorities where required, and the IRB/IEC prior to 
implementation.  
Only deviations to the protocol  that are required for subject  safety may be implemented 
immediately .  ITB -MED  and the applicable health authorities must be  subsequently notified of the  
protocol deviation(s) .  Additionally, the investigator must notify the reviewing IRB/IEC per the 
IRB/IEC’s protocol deviation reporting requirements. 
13.4.5  Quality Assurance  
ITB-MED maintains a Quality Management System (QMS) that includes  all activities involved in 
quality assurance and quality control, to ensure compliance with written Standard Operating 
Procedures  (SOPs)  as well as applicable global/local GCP regulations and ICH Guidelines.  
This study will be subject to audit by ITB -MED or its designee. Audits are conducted to assess 
GCP compliance with global and local regulatory requirements, protocols and internal SOPs. 
The investigator agrees to cooperate with the auditor during the visit and will be available to supply 
the auditor with direct access to source documents  and other necessary study files as necessary to 
conduct the audit.  In the event a regulatory authority notifies the site of an upcoming inspection, the Investigator shall notify ITB- MED immediately.  
13.5 Study Site Closure 
A study site’s participation in the study may be terminated at any time by ITB -MED.  At the end 
of the study, all study sites will be closed.  This will include the Investigator’s final approval and lock of all subject  data, return of unused study material and investigational product unless 
otherwise provided in writing by ITB-MED, and final visits by the monitor.   
13.5.1  Records Retention  
The Investigator must maintain adequate and accurate records to enable the conduct of t he study 
to be fully documented and the study data to be subsequently verified. Study documents should 
not be destroyed without prior written agreement between ITB -MED and the Investigator.  If the 
ITB-MED   Page 89 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Investigator wishes to assign the study records to another party or move them to another location, 
ITB-MED must be notified in advance.  
14 Ethical Considerations  
14.1 Regulatory and Ethical Compliance 
This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized T ripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki. 
14.2 Publication of Study Protocol and Results 
The protocol will be registered in a publicly accessible database such as clinicaltrials.gov  and as 
required in EudraCT. In addition, after finalization of the study report the results of this trial will 
be submi tted for publication and posted in a publicly accessible database of clinical trial results, 
such as the ITB-MED clinical trial results website and all required Health Authority websites ( e.g., 
Clinicaltrials.gov, EudraCT, etc. ). 
ITB-MED   Page 90 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
15 References  
Allen UD, Preiksaitis JK  (2013). AST Infectious Diseases Community of Practice. Epstein -Barr 
virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J 
Transplant ;13 Suppl 4:107-120. 
Andress L, Gupta A, Siddiqi N, Marfo K  (2014). Rabbit anti -thymocyte globulin induction in renal 
transplantation: review of the literature . Transplant Research and Risk Management ; 6:9-21.  
Arons MM, Hatfield KM, Reddy SC, et al. (2020) Presymptomatic SARS -CoV- 2 infections and 
transmission in a skilled nursing facility.  N Engl J Med ; 382:2081-2090.   
Bia M, Adey DB, Bloom RD, Chan L, Kulkarni S, Tomlanovich S  (2010). KDOQI US 
commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients.  Am J Kidney Dis ;56(2):189-218. doi: 
Branco L, Barren P, Mao SY, et al (1999). Selective deletion of antigen -specific, activated T cells 
by a humanized MAB to CD2 (MEDI -507) is mediated by NK 
cells.  Transplantation.;68(10):1588-1596.  
Curtis RE, Travis LB, Rowlings PA, et al  (1999). Risk of lymphoproliferative disorders after bone 
marrow transplantation: a multi- institutional study.  Blood;94(7):2208-2216. 
Damschroder MM, Kozhich AA, Woods RM, et al  (2004) . Analysis of human and primate CD2 
molecules by protein sequence and epitope mapping with anti -human CD2 antibodies. Mol 
Immunol ;41(10):985-1000. doi:10 
Davis SJ, van der Merwe PA  (1996). The stru cture and ligand interactions of CD2: implications 
for T -cell function. Immunol Today ;17(4):177-187. doi:10.1016/0167-5699(96)80617-7. 
Danziger -Isakov L, Kumar D. (2019)  Vaccination of solid organ transplant candidates and 
recipients: Guidelines from the American society of transplantation infectious diseases community of practice.  Clin Transplant ;33(9): e13563. 
Dojcinov SD, Fend F, Quintanilla -Martinez L (2018). EBV -Positive Lymphoproliferations of B - 
T- and NK-Cell Derivation in Non-Immunocompromised Host s. Pathogens;7(1):28. 
Fishman JA (2017). Infection in Organ Transplantation. Am J Transplant ;17(4):856-879.  
Fung M, Babik J, (2020) COVID -19 in Immunocompromised Hosts: What We Know So Far, Clin 
Infect Dis.,  ciaa863.   
Green M, Michaels MG (2013). Epstein- Barr virus infection and posttransplant 
lymphoproliferative disorder. Am J Transplant . 13 Suppl 3:41-54.  
Guirado L  (2018) . Does Rabbit Antithymocyte Globulin (Thymoglobuline®) Have a Role in 
Avoiding Delayed Graft Function in the Modern Era of Kidney Transplantation? J Transplant ; 
2018:4524837. Published 2018 Jul 12.  
ITB-MED   Page 91 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Haas M, Loupy A, Lefaucheur C, et al  (2017). The Ban ff 2017 Kidney Meeting Report: Revised 
diagnostic criteria for chronic active T cell -mediated rejection, antibody- mediated rejection, and 
prospects for integrative endpoints for next- generation clinical trials.  Am J Transplant ;18(2):293-
307.  
Hardinger KL, Schnitzler MA, Miller B, et al  (2004). Five-year follow up of thymoglobulin versus 
ATGAM induction in adult renal transplantation. Transplantation ;78(1):136-141.  
Hardinger KL, Brennan DC, Klein CL (2013).  Selection of induction therapy in ki dney 
transplantation. Transpl Int ;26(7):662-672.  
Hart A, Smith JM, Skeans MA, et al (2020). OPTN/SRTR 2018 Annual Data Report: Kidney. Am 
J Transplant ;20 Suppl s1:20-130.  
Juvonen E, Aalto SM, Tarkkanen J, et al (2003 ). High incidence of PTLD after non-T- cell-depleted 
allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant ;32(1):97-102.  
Kates S, Haydel M, Florman S, et al. (2020)  COVID -19 in solid organ transplant: A multi -center 
cohort study. Clin Infect Dis.  ciaa1097.  
Kaul DR, Valesano  AL, Petrie JG, et al. (2021) Donor to recipient transmission of SARS -CoV- 2 
by lung transplantation despite negative donor upper respiratory tract testing. Am J 
Transplant .21:2885–2889.  
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009). KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant ;9 Suppl 
3:S1-S155.  
Leitner J, Herndler -Brandstetter D, Zlabinger GJ, Grubeck -Loebenstein B, Steinberger P (2015). 
CD58/CD2 Is the Primary Costimulatory Pathway in Human CD28- CD8+ T Cells.  J 
Immunol ;195(2):477-487.  
Lo DJ, Weaver TA, Stempora L, et al. (2011) Selective targeting of human alloresponsive CD8+ 
effector memory T cells based on CD2 expression. Am J Transplant . 11(1):22–33. 
Marks WH, Ilsley JN, Dharnidharka VR (2011). Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc ;43(5):1395-1404. 
Murray JE, Merrill JP, Harrison JH (1958).  Kidney transpla ntation between seven pairs of identical 
twins.  Ann Surg;148(3):343-359.  
Parker A, Bowles K, Bradley JA, et al (2010). Diagnosis of post -transplant lymphoproliferative 
disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J 
Haematol ;149(5):675-692.  
ITB-MED   Page 92 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE et al. (2020) COVID -19 in 
solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant ;20(7):1800-
1808.   
Popow I, Leitner J, Grabmeier- Pfistershammer K, et al (2013). A comprehensive and quantitative 
analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J 
Transplant ;13(12):3103-3113.  
Rölle  A, Halenius A, Ewen EM, Cerwenka A, Hengel H, Momburg F  (2016). CD2 -CD58  
interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection. Eur J Immunol ;46(10):2420-2425.  
Roufosse C, Simmonds N, Clahsen- van Groningen M, et al  (2018 ). A 2018 Reference Guide to 
the Ban ff Classification of Renal Allograft Pathology [published correction appears in 
Transplantation. 2018 Dec;102(12): e 497]. Transplantation;102(11):1795-1814.   
Seed B, Aruffo A  (1987). Molecular cloning of the CD2 antigen, the T -cell erythrocyte receptor, 
by a rapid immunoselection procedure. Proc Natl Acad Sci U S A; 84(10):3365-3369.  
Shah DK, Betts AM  (2013). Antibody biodistribution coefficients: inferring tissue concentrations 
of monoclonal antibodies based on the plasma concentrations in several preclinical species and 
human. MAbs ;5(2):297-305.  
Song T, Yin S, Li X, Jiang Y, Lin T  (2020) . Thymoglobulin vs. ATG- Fresenius as Induction 
Therapy in Kidney Transplantation: A Bayesian Network Meta -Analysis of Randomized 
Controlled Trials.  Front Immunol ; 11:457. Published 2020 Apr 3.  
Springer TA, Dustin ML, Kishimoto TK, Marlin SD (1987). The lymphocyte function- associated 
LFA -1, CD2, and LFA -3 molecules: cell adhesion receptors of the immune system. Annu Rev 
Immunol ; 5:223-252.  
Tabrizi MA, Roskos LK  (2007). Preclinical and clinical safety of monoclonal antibodies. Drug 
Discov Today ;12(13-14):540-547.  
Tanriover B, Zhang S, MacConmara M, et al  (2015). Induction Therapies in Live Donor Kidney 
Transplantation on Tacrolimus and Mycophenolate with  or Without Steroid Maintenance.  Clin J 
Am Soc Nephrol ;10(6):1041-1049.  
Tanriover B, Jaikaransingh V, MacConmara MP, et al (2016) Acute Rejection Rates and Graft 
Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate. Clin J Am Soc Nephrol ;11(9):1650-1661.  
Uhlin M, Wikell H, Sundin M, et al  (2014) . Risk factors for Epstein- Barr virus -related post -
transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantatio n. Haematologica;99(2):346-352. 
Zou L, Ruan F, Huang M, et al. (2020) SARS- CoV -2 viral load in upper respiratory specimens of 
infected patients. N Engl J Med ; 382: 1177-1179.   
ITB-MED   Page 93 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 16 Appendices  
16.1 Appendix 1:  Schedule of Assessments  
 
ITB-MED   Page 94 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
  
ITB-MED   Page 95 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
  

ITB-MED   Page 96 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 16.2 Appendix 2:  Amendment No.1 – Summary of Changes 
Section/Title/Page  Original Text  Revision  Reason for Change  
    
Synopsis  
Exploratory Objectives  To explore changes in serum cytokines over time  
 To explore changes in serum and plasma cytokines over time  
 To clarify that both serum 
and plasma cytokines 
changes will be explored 
in the study.  
Synopsis  
Key Inclusion Criteria  Not applicable  Addition of the following inclusion criterion:  
 
Subjects who test negative for SARS -CoV-2 via molecular 
testing (PCR)  To ensure that study 
participants are tested for COVID-19 prior to study entry and only those who have a negative test are 
eligible for randomization  
 
Synopsis  
Planned Study Sites  Up to 5 study sites within the United States (US)  
and Europe (EU)  Up to 5 study sites within the United States (US)  Europe Sites will 
participate  in the 
TCD601B101,  and the 
United States are participating in the 
TCD601B102  study  
Synopsis , 
Data Analysis  
 
Section 6.8  
Treatment Exposure and 
Compliance, 2nd paragraph, 
last sentence 
 
Section 8.5  
Pharmacokinetic Assessments, 3
rd paragraph  
   Section 12.5.3  
Pharmacokinetics  
1
st Paragraph  
 Siplizumab plasma concentration data will be listed 
by treatment, subject, and visit/sampling time point.  
 
Siplizumab will be measured in plasma and TAC 
will be measured in whole blood.  
  
 
The following PK parameters will be determined 
using the actual recorded sampling times and non-compartmental method(s): Cmax, Tmax, area under 
the curve (AUC) last, AUCinf, T1/2, Vz/F and CL/F 
from the plasma concentration -time data.  
 Siplizumab plasma concentration data will be listed by treatment, subject, and visit/sampling time point.  Siplizumab serum concentration data will be listed by 
treatment, subject, and visit/sampling time point.  
 
 
Siplizumab will be measured in serum and TAC will be 
measured in whole blood.  
  
The following PK parameters will be determined using the actual recorded sampling times and non -compartmental 
method(s): Cmax, Tmax, area under the curve (AUC) last, 
AUCinf, T1/2, Vz/F and CL/F from the serum concentration-
time data.  
  
Siplizumab serum concentration data wi ll be listed by 
treatment, subject, and visit/sampling time point.  To clarify that siplizumab 
concentration data will be measured in serum and 
not plasma.  
 
Section 2  To the time -course and duration of siplizumab 
induced lymphocyte depletion and time to recovery  To measure the time -course and duration of siplizumab 
induced lymphocyte depletion and time to recovery  To include how the 
endpoint would be 
ITB-MED   Page 97 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
Objectives and Endpoints, 
Table 2 -1 assessed, which was  
inadvertently omitted in 
the original protocol  
 
Section 3.1  
General overview , 
6th paragraph  
 
 
 
Section 6.2.4  
Preparation of 
Siplizumab  
  Section 6.3.2  
Preparation of ATG 
 Every effort should be made to randomize the 
subject on Day 0, but when logistical considerations 
prevent this from occurring ( e.g., central pharmacy 
requirements), the subject may be randomized up to 
12 hours pre -transplant.  
 
The subject will be weighed within 12 hours of each 
infusion administration and this weight will serv e as 
the basis for final dose calculations and 
comp ounding . 
 
The subject will be weighed within 12 hours of each infusion administration and this weight will serve as 
the basis for final dose calculations and 
compounding.  
 Every effort should be made to ra ndomize the subject on Day 
0, but when logistical considerations prevent this from 
occurring ( e.g., central pharmacy requirements), the subject 
may be randomized up to 24 hours pre -transplant.  
 
 
The subject will be weighed within 24 hours of each infusion administration and this weight will serve as the basis for final dose calculations and compounding.  
 The subject will be weighed within 24 hours of each infusion administration and this weight will serve as the basis for final dose calculations and compoun ding.  The change from 1 2 to 24 -
hours was included to 
provide additional flexibility to sites when subjects may be scheduled 
for their transplant in the 
early hours of the morning.  
 
Section 4.5  
Risk and Benefits  
1st paragraph  
 Not applicable  New Text : 
Infection risk will be mitigated by following applicable 
national vaccination guidelines and by use of prophylaxis (See Section 6.5). Similarly, the risks of SARS -CoV- 2 will be 
minimized by following local, national and international 
guidelines for immunosuppressed and solid organ transplant patients (See Section 4.5.3).  
 The existing Risk and 
Benefits section of the protocol was expanded to include consideration of the current risk of SARS -
CoV-2.  
Section 4.5.1.3  
Lymphoproliferative Disorders 3
rd Paragrap h  
 
 
 Independent adjudication of all 9 EBV -LPD cases 
was conducted to assess the overall risk of EBV -
LPD in the setting of renal transplantation. While a notable risk of EBV -LPD in the setting of T-cell 
lymphoma was assessed by the committee it was 
stated that experience to date does not demonstrate 
that this risk exceeds that associated with ATG.  
 
In the setting of renal transplantation, siplizumab 
use is not expected to increase the risk of EBV -
LPD/PTLD over ATG -based induction in 
combination with background immunosuppression. Revision  
In the setting of renal transplantation, siplizumab  use is not 
expected to increase the risk of EBV -LPD/PTLD over ATG -
based induction in combination with background 
immunosuppression.  Independent adjudication of all 9 EBV -
LPD cases was conducted to assess the overall risk of EBV -
LPD in the setting of rena l transplantation.  While a notable 
risk of EBV -LPD in the setting of T-cell lymphoma was 
assessed by the committee it was stated that experience to date does not demonstrate that this risk exceeds that associated with 
ATG.  Additional information 
added to harmonize the section on EBV -LPD risk 
with that of the global siplizumab development 
program.  Update incl udes 
overall conclusion from 
an independent committee who conducted a case 
adjudication and risk 
assessment of siplizumab 
in comparison to ATG. 
ITB-MED   Page 98 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
This rate in the US has been reported to be 1.03% 
(Hart et al 2020) and as high as high as 2.4% with 
ATG induction (Thymoglobulin PI 2020). The rate 
of EBV -LPD is known to be higher in patients who 
are EBV -seronegative with a relative ri sk up to 33-
fold that of EBV+ recipients (Marks et al 2011). 
Therefore, all recipients will be screened prior to 
administration of siplizumab,  and EBV -
seronegative subjects excluded from participating 
in the TCD601B102 clinical trial. In addition, 
clinicia ns who specialize in transplant 
immunosuppression, and are aware of the risks for EBV-LPD, will be managing patients enrolled in 
this study. Regular assessments of hematology, 
EBV- viral load as well as PTLD surveillance 
including full physical exams at each visit as well as monitoring of clinical signs and symptoms will be conducted during the 12 -month study.  
 This rate in the US has been rep orted to be 1.03% ( Hart et al 
2020 ) and as high as high as 2.4% with ATG induction 
(Thymoglobulin PI 2020).  The rate of EBV -LPD is known to 
be higher in patients who are EBV -seronegative with a relative 
risk up to 33-fold that  of EBV+ recipients ( Marks et al 2011 ).  
Therefore, all recipients will be screened prior to 
administration of siplizumab,  and EBV -seronegative subjects 
excluded from participating in the TCD601B102 clinical trial. In addition
, clinicians who specialize in transplant 
immunosuppression, and are aware of the risks for EBV -LPD, 
will be managing patients enrolled in this study.  Regular assessments of hematology, EBV -viral load as well as PTLD 
surveillance including full physical e xams at each visit as well 
as monitoring of clinical signs and symptoms will be conducted 
during the 12-month study.  
 There is no change in risk 
based on this update.  
Section 4.5.3  
Risks of SARS -CoV-2 
(COVID-19)  Not applicable  New Text:  
The novel coronavirus, severe acute respiratory syndrome 
coronavirus 2 (SARS -CoV -2), can spread rapidly within 
healthcare settings and communities and poses a special challenge for organ transplantation. Ongoing community transmission has been noted on all continents except Antarctica. Person -to-person transmission of SARS -CoV- 2 
occurs during close exposure (< 2 meters) to an infected person, primarily via respiratory droplets produced when the infected person coughs or sneezes. COVID -19 disease i s a 
respiratory illness caused by the SARS -CoV-2 virus with 
variable presentation from asymptomatic to severe. Shedding of high viral titers has been documented from the respiratory tract, including shedding before the onset of symptoms, and results in droplet transmission of SARS -CoV-2 (Zou et al 
2020). Transmission via droplet spread can occur from both symptomatic and asymptomatic individuals (Arons et al 2020) and it appears that patients with COVID -19 have the highest 
viral loads early in the course of  their infection. Thus, a 
reliance on symptom -based screening strategies alone is not 
sufficient to prevent or diagnose infection; consideration of Inclusion of additional 
text to address the current pandemic including 
SARS -CoV-2 and 
COVID-19 disease.  
ITB-MED   Page 99 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
symptoms and exposure history, along with PCR -based 
testing is imperative.  
 
COVID-19 Disease:  
Case series on COVID-19 disease in transplant recipients have been published, however data remains very limited. Imaging 
demonstrates pneumonia in the majority of patients that are 
hospitalized (75- 100%). Patients with less severe infections 
may have lower rates of cl inical abnormalities. Mild infections 
are common, however preliminary experience suggests that 
infection, once acquired by immunosuppressed transplant 
recipients, may be of greater severity than in normal hosts after the initial incubation period. Experien ce with other viruses 
including prior outbreaks of coronaviruses, also suggests that 
severe infections will occur in some transplant recipients.  
 
At this time, the risk factors for severe disease have been 
characterized by observational studies. An initia l report by 
(Pereira et al 2020) showed that advanced age was associated with severe disease in their transplant cohort, which is not different from the disease profile in the immunocompetent population (Kates et al 2020) reported age >65, chronic lung 
dis
ease, congestive heart failure, and obesity were 
independently associated with poor outcomes of COVID -19 in 
solid organ transplantation. It is anticipated that transplant 
recipients may have a greater viral burden and shedding 
resulting in greater infectiv ity and potential spread to other 
individuals.  
 
Limited data are available on optimal treatment protocols, and none have been clearly demonstrated to optimize outcomes. 
When considering potential therapies, clinicians should 
consider the need for immunosu ppression reduction and 
presence of potential drug -drug interactions that may result in 
toxicity or therapeutic failure, e.g., beta interferon or CYP3A inducers/inhibitors.  
 
The risk of a COVID -19 infection from an infected organ donor 
is unknown at this time. To date, there has been one 
documented case ( Kaul et al 2021 ) of donor -derived disease 
ITB-MED   Page 100 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
transmission in a bilateral lung transplant recipient. 
Transmission from blood banks has not been documented at 
this time.  
 
Guidelines on the risks and management of SARS -CoV -2 in 
the setting of clinical trials as well as that of renal transplant 
patients have been published by the European Medicines 
Agency (EMA), US National Institutes of Health (NIH), 
Transplantatio n Society (TTS) and American Society of 
Transplantation (AST). Treatment guidelines on the use in immunocompromised and transplant recipients are updated 
periodically as knowledge of COVID -19 disease management 
evolves. Cumulative cases and incidence rates  are tracked and 
published by the World Health Organization (WHO) and other 
public and private entities and should be used to guide local 
management of patients.  
 
With active circulation of SARS -CoV-2 in the community, it is 
appropriate to counsel all can didates about the risk for 
acquisition from the community and hospital environment. Candidates should be educated about preventive strategies such as social distancing, masking when in proximity to non-
household contacts, frequent hand washing, and avoidance of 
travel to high-risk areas.  
 A compendium of global guidance documents is maintained by 
the NOTIFY library and can be found at the following URL: 
https://www.notifylibrary.org/background-documents#SARSCoV -2.  
 
Section 4.5.4  
Risk Mitigation Strategy,  2 – 9 Paragraph  
consolidated and moved  
14-16 Paragraph  (new text)  
 Safety and tolerability data for doses up to 15 
mg/kg IV have been collected in patients with T -
cell lymphoma with good tolerability. With initial administration of a biologic, the first 4 hours of 
exposure are most critical with most infusion 
reactions (i ncluding hypersensitivity, cytokine 
release, anaphylaxis) occurring within the first 2 hours of exposure (Tabrizi and Roskos 2007). No 
cytokine release has been detected with IV or s.c. 
siplizumab (MEDI -507) administration in the Infections are a common risk for all transplant recipients. 
Subjects will be regularly evaluated while hospitalized and 
upon return to the clinic for signs and symptoms which might indicate a severe infection, i.e., fever, nausea, myalgia, 
headache, arthralgia, chills, diarrhea, stiff neck, and malaise, 
and will be treated as appropriate per local practice depending on the infectious agent. Subjects will be informed to report any of the aforementioned symptoms to the clinical staff to 
assure proper assessment and care can be administered in a 
timely manner.   Text consolidated  and 
moved to improve flow of 
Risk mitigation section.  
 
Inclusion of text around 
SARS -CoV-2 
ITB-MED   Page 101 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
completed patient studies.  Cytokine release or 
anaphylaxis have not been reported with similar 
compounds specifically targeting the CD2 
receptor. A mild infusion reaction has been described in primates as well as clinical studies with siplizumab following the first dose. This first-
dose-effect presents as mild and transient pyrexia 
with chills, nausea and fatigue. These infusion 
reactions are self -limiting and respond well to 
premedication with acetaminophen and 
diphenhydramine. Subjects will receive their first 
dose of siplizumab i n the pre - to inter -operative 
time period, at a time when patients are under the close supervision of clinical staff in a hospital 
environment. Any infusion related reactions can be 
managed at that time in accordance with local protocols. In the TCD601B102 study all subjects 
will receive premedication prior to each dose of 
siplizumab to mitigate any infusion reactions.  
 
Considering the expected immunosuppressive nature of the compound, subjects will be screened 
for a history of latent infections. Viral rea ctivation 
will be assessed for CMV and BK virus according 
to local practice on a regular basis. Prophylaxis for CMV and pneumocystis pneumonia (PCP) will be 
administered to all subjects during the trial 
according to local practice. A negative test result for TB performed within 6 months of randomization will be required prior to enrollment. 
If there is suspicion of TB, a chest x -ray may be 
performed in accordance with local guidelines; 
subjects with a positive test will be excluded from participation.  
EBV serology will serve as a key inclusion 
criterion, where EBV -sero negative subjects will be 
excluded from participation. EBV viral loads via EBV-PCR will be collected from all subjects throughout the trial and will be analyzed centrally 
to minimize inter -laboratory variation. Positive Considering the expected im munosuppressive nature of the 
compound, subjects will be screened for a history of latent 
infections. Viral reactivation will be assessed for CMV and BK 
virus according to local practice on a regular basis. Prophylaxis for CMV and pneumocystis pneumonia (P
CP) will be 
administered to all subjects during the trial according to local 
practice. A negative test result for TB performed within 6 
months of randomization will be required prior to enrollment. If there is suspicion of TB, a chest x-ray may be performed in accordance with local guidelines; subjects with a positive test 
will be excluded from participation.   
EBV serology will serve as a key inclusion criterion, where 
EBV-sero negative  subjects will be excluded from 
participation. EBV viral loads via EBV -PCR will be collected 
from all subjects throughout the trial and will be analyzed centrally to minimize inter -
laboratory variation.  Positive 
results that demonstrate an increase over time will be 
communicated to the investigator for additional follow -up an d 
per-protocol PTLD surveillance as described in Section 8.4.5 .  
The ongoing SARS -Cov -2 pandemic represents a challenge for 
all renal transplant candidates and recipients. Due to the 
dynamic nature of COVID -19 infe ction rates, centers should 
continue to follow local and national guidelines and set policies based on the local incidence and prevalence of infections as well as hospital and staffing resources. This includes decisions to conduct or defer solid organ transplant procedures as well as 
the ongoing management of donors and recipients.  
Subjects eligible for the TCD601B102 study will be 
randomized from the pool of active candidates who are 
currently undergoing transplantation and will be receiving T -
cell depleti ng induction and standard of care 
immunosuppression. All eligible subjects will be informed of 
the risks of SARS -COV-2 during the consent process. To 
decrease the risk to study subjects, all candidates will be screened for SARs -CoV-2 prior to enrollment and excluded if 
positive.  
Ongoing surveillance per standard of care will occur thereafter based on local conditions and signs and symptoms. In renal transplant patients who experienced COVID -
19 disease, 
common presenting symptoms were fever, dry cough, and 
ITB-MED   Page 102 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
results that demonstrate an increase over time will 
be communicated to the investigator for additional 
follow -up and per -protocol PTLD surveillance as 
described in Section 8.4.5.  
 
Subjects will be regularly evaluated while 
hospitalized and upon return to the clinic for signs 
and symptoms which might indicate a severe 
infection, i.e., fever, nausea, myalgia, headache, 
arthralgia, chills, diarrhea, stiff neck, and malaise, 
and will be treated as appropriate per local practice 
depe nding on the infectious agent. Subjects will be 
informed to report any of the aforementioned 
symptoms to the clinical staff to assure proper 
assessment and care can be administered in a timely manner.  
 
Subjects will be hospitalized for several days post -
transplant. Following discharge from the hospital, 
subjects will return to the clinic for routine 
assessments. During these visits, safety and PK/PD 
assessments will be collected. Standard safety 
assessments will include vital signs, physical 
examinations, clinical laboratory evaluations 
(hematology, blood chemistry and urinalysis), AE and SAE monitoring as outlined in the Schedule of 
Assessments. In addition to standard clinical 
laboratory assessments, subjects will be monitored regularly for signs and symptoms of infectious, 
inflammatory, hematologic or renal toxicity / 
rejection as outlined below.  
 
Subject’s serum creatinine will be measured frequently in the first few weeks post -transplant 
and thereafter with a focus on renal injury and 
dysfunction. Changes in renal function will be 
assessed via serum creatinine and estimated glomerular filtration rates (eGFR) using Modification of Diet in Renal Disease (MDRD) 
formula. In the event subjects present with a diarrhea, with most patients exhibiting lymphopenia and 
elevated C -reactive protein (CRP) ( Fung and Babik 2020 ). 
Subjects will be counseled to report any of these physical symptoms to the clinical staff. Clinicians should also c onsider 
the common laboratory changes when assessing the potential for COVID -19 disease.  
 
Subjects who may be exposed to SARS -CoV -2 or contract 
active disease will be managed per local practice and 
international guidelines including recommendations for 
seeking treatment or self -quarantine. As with all infection 
events, SARS -CoV -2 positivity and  COVID-19 disease will be 
captured in the safety database and will be evaluated by the DMC during their periodic dose escalation and ongoing safety 
review. Within the clinical trial setting, subjects may be 
required to attend in- person study visits in exce ss of those 
based on standard of care for clinical laboratory assessments as well as PK/PD sample collection; this may increase their risk 
of SARS -CoV -2 exposure. To minimize the time patients, 
spend indoors and within the clinic for these assessments, 
phone contact or virtual / telehealth technology will be utilized 
where appropriate by the site staff. In addition, patients will be 
counseled on the importance of following proper hygiene, 
masking and social distancing practices to minimize 
community and hos pital exposure during their standard of care 
and study specific visits.  
 
SARS -CoV-2 vaccines (i.e., mRNA, adenoviral vector) are 
under development or have been authorized for clinical use 
globally. The effectiveness of these vaccines in 
immunocompetent adults is between 76 -95%, however the 
effectiveness in solid organ transplant recipients is unknown 
(See Section 6.5). Based on current vaccination guidelines, it is 
recommended that all transplant candidates and their 
household members receive SARS -CoV-2 vac cination when it 
becomes available. Ideally, transplant candidates should be targeted for vaccination while they are awaiting transplant or 3-6 months post -transplant in this trial, based on T-cell 
recovery.  
ITB-MED   Page 103 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
significant increase in SCr and/or BPAR for -cause 
biopsies are to be collected for evaluation 
according to the standard Banff histology system. 
In addition, urinary injury biomarkers will be collected for future analysis. This exploratory biomarker assessment will allow for an additional 
dataset which may help to better assess the type 
and gross location of renal injury, i.e., glomerular or tubular, should a signal for such emerge during the trial.  
 Immunophenotyping via fluorescence -activated 
cell sorter (FACS) analysis will be conducted periodically duri ng the study to assess the potential 
for an increased risk of infection, changes in leukocyte subsets and recovery following depletion anticipated with all siplizumab dosing arms.  
Coagulopathy will be assessed using standard hematology (platelets) and coagulation studies, including international normalized ratio (INR)/prothrombin time (PT) and activated partial 
thromboplastin time (aPTT) according to local 
practice.  
 Finally, considering the open-label study design, 
ITB-MED and an independent DMC will review 
study data regularly and on an ad hoc basis. In 
addition to the clinical opinion of the Investigator and biopsy results, a priori defined stopping 
criteria and gui delines will be used to protect 
individual subject safety during the trial.  
Overall, the non -clinical results, together with 
completed single- and multiple -dose studies with 
siplizumab in humans to date, as well as the comprehensive monitoring plan, a pri ori defined 
study stopping criteria and monitoring by an 
independent DMC in the TCD601B102 study support the continued development of this Subjects will be hospitalized for several days p ost-transplant. 
Following discharge from the hospital, subjects will return to 
the clinic for routine assessments frequently during the first 3- 
6 months per standard of care.  During these visits, safety and PK/PD assessments will be collected. Standard s afety 
assessments will include vital signs, physical examinations, 
clinical laboratory evaluations (hematology, blood chemistry 
and urinalysis), AE and SAE monitoring as outlined in the 
Schedule of Assessments . In addition t o standard clinical 
laboratory assessments, subjects will be monitored regularly 
for signs and symptoms of infectious, inflammatory, 
hematologic or renal toxicity / rejection.  
  
 
Subject’s serum creatinine will be assessed frequently in the 
first few week s post -transplant and thereafter with a focus on 
renal injury and dysfunction.  Changes in renal function will 
be assessed via serum creatinine and estimated glomerular 
filtration rates (eGFR) using Modification of Diet in Renal Disease (MDRD) formula.  In  the event subjects present with 
a significant increase in SCr and/or BPAR for -cause biopsies 
are to be collected for evaluation according to the standard Banff histology system.  In addition, urinary injury biomarkers will be collected for future analysis .  This 
exploratory biomarker assessment will allow for an additional 
dataset which may help to better assess the type and gross 
location of renal injury, i.e., glomerular or tubular, should a signal for such emerge during the trial.   
Immunophenotyping via fluorescence -activated cell sorter 
(FACS) analysis will be conducted frequently during the study 
to assess the potential for an increased risk of infection, 
changes in leukocyte subsets and recovery following depletion anticipated with all siplizumab  dosing arms.  
Coagulopathy will be assessed using standard hematology 
(platelets) and coagulation studies, including international 
normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) according to local practice.  
Finally, considering the open-label study design, ITB -MED 
and an independent DMC will review study data, including 
ITB-MED   Page 104 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
immunomodulatory compound in further 
investigational studies.  
 
Based on the information outlined above, the risks 
of administering siplizumab in combination with 
TAC, MMF, and CS are monitorable, manageable 
and the benefit -risk assessment in the intended 
patient population remains positive.  safety events and AEs of special interest, regularly and on an 
ad hoc  basis. Furthermore, a priori  defined stopping criteria, 
infection surveillance and pharmacovigilance by ITB-MED  as 
well as ongoing clinical assessments by Investigator and site 
staff will be employed to protect individual subject safety during the trial.  
Overall, the non -clinical and clinical safety results with 
siplizumab in human, as well as the comprehensive mo nitoring 
plan, a priori  defined study stopping criteria and ongoing 
review by an independent DMC support the continued 
development of this immunomodulatory compound and 
conduct of further investigational studies.  Moreover, in 
consideration of the ongoing SARS -CoV-2 pandemic, each 
center will manage their ongoing transplant program and 
enrollment of patients in this trial based on the Investigator’s clinical judgement and individual patient risk assessment in consideration of both local and per protocol ris k mitigation 
plans.  
The overall benefit -risk assessment including the 
aforementioned mitigation strategies and monitorable and 
manageable risks of administering siplizumab in this patient population is positive and support the conduct of this clinical 
trial. 
 
Section 5.1  
Inclusion Criteria  
  New Text: 
Subjects who test negative for SAR -CoV-2 test via molecular 
testing (PCR)  Addition of SARS -CoV -2 
as an exclusion criterion  
Section 5.2  
Exclusion Criteria  
 hemoglobin (Hbg) < 8 mg/dL  
 hemoglobin (Hgb) < 8 mg/dL  
 Correction to units of 
measure  
Section 6.2.1 . 
Identification of 
Investigational Product  
 Siplizumab is a humanized IgG1 [kappa] class 
monoclonal antibody, supplied as a clear to slightly opalescent, colorless to slightly brownish, 
preservative -free solution for infusion.  Siplizumab  is a humanized IgG1 [kappa]  class monoclonal 
antibody, supplied as a clear to slightly opalescent, colorless  
to slightly brownish, preservative -free, concentrate for 
solution.   Clarification that 
siplizumab is supplied as 
a concentrate for solution  
Section 6.2.2  
Management of 
Investigational Product  
 Please refer to the Pharmacy Manual for detailed 
instructions on the receipt, storage, accountability, 
and return or destruction will be described in the 
ITB-MED provided Pharmacy Manual.  Detailed instructions for the receipt, storage, accountability, 
and return or destruction will be described in the IT B-MED 
provided Pharmacy Manual.  Clarification to refer to 
the siplizumab Pharmacy 
Manual  for specifics on 
the preparation and management of 
siplizumab infusions  
ITB-MED   Page 105 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
 
Section 6.5  
Infectious Prophylaxis 
Treatment (Immunization)   New Text:  
Immunization of transplant candidates for vaccine preventable 
diseases is recommended more than 2 weeks prior to 
transplantation or starting at 1-6 months after transplantation If 
given prior to transplantation, the full immunization series 
should be compl eted before the transplant procedure. In certain 
situations, it may be appropriate to wait until 3 or more months after transplantation to vaccinate, such as following T - or B-
cell depletion therapy. Waning vaccine titers to other routine immunizations hav
e been well documented after 
transplantation. Lower seroconversion rates to influenza 
vaccination are well documented in the setting of 
mycophenolate mofetil and tacrolimus use (Danziger -Isakov et 
al 2019). Vaccination during treatment with siplizumab and 
prior to clearance of the antibody and pharmacodynamic 
effects are likely to result in therapeutic failure (i.e., non -
protective antibody titers). Administration of live attenuated agents should be avoided while receiving siplizumab treatment and for up to 6 months thereafter, depending on the dose and 
time for reconstitution of immune function.  Information on 
immunization of transplant recipients and candidates consolidated 
and exp anded under a new 
section for clarity.  
Section 8  
Visit Assessments   New Text: 
While COVID-19 disease remains a risk, efforts to minimize 
the time a subject spends indoors at the clinic may be 
considered. These efforts could include use of virtual or 
telehealth technology, where appropriate, to remotely capture 
applicable study data (e.g., overall health status, assessment of medication compliance, review of adverse events). The intent is to allow centers to minimize in -person onsite clinic visit 
activities to those assessments that require the subject to be physically prese
nt (e.g., laboratory collections or physical 
assessments). In the event virtual or telehealth technology is utilized to facilitate data collection, it should be done per 
institutional practice and local regulations. Detailed 
documentation of all contact an d information collected 
virtually is to be recorded in the study records.  
 Clarification on flexible 
visit scheduling during the ongoing SARS -CoV- 2 
pandemic to minimize the 
amount of time and in -
person contact necessary 
for per protocol study visits.  
Section 8 
Visit Assessments  
3rd Paragraph  This protocol defines 7 days to a week and 4 weeks 
(or 28 days) to a Study Month. For example, Week This protocol defines 7 days to a week and 4 weeks (or 28 days) 
to a Study Month. For example, Week 2 is considered to start Clarification of protocol 
definitions  
ITB-MED   Page 106 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
2 is considered to start on Day 7 and Study Month 
2 is considered to start on Week  5/Day 2.  on Day 8 and Study Month 2 is considered to start on Day 29 
(Start of W eek 5).  
Section 8.4.2  
Vital Signs  Vital signs (radial pulse rate, blood pressure and 
body temperature) will be recorded as indicated in 
the Schedule of Assessments . Vital signs (radial pulse rate, blood pressure, respiratory rate, 
and body temperature) will be recorded as indicated in the 
Schedule of Assessments . Clarification that 
respiratory rate is assessed  
Section 8.4.4.5  
Pregnancy  Serum or urine pregnancy testing will be required 
for all females  regardless  of child -bearing potential, 
at timepoints as designated in the Schedule of 
Assessments . Serum or urine pregnancy testing will be required for femal es 
of child-bearing potential, at timepoints as designated in the 
Schedule of Assessments . Clarification to only 
conduct pregnancy testing 
in WOCBP  
Appendix 1  
Schedule of Assessments  Not applicable  
 The following assessments were added:  
• SARS -CoV-2 Molecular Testing at screen  
• EBV-PCR (added v isit 13 and visit 17)  
 The Schedule of 
Assessments was updated to reflect the addition of 
study assessments and 
procedures.  
Appendix 1  
Schedule of Assessments  • Footnote (b) vitals collected pre -dose, 
immediately following the end of the infusion, 
and 6 hours after completion of infusion with 
siplizumab or ATG. Other time points 
captured as indicated.  
  
• Footnote ( d) results obtained within the past 6 
months are a cceptable for the initial 
assessment; serology samples and donor EBV only at screening  
  
• HIV, HbsAg, HCV serology (D and R)
d 
 
• Footnote (f) a negative pregnancy test must be available prior to randomization  
 
• Footnote (i) Subjects randomized to ATG 
(Control)  
 
• Footnote (m) TCD601 PK Sampling on Day 0 dosing (pre -dose, hrs 1, 3, 6 and 24) and Day 
4 dosing (pre -dose, hrs 1, 3 and 6).  Additional 
samples include collection on post -operative 
Days 2, 3, 7, 14, 21, 28, 35, 42, 49, 56, 63*, • Footnote (b) vitals collected pre -dose, immediately 
following the end of the infusion, and 6 hours after 
completion of infusion with siplizumab or rATG. Other time points captured as indicated. Weight is captured pre -
dose on Days  0 and 4 for siplizumab treated subjects and 
pre-dose on Days 0,1 and 2 for rATG treated subjects  
 
• Footnote (d) results obtained within the past 12 months are acceptable for the initial assessment of EBV (donor and recipient) and CMV. Serological testing for BKV is not required at Screening. EBV, CMV and BKV viral testing 
via PCR should be conducted thereafter  
 
• HIV, HbsAg, HCV serology (D and R)  
 
• Footnote (f) a negative pregnancy test must be available 
prior to randomization (for females of childbearing 
potential)  
 
• Footnote (i) Subjects randomized to rATG (Control)  
 
 
• Footnote (m) New Text: Post -dose collection time is 
based on the START time of infusion.  
 Updates to footnotes  b, d, 
f, and i in the Schedule of 
Assessments.  
ITB-MED   Page 107 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Section/Title/Page  Original Text  Revision  Reason for Change  
70*, 84*, 112*, *140, 168*, 196*, 224*, and 
252* (* Note: latter collections may be 
truncated based on half -life of TCD601 and 
serum concentrations belo w limit of 
quantification)  
Appendix 7:  
Update 201 8 Banff 
Classification  Not applicable  New Text:  
Category 5: IFTA  
• Grade I (Mild): Banff Lesion Score ci1  OR Banff Lesion 
Score ct1 
• Grade Il (Moderate) Banff Lesion Score ci2  OR Banff 
Lesion Score ct2  
• Grade III (Severe) Banff Lesion Score ci3 OR Banff 
Lesion Score ct3  
Category 6:  Other changes not considered to be caused by 
acute or chronic rejection  
• BK-Virus Nephropathy  
• Posttransplant Lymphoproliferative Disorder  
• Calcineurin Inhibitor Toxicity  
• Acute Tubular Injury  
• Recurrent Disease  
• De Novo Glomerulopathy (Other Than TG)  
• Pyelonephritis  
• Drug -Induced Interstitial Nephritis  
 Appendix updated to 
reflect the 2018 update of the Banff classification 
standards  
Various  Not defined  Correction of minor typos and clarifications throughout the 
protocol  Typos and minor updates 
to the text to provide clarification were included throughout the 
document and are visible 
within the redlined 
version of the protocol.  
ITB-MED   Page 108 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 16.3 Appendix 3: Investigator Agreement Page 
 
INVESTIGATOR AGREEMENT  
 
Protocol Number: TCD601B102 Version: 2.0, Incorporating Amendment No.: 1.0  I have read the Investigator’s Brochure and protocol TCD601B102, “A 12 -Month, Randomized, 
Controlled, Open -Label, Dose Escalation Study evaluating Safety, Tolerability, Pharmacokinetics 
(PK) and Pharmacodynamics (PD) of an anti -CD2 monoclonal antibody, TCD601 (siplizumab)  
compared to anti -thymocyte globulin ( rATG), as induction therapy in de novo  Renal Transplant 
Recipients” and agree to conduct this clinical study as outlined in the protocol. I will also ensure 
that all sub -investigators and other study staff members have read and understand all aspects of 
the protocol.   I agree to cooperate fully with ITB -MED and its designated vendors during the study.  I will carry 
out the study in accordance with  FDA, EMA  and ICH guidelines and applicable local and 
government regulations. I agree to the following: 
• To use the investigational product ( siplizumab ) only as specified in the protocol and 
Pharmacy Manual  
• Agree to reference the Laboratory Manual provided by ITB -MED for detailed instructions 
on sample collection, processing and analysis (where applicable)  
• Understand that changes cannot be made to the protocol and study procedures without prior 
written approval from ITB- MED  
• Understand that any violation of the protocol may lead to termination of the study 
• Agree to comply with ITB -MED and regulatory requirements for the monitoring and 
auditing of the study 
 
–––––––––––––––––––––––––––––––––––––––––– Principa l Investigator Name  
 ––––––––––––––––––––––––––––––––––––––––––                   –––––––––––––––––––––– Principal Investigator Signature     Date  
     
ITB-MED   Page 109 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 16.4 Appendix 4: US -Specific CellCept® Pregnancy and Safety 
Information  
 
• Use of CellCept® during pregnancy is associated with an increased risk of first trimester 
pregnancy loss and an increased risk of congenital malformations, especially external ear and 
other facial abnormalities including cleft lip and palate, and anom alies of the distal limbs, heart, 
esophagus, and kidney. 
• Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations with MPA products and must be counseled regarding pregnancy prevention and planning. 
• For those females using Cellcept
® at any time during pregnancy and those becoming pregnant 
within 6 weeks of discontinuing therapy, the Investigator or healthcare practitioner should report the pregnancy to the Mycophenolate Pregnancy Registry ( 1800-617- 8191). The 
Investigator or healthcare practitioner should strongly encourage  the subject to enroll in the 
pregnancy registry.  
• Risks and benefits of CellCept
® should be discussed with the subject . When appropriate, 
consider alternative immunosuppressants with less potential for embryofetal toxicity. 
In certain situations, the subject  and her healthcare practitioner may decide that the maternal 
benefits outweigh the risks to the fetus. If this drug is used during pregnancy, or if the subject  
becomes pregnant while taking this drug, the subject should be apprised of the potential hazard 
to the fetus.  
• To prevent unplanned exposure during pregnancy, females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting CellCept
®. Another pregnancy test with the same sensitivity should be done 8 
to 10 days later. Repeat pregnancy tests should be performed during routine follow -up visits. 
Results of all pregnancy tests should be discussed with the subject . 
• Females of reproductive potential taking CellCept® must recei ve contraceptive counseling and 
use acceptable contraception. Patients must us e acceptable birth control during entire 
CellCept® therapy, and for 6 weeks after stopping CellCept®, unless the subject  chooses 
abstinence (she chooses to avoid heterosexual int ercourse completely ). 
• Patients should be aware that CellCept® reduces blood levels of the hormones in the oral 
contraceptive pill and could theoretically reduce its effectiveness.  
 
     
ITB-MED   Page 110 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Acceptable Contraception Methods for Females of Reproductive Potential using 
MMF*  
Option 1  
Methods to Use Alone  • Intrauterine device (IUD)  
• Tubal sterilization  
• Patient’s partner had a vasectomy  
OR 
Option 2  
Choose One Hormonal 
Method AND One Barrier 
Method  Hormone Methods  
choose 1   Barrier Methods  
choose 1  
 Estrogen and 
Progesterone  
• Oral contraceptive pill  
• Transdermal patch  
• Vaginal ring  
Progesterone -only 
• Injection  
• Implant  AND  • Diaphragm with spermicide  
• Cervical cap with 
spermicide  
• Contraceptive sponge  
• Male condom  
• Female condom  
OR 
Option 3  
Choose One Barrier Method from  Each Column (must 
choose two methods ) Barrier Methods  
choose 1   Barrier Methods  
choose 1  
 • Diaphragm with 
spermicide  
• Cervical cap with 
spermicide  
• Contraceptive sponge  AND  • Male condom  
• Female condom  
*Females of reproductive potential include girls who have entered puberty and all women who have a uterus 
and have not passed through menopause.  
 
 
ITB-MED   Page 111 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 16.5 Appendix 5: Guidelines for MMF D ose Reduction 
An Investigator may interrupt temporarily or reduce the dosage of MMF if  in his/her opinion this 
is clinically warranted, in response to any causally associated AE (e.g., neutropenia, 
thrombocytopenia, leucopenia, hyperlipidemia, hypertriglyceridemia or gastrointestinal intolerance). The following guidelines should be follow ed: 
Dose reduction or temporary interruption may be performed for MMF  
Implementation of MMF dose reduction will be based on thrombocytopenia, leukopenia, 
neutropenia, or other AEs which are suspected to be related to this  medication, and in the opinion 
of the Investigator, are clinically warranted. The following guidelines should be used for both dose 
reduction and, once the event has resolved, restarting or increasing the dose of MMF back to original levels.  
MMF Dose Reduction Guidelines  
Platelets  
• platele t count < 100,000/mm³ dose may be reduced at the discretion of the Investigator 
• platelet count < 75,000/mm³ a second dose reduction should be considered  
• platelet count < 50,000/mm³ MANDATORY interruption of medication  
WBC  
• WBC < 3500/mm³ dose may be reduced  at the discretion of the Investigator 
• WBC < 2500/mm³ a second dose reduction should be considered  
• WBC < 2000/mm³      interruption of medication should be considered  
All these changes must be recorded on the MMF Dosage Administration Record eCRF. 
ITB-MED   Page 112 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 16.6 Appendix 6: Tacrolimus Drug-Drug Interactions 
Please refer to most recent national prescribing information for current labeling recommendations.  
Drug interactions  
Due to the potential for additive or synergistic impairment of renal function, care should be taken 
when administering Tac with drugs that may be associated with renal dysfunction. These include, but are not limited to, aminoglycosides, amphotericin B, and cisplatin. Initial clinical experience with the co -administration of T AC and CsA  resulted i n additive/synergistic nephrotoxicity. 
Drugs that may alter tacrolimus concentrations 
Since T AC is metabolized mainly by the CYP3A enzyme systems, substances known to inhibit 
these enzymes may decrease the metabolism or increase bioavailability of T AC as indicated by 
increased whole blood or plasma concentrations. Drugs  known to induce these enzyme systems 
may result in an increased metabolism of T AC or decreased bioavailability as indicated by 
decreased whole blood or plasma concentrations. Monitoring of blood concentrations and 
appropriate dosage adjustments are essential when such drugs are used concomitantly. 
*Drugs that may increase tacrolimus blood concentrations  
Calcium  
Channel  
Blockers  Antifungal  
Agents  Macrolide  
Antibiotics  Gastrointestinal  
Prokinetic  
Agents  Other Drugs  
diltiazem  
nicardipine  
nifedipine  
verapamil  clotrimazole  
fluconazole  
itraconazole  
ketoconazole**  
voriconazole clarithromycin  
erythromycin  
troleandomycin  cisapride  
metoclopramide  bromocriptine  
chloramphenicol  
cimetidine  
cyclosporine  
danazol  
ethinyl estradiol  
methylprednisolone  
lansoprazole***  
omeprazole  
protease inhibitors  
nefazodone  
magnesium -aluminum 
hydroxide  
**In a study of 6 normal volunteers, a significant increase in Tac oral bioavailability (14±5% vs. 30±8%) was observed 
with concomitant ketoconazole administration (200 mg). The apparent oral clearance of Tac during ketoconazole 
administration was significantly decreased compared to Tac alone (0.430±0.129 L/hr/kg vs. 0.148±0.043 L/hr/kg). Overall, IV clearance of Tac was not significantly changed by ketoconazole co- administration, although it was highly 
variable between patients.  
*** Lansoprazole (CYP2C19, CYP3A4 substrate) may potentially inhibit CYP3A4-mediated metabolism of Tac and thereby substantially increase Tac whole blood concentrations, especially in transplant patients who are intermediate 
or poor CYP2C19 metabolizers, as compared to those patients who are efficient CYP2C19 metabolizers.  
 
ITB-MED   Page 113 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 *Drugs that may decrease tacrolimus blood concentrations  
Anticonvulsants  Antimicrobials  Herbal Preparations  Other Drugs  
carbamazepine  
phenobarbital  
phenytoin  rifabutin  
caspofungin  
rifampin  St. John’s Wort  sirolimus  
* This table is not all inclusive.  
St. John’s Wort (Hypericum perforatum) induces CYP3A4 and P -glycoprotein. Since  Tac is a 
substrate for CYP3A4, there is the potential that the use of St. John’s Wort in patients receiving 
Tac could result in reduced T AC levels.  
In a single -dose crossover study in healthy volunteers, co- administration of Tac and 
magnesium- aluminum hydroxide resulted in a 21% increase in the mean Tac AUC and a 10% 
decrease in the mean Tac Cmax relative to Tac administration alone.  
In a study of 6 normal volunteers, a signific ant decrease in T AC oral bioavailability (14±6% vs. 
7±3%) was observed with concomitant rifampin administration (600 mg). In addition, there was a significant increase in Tac clearance (0.036±0.008 L/hr/kg vs. 0.053±0.010 L/hr/kg) with concomitant rifampin  administration.  
Interaction studies with drugs used in HIV therapy have not been conducted. However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administer ed concomitantly with T AC. Similarly, care should be 
exercised when HCV protease inhibitors (e.g., boceprevir and telaprevir), also metabolized by CYP3A, are administered concomitantly with Tac. 
Tac may affect the PK of other drugs (e.g., phenytoin) and increase their concentration. Grapefruit 
juice affects CYP3A -mediated metabolism and should be avoided. 
Other Drug Interactions  
Immunosuppressants may affect vaccination. Therefore, during treatment with Tac, vaccination may be less effectiv e. The use of live vaccines should be avoided; live vaccines may include, but 
are not limited to measles, mumps, rubella, oral polio, BCG, yellow fever, and TY 21a typhoid (Prograf
® PI 2019). 
ITB-MED   Page 114 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 16.7 Appendix 7: Updated 2018 Banff Classification 
Category 1:   Normal biopsy or nonspecific changes 
Category 2:   Antibody- mediated changes  
• Active ABMR:  all three features must be present for diagnosis. Biopsies showing histological 
features plus evidence of current/recent antibody interaction with vascular endothelium or 
DSA, but not both, may be designated as suspicious for acute/active ABMR. Lesions may be clinically acute or smoldering or may be subclinical; it should be noted if the lesion is C4d-positive or C4d-negative, based on the following criteria: 
1. Histologic evidence of acute tissue injury, including one or more of the following: 
o Microvascular inflammation (g >0 in the absence of recurrent or de novo  
glomerulonephritis, and/or ptc >0) 
o Intimal or transmural arteritis (v >0)1 
o Acute thrombotic microangiopathy in the absence of any other cause 
o Acute tubular injury in the absence of any other apparent cause 
2. Evidence of current/recent antibody interaction with vascular endothelium, including 
at least one of the following: 
o Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections or C4d >0 by IHC on paraffin sections) 
o At least moderate microvascular inflammation ([g + ptc] ≥ 2), although in the 
presence of acute TCMR, borderline infiltrate, or infection; ptc ≥ 2 alone is not 
sufficient, and g must be ≥1 
o Increased expression of gene transcripts in the biopsy tissue strongly associated with ABMR , if thoroughly validated  
3. Serologic evidence of DSAs (HLA or other antigens) 
C4d staining or expression of validated transcripts/classifiers as noted above in criterion 2 may substitute for DSA; however thorough DSA testing, including testing for non- HLA 
antibodies if HLA antibody testing is negative, is strongly advised whenever criteria 1 and 2 are met  
 
• Chronic active ABMR2: all three features must be present for diagnosis. As with active 
ABMR, biopsies showing histological features plus evidence of current/recent antibody interaction with vascular endothelium or DSA, but not both, may be designated as suspicious, and it should be noted if the lesion is C4d- positive or C4d- negative, based on the criteria listed:  
ITB-MED   Page 115 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 1. Morphologic evidence of chronic tissue injury, including one or more of the following: 
o TG (cg >0), if no evidence of chronic thrombotic microa ngiopathy or chronic 
recurrent/ de novo glomerulonephritis; includes changes evident by electron 
microscopy (EM) alone (cg1a) 
o Severe peritubular capillary basement membrane multilayering (requires EM)3 
o Arterial intimal fibrosis of new onset, excluding other  causes; leukocytes within the 
sclerotic intima favor chronic ABMR if there is no prior history of biopsy-proven 
TCMR with arterial involvement but are not required 
2. Identical to criterion 3 for active ABMR, above, 
3. Identical to criterion 3 for active ABMR, above, including strong recommendation for DSA testing whenever criteria 1 and 2 are met   
 
• C4d staining without evidence of rejection 
All three features must be present for diagnosis4 
1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d >0 by IHC on paraffin sections) 
2. Criterion 1 for active or chronic, active ABMR not met. 
3. No molecular evidence for ABMR as in criterion 2 for active and chronic, active ABMR  
4. No acute or chronic active TCMR, or borderline changes 
Category 3:   Borderline changes  
• Suspicious for acute TCMR  
o Foci of tubulitis (t>0 ) with minor interstitial inflammation (i0 or i1) or interstitial 
inflammation (i2, i3) with mild (t1) tubulitis; retaining the i1 threshold for borderline with t >0 is permitted although this must be made transparent in reports and 
publications 
o No intimal or transmural a rteritis (v = 0) 
 
Category 4:   TCMR  
• Acute TCMR   
o Grade I A.  I nterstitial inflammation (>25% of nonsclerotic cortical 
parenchyma, i2 or i3) and foci of moderate tubulitis (t2)  involving 1 or more  
tubules, not including tubules that are severely atrophic5 
o Grade IB.   Interstitial inflammation involving >25% of nonscler otic cortical  
parenchyma (i2 or i3) with severe tubulitis (t3) involving 1 or more  tubules, not 
including tubules that are severely atrophic5 
ITB-MED   Page 116 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 o Grade IIA.  Mild to moderate intimal arteritis (v1) with or without interstitial 
inflammation and tubulitis  
o Grade I IB.  Severe intimal arteritis (v2), with or without interstitial 
inflammation  and/or tubulitis 
o Grade III.  Transmural arteritis and/or arterial fibrinoid necrosis of medial smooth 
muscle cells with accompanying mononuclear cell intimal arteritis (v3), with  or 
without interstitial inflammation and/or tubulitis  
• Chronic active TCMR  
o Grade IA : Interstitial inflammation involving >25% of the total cortex (ti score 2 
or 3) and >25% of the sclerotic cortical parenchyma (i -IFTA score 2 or 3) with 
moderate tubulitis (t2) involving 1 or more tubules, not including severely atrophic 
tubules5; other known causes of i-IFTA should be ruled out 
 
o Grade IB:  Interstitial inflammation involving >25% of the total cortex (ti score 2 
or 3) and >25% of the sclerotic cortical parenchyma (i -IFTA score 2 or 3) with 
severe tubulitis (t3) involving 1 or more tubules, not including severely atrophic 
tubules5; other known causes of i-IFTA should be ruled out 
 
o Grade II:  Chronic allograft arteriopathy (arterial intimal fibrosis with mononuclear  
cell inflammation in fibrosis and formation of neointima)   
Category 5:  IFTA   
• Grade I (Mild): Banff Lesion Score  ci1 OR Banff Lesion Score ct1   
• Grade Il (Moderate) Banff Lesion Score ci2  OR Banff Lesion Score ct2   
• Grade III (Severe) Banff Lesion Score ci3  OR Banff Lesion Score ct3   
Category 6:  Other changes not considered to be caused by acute or chronic rejection   
• BK-Virus Nephropathy  
• Posttransplant Lymphoproliferative Disorder  
• Calcineurin Inhibitor Toxicity   
• Acute Tubular Injury  
• Recurrent Disease  
• De Novo Glomerulopathy (Other Than TG)  
• Pyelonephritis  
• Drug -Induced Interstitial Nephritis  
 
ITB-MED   Page 117 of 117 
Protocol TCD601B102 (2 .0)  Confidential   
 
 Legend:  
ABMR, antibody -mediated rejection; cg, glomerular double contours; DSA, donor -specific antibody; EM, 
electron microscopy; g, glomerulitis; i, inflammation; IF, immunofluorescence; IHC, immunohistochemistry; 
ptc, peritubular capillaritis; t, tubulitis; TCMR , T-cell mediated rejection; TG, transplant glomerulopathy; 
TMA, thrombotic microangiopathy; v, intimal arteritis.  
1 It should be noted that these arterial lesions may be indicative of ABMR, TCMR, or mixed ABMR/TCMR. 
The v lesions are only scored in arteries having a continuous media with two or more smooth muscle layers.  
2 Lesions of chronic, active ABMR can range from primarily active lesions with early TG evident only by EM 
(cg1a) to those with advanced TG and other chronic changes in addition to active microvascular inflammation. In the absence of evidence of current/recent antibody interaction with the endothelium, the term “active” should be omitted; in such cases, DSAs may be present at the time of biopsy or at any 
previous time after transplantation.  
3 Seven or more layers in one cortical peritubular capillary and five or more in two additional capillaries, 
avoiding portions cut tangentially.  
4 The clinical significance of these findings may be quite different in grafts exposed to anti –blood group 
antibodies (ABO -incompatible allografts), in which they do not appear to be injurious to the graft and may 
represent accommodation; however, with anti- HLA antibodies, such lesions may progress to chronic 
ABMR,  and more outcome data are needed.  
5 A severely atrophic tubule is defined as one with each of the following 3 features: a diameter <25% of that of unaffected or minimally affected tubules  on the biopsy, an undifferentiated- appearing,  cuboidal or 
flattened epithelium, and pronounced wrinkling and/or thickening of the tubular bas ement  membrane  
(Source: Haas  et al 2017 , Roufosse 2018) .  
 